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Abstract
The preprotachykinin-A (PPT-A) gene encodes the neuropeptides substance
P, neurokinin A, neuropeptide K and neuropeptide y, each derived by alternative
mRNA splicing and post-translational processing of precursor polypeptides. The
PPT-A gene is regulated by a variety of extracellular stimuli including NGF, GDNF,
steroids, and inflammation and it is likely that many of these stimuli act at the level
of transcription.
This study set out to investigate transcriptional regulation of the rat PPT-A
gene promoter in dorsal root ganglia neurons (DRG). The proximal promoter region
of the PPT-A gene has been extensively studied however, functional studies have
been greatly hindered due to the lack of clonal cell lines, which express endogenous
PPT-A or can support PPT-A promoter function in reporter gene constructs. DRG
express the PPT-A gene endogenously however neurons are refractory to all methods
of transfection. Adeno-associated virus vectors (AAV) were therefore used as a tool
for the transduction ofPPT-A promoter fragments driving a reporter gene to
investigate PPT-A promoter activity.
AAV vectors were shown to achieve 100% transduction efficiency of both
neuronal and nonneuronal cells in DRG cultures and AAV vectors containing the
PPT-A promoter demonstrated a more restricted expression pattern. In addition,
AAV vectors allowed long-term reporter gene expression in cultured DRG neurons
in which expression was predominately neuronal.
The definition of functional promoter elements supporting tissue specific
expression of the PPT-A gene was firstly analysed by infection of adult and neonate
cultured DRG neurons with AAV vectors that contained different lengths of the PPT-
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A proximal promoter driving the luciferase reporter gene. The PPT-A promoter was
found to contain elements that are differentially regulated between neonate and adult
DRG neurons. Secondly, the effect of growth factors NGF, LIF, IL-6, BDNF and
GDNF on the PPT-A promoter fragment (nucleotides -865 to +92) were examined in
cultured adult DRG neurons. These growth factors are known to alter neuropeptide
levels and neuronal phenotype. It was found that NGF, LIF and GDNF
independently acted to influence PPT-A promoter activity in adult DRG neurons.
This suggests that the proximal PPT-A promoter contains regulatory elements that
can mediate the effects of these growth factors.
Furthermore, the role of a specific binding motif for the basic helix-loop-
helix (bHLH) family of transcription factors was addressed. Previous biochemical
and cell line models have implicated this motif as an important regulator ofPPT-A
promoter activity. The activity of the PPT-A promoter fragment -865+92 containing
an insertional mutation at nucleotide -60 disrupting the bHLH binding motifwas
compared to the wild-type promoter fragment in the presence or absence ofNGF. It
was established that this bHLH binding motif could be bound by a repressor in the
absence ofNGF and might be an important regulator of basal levels ofPPT-A
promoter activity. This suggests a novel mechanism by which bHLH factors might
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This study set out to investigate the transcriptional regulation of the rat
preprotachykinin-A (PPT-A) gene in rat dorsal root ganglia (DRG). The PPT-A gene
encodes the precursors of the tachykinins that are a family of structurally related
neuropeptides. The tachykinins are widely but selectively distributed throughout the
central and peripheral nervous system.
The first tachykinin member to be discovered was substance P in 1931 by Von
Euler and Gaddum and its structure was later elucidated by Chang et al. (1971). Until
1983, substance P was the only representative of the mammalian tachykinins,
consequently it has been the most extensively characterised. Several other
tachykinins have now been identified including neurokinin A (Nawa et al., 1984;
Krause et al., 1987), neurokinin A (3-10) (Tatemoto et al., 1985), neurokinin B
(Kotatini et al., 1986), neuropeptide y (Kage et al., 1988) and neuropeptide K
(Tatemoto et al., 1985).
1.1.1 Genes encoding tachykinins
Substance P (SP), neurokinin A (NKA), neurokinin A (3-10) (NKA (3-10)),
neuropeptide K (NPK) and neuropeptide y (NPy) are encoded by the
preprotachykinin-A gene (PPT-A). Neurokinin B (NKB) is encoded by the
preprotachykinin B gene. The rat PPT-A gene is approximately 8 kb in length,
containing 7 exons and 6 introns (Nawa et al., 1984).
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The primary RNA transcript produced from the PPT-A gene is alternatively
spliced to produce 4 mRNAs (figure 1.1): a-, P-, y- and 5-PPT mRNA, with each
mRNA differing in exon usage. (3PPT mRNA contains all seven of the PPT-A gene
exons. Exon 6, which encodes NKA, is absent in ot-PPT mRNA, whereas exon 4 is
absent in y-PPT mRNA (MacDonald et al., 1989; Carter and Krause, 1990). Another
splicing variant of the rat PPT-A gene is 5-PPT mRNA, which lacks both exon 4, and
exon 6 (Harmar et al., 1990). The precursor polypeptides produced from these
mRNAs undergo post-translational modification to produce the corresponding
neuropeptides. Part of exon 3 encodes substance P and therefore all mRNAs can
produce SP, whereas NKA will be produced only from P- and y-PPT precursors.
NPK and NPy are N-terminally extended derivatives ofNKA and are the final
products of post-translational modification of p- and y-PPT in some tissues
(Tatemoto et al., 1985; Kage et al., 1988).
Alternative RNA splicing is regulated in a tissue specific manner so the amounts
ofmRNA and therefore the amount of SP and NKA vary in different tissues. In the
rat, a-PPT levels are relatively low in all central nervous system (CNS) and
peripheral nervous system (PNS) tissues examined (<0.1%), whereas y-PPT mRNAs
are the most abundant (80%). P- and 5-PPT mRNAs have been shown to be present
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Figure 1.1: Schematic diagram of the PPT-A gene. Boxes and numbers represent the exons and
horizontal lines represent the introns. Exon 3 contains the sequence information for SP and exon 6
contains the sequence information for NKA. Following alternative RNA splicing, 4 mRNA species
are produced. The polypeptide precursors then undergo post-translational modification to generate
neuropeptides SP, NKA, NKA(3-10), NpK and Npy.
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1.1.2 Distribution and role of tachykinins
Tachykinins are widely distributed throughout the mammalian body in both
the central nervous system and peripheral tissues and numerous functions have been
attributed to tachykinins in each of these tissues. SP and NKA are mostly synthesised
in neurons of the peripheral and central nervous system where they are stored in
large dense-core vesicles (McCarthy and Lawson, 1989). Upon excitation of these
neurons, SP and NKA are released and act on their receptors on target cells to evoke
various cellular responses. Consequently, a role for SP as a neurotransmitter was
proposed (Otsuka and Yoshioka, 1993).
1.1.2.1 Central roles of tachykinins
Particular attention has been paid to the role of SP in the spinal cord, where it
is highly concentrated in the neurons of the dorsal horn (McCarthy and Lawson,
1989). The dorsal horn neurons receive input from the DRG cells in the peripheral
nervous system, which then process and relay somatosensory information to the
CNS. PPT-A mRNA is expressed in approximately 20-30% of the dorsal root ganglia
cells (Boehmer et al., 1989). Most of these PPT-A containing neurons are small
diameter cells (Tuchscherer and Seyboid, 1985) which give rise to the predominately
nociceptive C- and AS-fibres. Subsequently, a role for SP as a neurotransmitter of
afferent neurons in the spinal cord, and its involvement in pain transmission
(nociception) has been the focus ofmany studies. Recently, mice with a disrupted
PPT-A gene were studied (Cao et al., 1998; Zimmer et al., 1998). The mice
generated by Cao et al. appeared to have normal thresholds for reactions to various
painful stimuli, such as heat, mechanical pressure or chemical irritants. However,
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there seemed to be a 'window' of painful intensities in which the animals showed
reduced responses to the stimuli compared to the wild-type mice. The second study
by Zimmer et al. (1998) demonstrated that the knock out animals show increased
pain thresholds to certain painful stimulus, such as heat and noxious chemical
stimuli, while other assays revealed no differences to the wild-type animal. Both
studies demonstrate that tachykinins may play a role as a neurotransmitter in some
but not all nociceptive responses, depending on the type and intensity of the painful
stimuli. The difference in results obtained from these two studies could reflect the
different genetic background of the mice studied or the experimental approaches
taken. It has recently been shown that genetic variability of mice strains can affect
the observed responses to common measures of nociception (Mogil et al., 1999).
In addition to their roles in sensory transmission, tachykinins have been
implicated in a variety of CNS functions such as the control ofmotor activities,
autonomic and endocrine functions, and memory processings (Otsuka and Yoshioka,
1993). Recently, SP has also been implicated in the modulation of stress responses,
mood, and anxiety (Rupniak and Kramer, 1999), but its exact role remains unclear.
Localised administration of SP in the CNS may increase or reduce anxiety,
depending on the animal species and location of injection (Teixeira et al., 1996; File,
1997; de Araujo et al., 1998). In humans, a SP receptor antagonist has been reported
to be an effective antidepressant and anxiolytic (Kramer et al., 1998). SP expression
has also been studied in relation to several neurodegenerative disorders such as,
Parkinson's disease (Gresch and Walker, 1999), Alzheimer's disease (Bouras et al.,
1990) and Huntington's disease (Richfield et al., 1995) which are all associated with
a progressive loss of SP expression within the brain.
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1.1.2.2 Peripheral roles of the tachykinins
The majority of SP synthesised in neurons of the DRG is transported to the
periphery (Harmar and Keen, 1984). SP has been found in a variety of peripheral
nerves, including the phrenic (Malthe-Sorensen and Oktedadlon, 1982) and sciatic
nerves (Lembreck et al., 1981). Additionally, SP-containing nerves have been
demonstrated in skin (Dalsgaard et al., 1988), the respiratory, urinary and
gastrointestinal tracts (Lecci et al., 2000) and spleen, thymus and lymph nodes (Fink
and Weihe, 1988; Popper et al., 1988; Weihe et al., 1989; Kurkowski et al., 1990).
Peripheral SP is also thought to be involved in processes such as arthritis
associated neurogenic inflammation (Donaldson et al., 1992; Smith et al., 1993),
stimulation of immune function (Bar-Shavit et al., 1980) and growth of fibroblasts
and smooth muscle (Nilsson et al., 1985). In addition, peripheral SP can function in
hypertension, smooth muscle contraction and cellular proliferation (Lecci et al.,
2000). An increase in SP gene expression in DRG neurons has been associated with
peripheral inflammation (Leslie et al., 1995) and neuropathic pain (Noguchi et al.,
1994; Fukuoka et al., 1998).
1.1.3 Regulation of the tachykinins
Tachykinins and their precursor mRNAs have been shown to display a
significant degree of plasticity in expression levels. The term plasticity is used to
describe short or long-lasting changes in neuronal phenotype in response to different
stimuli. Much work has been carried out to define potential regulators involved in
mediating plasticity of the PPT-A gene and its products in DRG neurons. A number
of regulators have been determined and one such influencing factor is the
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neurotrophin, nerve growth factor (NGF). NGF transported from the peripheral tissue
regulates synthesis of SP in primary sensory neurons. NGF has been shown to
regulate PPT-A gene expression in cultured DRG neurons (Lindsay and Harmar,
1989; Vedder et al., 1993; Mulderry, 1994; Jiang and Smith; 1995) and in vivo
(Leslie et al., 1995; Otten and Lorez, 1983). These studies show that the addition of
NGF can lead to an induction in SP expression or increased PPT-A mRNA
production. In addition, the concentration of SP is decreased in sensory neurons
following peripheral nerve transection or injury (Fitzgerald et al., 1985; Noguchi et
al., 1989; Henken et al., 1990; Noguchi et al., 1993; Noguchi et al., 1994; Noguchi
et al., 1995; Verge et al., 1995). This suggests that SP synthesis is down-regulated by
the depletion ofNGF, which in the case of peripheral axotomy, is caused by the
blockade of axonal flow in the peripheral branches of sensory neurons. Furthermore,
peripheral inflammation is thought to influence SP levels in DRG neurons in vivo
and is mediated by increased NGF expression (Cho et al., 1996; Donaldson et al.,
1992; Donnerer et al., 1992; Leslie et al., 1995; Minami et al., 1989; Woolf et al.,
1994). To assess whether the availability of endogenous NGF plays a role in
triggering changes in PPT-A mRNA and SP levels, Shadiack et al. (2000) injected
animals with antiserum against NGF. The results showed that SP levels were reduced
in part suggesting NGF can influence these changes.
In addition to NGF, other neurotrophic factors can regulate SP expression in
sensory neurons (Mulderry, 1994) and other stimuli have been shown to regulate
PPT-A and SP levels in DRG neurons. These include capsaicin (Geppetti et al.,
1988; Jessell et al., 1978; Kashiba et al., 1997a) and long-term exposure to steroids
(Liuzzi et al., 1999) which act to decrease expression. In addition short term
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exposure to steroids (Smith et al., 1991) and morphine (Ma et al., 2000) can increase
SP expression.
1.1.4 Tachykinin receptors
The tachykinins mediate their effect by binding to G protein linked receptors
that are characterised by the presence of a seven transmembrane domain. Upon
binding the receptor, the tachykinins are believed to activate phospholipase C (PLC).
This results in the stimulation of phosphatidyl inositol turnover and a resulting
• • • • 2"Pincrease in intracellular inositol 1,4,5-triphosphate (IP3), which evokes Ca release
from intracellular stores. PLC activation can also result in protein kinase C (PKC)
activation through diacylglycerol (DAG) (reviewed in Zeiglgansberger and Tolle,
1993). All of the tachykinins are able to induce similar biological actions, although
their potency at inducing individual physiological responses differ suggesting they
may act through different receptors. Ligand binding studies and molecular biology
techniques have identified three tachykinin receptors NK1, NK2 and NK3, which are
preferentially bound by SP, NKA and NKB respectively (Buck and Burcher, 1986;
Masu et al., 1987; Yokota et al., 1989; Shigemoto et al., 1990).
Recently mice which lack the gene encoding the NK1 receptor (De Felipe et
al., 1998; Laird et al., 1999) or have had it specifically ablated with the toxin saporin
(Mantyh, 1997) have shown that this receptor has an important role in hyperalgesia,
pain responses and anxiety.
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1.2 Transcriptional regulation of the PPT-A gene
1.2.1 Overview of transcription
The regulation of transcription is central both to tissue specific gene
expression, and the regulation of gene activity in response to specific stimuli. Many
of the factors acting to regulate PPT-A gene expression may be acting at the level of
transcription. To understand the factors that are involved in mediating PPT-A mRNA
synthesis, studies have focused on investigating transcriptional regulation of the
promoter region of the PPT-A gene spanning nucleotides -3356 to +447. The
initiation of transcription takes place through the interaction of defined proteins
(transcription factors) with specific DNA sequences located on the promoter of a
gene. The minimal promoter consists of basal promoter elements, which are the
minimal DNA sequences necessary for transcription and can include a TATA box, or
initiator elements. The TATA box is an AT-rich sequence, which is found
approximately 30 bases upstream of the transcriptional start site in a variety of
different genes (although is absent from some constitutively expressed and tissue-
specific genes). It plays a critical role in positioning the start site of transcription.
Initiator elements are found in the vicinity of the transcriptional start site of several
eukaryotic genes and can serve a variety of functions and interact with a wide range
of transcription factors (Du et al., 1993; Seto et al., 1991; Shi et al., 1991). These
basal elements interact with the basal transcription factors and this complex produces
low rates of transcription. In addition, the promoter contains regulatory DNA
elements, which bind other transcription factors to enhance or repress the rate of
basal transcription. Eukaryotic promoters can span many kilobases, therefore these
regulatory DNA elements may be located far from the basal promoter elements.
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The PPT-A promoter spanning nucleotides -3356 to +447 has been
previously characterised, as it is believed that the majority of important regulatory
elements are located in this promoter fragment. It consists of basal promoter
elements including a TATA box spanning nucleotides -22 to -28 (identified by
Carter and Krause, 1990) and potential initiator elements located between
nucleotides -20 to +4 (Mendelson, 1994). For transcription initiation, these basal
promoter elements must bind the basal transcription machinery which comprises the
general transcription factors TATA-binding protein (TBP), TFIIB, TFIIE, TFIIF,
TFIIH and TBP-associated factors (TAFs). These bind the DNA in a defined order to
build a complex that is bound by RNA polymerase II (figure 1.2). The first step
involves the binding of TBP and a variety of subunits termed TAFs, to a region that
extends upstream of the TATA box. TFIIA also joins this complex and this is
followed by TFIIB. TFIIF is next in order and this binds RNA polymerase II. Two
final factors join the complex, TFIIE and TFIIH. This complex results in minimal
transcription. However as stated earlier, the efficiency and specificity with which the
promoter is recognised by transcription factors depends upon the regulatory DNA
sequences. These bind regulatory transcription factors and ultimately result in the
activation or repression of transcription (Latchman, 1995; Roeder, 1996) (figure 1.3).
In addition to the core promoter elements described above, this PPT-A
fragment spanning nucleotides -3356 to +447 contains a number of potential
regulatory DNA elements upstream and downstream of the transcriptional start site
(Fiskerstrand and Quinn, 1996). These elements can bind transcription factors, which
ultimately act to influence transcription positively or negatively. These DNA motifs
may mediate the action ofmultiple stimuli. There are a limited number of such DNA
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motifs that can occur in all promoters. However, the arrangements of different motifs
within a promoter and the fact that different members of transcription factor families
have the ability to recognise similar motifs can generate functional specificity. The
various members can be regulated in a tissue-specific and tissue-inducible manner.










Figure 1.2: Assembly of the promoter initiation complex. The initiation complex assembles
at promoters for RNA polymerase II by an ordered sequence of association with transcription
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Direct
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Figure 1.3: Mechanisms of (I) activation and (II) repression of gene expression (I) An activator (A)
bound to its binding site can stimulate either the assembly of the basal transcriptional complex
consisting ofRNA polymerase and its associated factors, or stimulate its activity once it has
assembled. (II) Repression can occur by (a) the repressor (R) binding to DNA and preventing an
activator from binding and activating gene expression; (b) by the repressor interacting with the
activator in solution and preventing its DNA binding; (c) by the repressor binding to DNA with the
activator and neutralising its ability to activate gene expression; or (d) by direct repression by an
inhibitory transcription factor.
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1.2.2 Potential transcription factors involved in PPT-A promoter regulation
Sequence analysis of the PPT promoter revealed several candidate DNA
sequences that were related to known consensus sequences for binding transcription
factors (Carter and Krause, 1990; Chapman et al., 1993; Quinn, 1992 and Mendelson
and Quinn, 1995). They include putative octamer binding protein sites, API sites,
cAMP response elements, GC boxes, and E box motifs. The transcription factor
families, which are known to bind these consensus sequences, will first be described
with specific reference to members that have been implicated in regulating PPT-A
neuron specific gene expression. Subsequently, the experiments that have
functionally defined the PPT-A promoter regulatory elements and implicated these
transcription factors in regulating transcription of the PPT-A promoter will be
discussed.
1.2.2.1 E box binding proteins
The E box binding proteins are a subset of a larger family of transcription
factors termed the basic helix-loop-helix (bHLH) family and can bind the consensus
sequence CANNTG. The actual sequence of a specific E box motif determines the
affinity or specificity with which it will bind members of the E box binding proteins.
The activities of these proteins are modulated by homodimer and heterodimer
formation and they are often involved in tissue specific gene expression (Ball et al.,
1992; Murre et al., 1989a; Therrien and Drouin, 1993). Neurons express specific
bHLH factors in addition to a variety ofmore constitutively expressed bHLH factors
such as upstream stimulatory factor (E1SF) and c-Myc and related proteins. Members
that are specifically present in DRG neurons include neurological stem cell leukemia
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factor (NSCL) (Begley et al., 1992) and mammalian achaete-scute homologous-1
(MASH-1), the latter protein being upregulated in PC 12 cells by NGF (Johnson et
al., 1990). Heterodimerization between ubiquitous and cell-lineage specific family
members has been proposed as a mechanism for the regulation of tissue specific gene
expression (Murre et al., 1989b).
1.2.2.2 AP1 and CRE protein binding families
API and cyclic AMP response element binding proteins (CREB) are
subfamilies of the basic leucine zipper (bZIP) family of transcription factors.
Commonly, members contain a 35 amino acid domain in which every seventh amino
acid is a leucine. The collective term AP-1 is used to describe dimeric transcription
factors composed of Jun and Fos subunits that bind to a common DNA site, the API
binding site (TGA°/cTCA). Members of the CREB family bind the cAMP reponse
element (CRE) (TGACGTCA). All members of this bZIP family can form homo or
heterodimers with members of their own subfamily or other families. Jun proteins
form very stable heterodimers with Fos and CREB family members or can
homodimerise among themselves (Kouzarides and Ziff, 1988; Smeal et al., 1989;
Hai and Curran, 1991). The resulting dimers are thought to possess different DNA
binding specificities and affinities allowing targeting to different but related DNA
sites. In both AP1 and CRE sites the structure which the consensus sequence and
flanking DNA can adopt can play a role in determining both the identity of the
specific complex that binds and the functional consequence of binding (Franza et al.,
1988).
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NGF modulates CREB family members, which in turn regulates CRE activity
(Ginty et ah, 1994; Hawley et ah, 1992). Jun has also been demonstrated to be
regulated by NGF in DRG neurons (Gold et ah, 1993). Induction of Fos by NGF in
PC12 cells is well established (Kruijer et ah, 1985; Curran and Franza; 1988; Curran
and Morgan, 1985; Milbrant, 1986) and other growth factors have been shown to
induce Fos in primary neuronal cultures of varying types (Collazo et ah, 1992;
Engele and Schilling, 1996; Bilsland and Harper, 1998). In addition, compositional
variations of proteins binding to API sites changes in response to stimuli including
NGF (Gizang-Ginsberg and Ziff, 1994; Quinn et ah, 1989) and can vary in a tissue
specific manner (Andrews et ah, 1993).
1.2.2.3 Octamer binding proteins
Octamer binding proteins are part of a larger family of pituitary octamer and
unc (POU) proteins, which contain both a homeobox-like sequence and a conserved
POU domain (Herr et ah, 1988). This POU domain is important for site-specific
DNA binding and protein-protein interactions between POU domain proteins and
other transcription factors. Members of the octamer binding protein family recognise
and bind to the octameric DNA consensus sequence ATTTGCAT. It has been shown
that the consensus sequence is highly degenerate (Baumruker et ah, 1988) with
flanking sequences also being important for mediating protein/DNA interactions.
Members serve a number of different functions and each show varying and
overlapping tissue distributions (Herr et ah, 1988). POU domain proteins include the
ubiquitously expressed Oct-1 protein and a number of nervous-tissue specific
members including Brn-1, Brn-2, Brn-3a, 3b and Brn-4. These proteins can act as
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both transcriptional repressors and activators (Morris et al., 1997). Brn-3a and Brn-
3b differ in their effect on a number of neuronal specific promoters (Morris et al.,
1997). Adult DRG neurons are known to express a number of POU-domain proteins
including Oct-1, Oct-2 and Brn-3 and levels ofOct-2 are increased in DRG
following treatment with NGF (Wood et al., 1992; Kendell et al., 1995).
1.2.2.4 Zinc finger transcription factors
Members of the zinc finger family of transcription factors contain a 30 amino
acid zinc finger motif, which is present in variable numbers in many regulatory
proteins (Rhodes and Klug, 1993). Members of the zinc finger family of transcription
factors include Spl, which can recognise and bind purine-rich and G-rich regions of
DNA (Lania et al., 1997). Spl binding sites are often found near binding sites for
other transcription factors suggesting these factors act in conjunction to modulate
transcription. Another member, Egr-1 has been shown to mediate growth factor and
phorbol 12-myristate (TPA) activation of transcription (Christy et al., 1988;
Sukhatme et al., 1988).
1.2.2.5 Helix-span-helix (HSHltranscription factors
Members of the HSH family of transcription factors contain a region rich in
basic residues essential for DNA binding and dimerisation. Members include AP2
(Williams and Tjian, 1991) that recognizes sequences rich in dG nucleotides. AP2
has been detected in DRG neurons (Mitchell et al., 1991) and expression in DRG
neurons in vivo has been correlated with increased levels of PPT-A gene expression
in an animal model of arthritis (Donaldson et al., 1993).
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1.2.3 Analysis of the PPT-A promoter
Investigating transcriptional regulation of the PPT-A promoter has been
difficult, due to the lack of cell lines which endogenously express the gene or will
support expression from transfected plasmids containing fragments of the PPT-A
promoter driving reporter gene expression (Wood et al., 1990; Mulderry et al., 1993;
Morrison et al., 1994a). In addition, DRG primary cultures are generally resistant to
transfection. Therefore, two strategies have been employed to investigate the
transcriptional regulation and stimulus inducibility of the PPT-A promoter. Firstly,
reporter gene constructs containing the PPT-A promoter were microinjected into
cultured DRG neurons since DRG neurons express endogenous PPT-A and
demonstrated activity of the PPT-A promoter (Mulderry et al., 1993). It was found
that the promoter fragment spanning base pairs -3356 to +447 was three times more
active than a fragment spanning -3356 to +92. The activity of promoter fragment
spanning -3356 to +92 was equal to that of fragment -865 to +92, therefore it was
concluded that the majority of positive regulatory elements in the PPT-A promoter
were located between base pairs -865+92. Subsequent analysis focused on DNA
elements within this domain (Mulderry et al., 1993). In addition, Mulderry et al.
investigated whether the PPT-A promoter was NGF regulated in DRG cultures.
Reporter gene constructs containing promoter fragments spanning base pairs -3356
to +92 and -3356 to +447, were microinjected into DRG neurons and maintained in
the presence or absence ofNGF. No difference in reporter gene activity was found
between NGF treated and untreated cultures. It has recently been proposed that this
may be a reflection on the process ofmicroinjection ofDNA into the DRG cultures
(Quinn et al., 2000). Quinn et al. (2000) suggested that this technique of
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microinjection might not be suitable for investigating potential growth factor
responses in cultured DRG neurons.
Secondly, the PC 12 cell line was used as a model for the analysis of reporter
gene constructs. The PC 12 cell line was derived from rat adrenal chromaffin cell
(Greene and Tischler, 1976) and has been extensively used as a model for neuronal
gene expression. In the presence ofNGF, PC 12 cells will develop many
characteristics indicative of a neuronal phenotype (Greene and Tischler, 1976). The
PPT-A promoter is inactive in PC 12 cells under basal conditions (Morrison et al.,
1994a) however, DNA elements contained within the promoter can interact in a
sequence specific manner with transcription factors present in PC 12 cells (Quinn,
1992). Therefore small fragments from the PPT-A promoter linked to a heterologous
reporter construct were used. This allowed the ability of individual PPT-A DNA
elements to stimulate transcription in PC 12 cells to be determined. Many individual
elements were found to be both active and NGF regulated in PC 12 cells (section
1.2.3.2).
As DRG cultures do not allow sufficient quantities of nuclear extract for use
in DNA binding studies, PC 12 and HeLa cell lines were used for the characterisation
ofDNA binding motifs and the transcription factor families binding these motifs.
These cell lines contain a variety of consitutively expressed transcription factors that
can interact with the PPT-A promoter. DNasel footprinting studies identified
potential DNA-protein interactions on the PPT-A promoter. Electrophoretic mobility
shift assays (EMSA) allowed the investigation of sequence specific binding factors.
The PC 12 cell line was therefore a useful model for the identification of potential
transcription factors, which can interact with the PPT-A promoter, and can allow
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signal transduction pathways to be postulated. The PC 12 cell line can respond to a
variety of stimuli, which induce the synthesis of various neuropeptides and
neurotransmitters (Lewis et al., 1987; Tischler et al., 1986; Van Nguyen et al.,
1990). Together these models allowed several potentially important regulatory motifs
to be identified (Morrison et al., 1994a; 1994b; Mendelson et al., 1995; Paterson et
al., 1995a, 1995b, 1995c). The PPT-A promoter has been shown to contain many
activator and repressor binding sites that may function in vivo to allow tissue specific
and stimulus-inducible expression of the PPT-A gene. The important regulatory
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1.2.3.1 Repression of the PPT-A promoter
It is known that negative regulatory elements are present in neuronal-specific
genes (Hoyle et al., 1994; Maue et al., 1990; Mori et al., 1990; Mori et al., 1992).
The promoter domain -865+92 can drive high levels of reporter gene expression in
DRG neurons but not in clonal cell lines HeLa and PC 12 (Mendelson and Quinn,
1995). This indicated that cA-acting elements may be regulated by neuron specific
factors or that PPT-A promoter activity is repressed in non-neuronal cells. DNasel
footprinting demonstrated that the PPT-A promoter bound a sequence specific
complex between the TATA box and the major transcription initiation site. This was
believed to be a dominant repressor that could potentially interfere with the binding
of the basic transcription machinery and could therefore account for neuron-specific
expression of the PPT-A promoter. Reporter gene constructs containing the PPT-A
promoter spanning base pairs -3356 to +92 were co-transfected into HeLa cells with
increasing concentrations of a plasmid, containing multiple copies of the potential
repressor binding site. PPT-A promoter activity was observed in the presence of high
levels of the repressor sequence suggesting that the multiple copies of the repressor
binding site acted to titrate the repressor from the PPT-A promoter allowing
expression (Mendelson and Quinn, 1995).
In addition to this dominant repressor, other elements have been associated
with exerting negative effects on PPT-A promoter activity. The region spanning
nucleotides -198 to - 155 contains both an AP1/CRE element in addition to an E box
motif. Originally it was shown that the AP1/CRE motif alone (spanning nucleotides
-198 to -182) could activate reporter gene expression in DRG neurons and in HeLa
and PC 12 cell lines, when linked to a heterologous minimal promoter. In addition,
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this potential AP1/CRE element was found to preferentially bind a protein complex
that is distinct from CREB, ATF1, Fos and Fra. (Morrison et al., 1994a). Later when
the entire region spanning -198 to -155, incorporating the AP1/CRE elements
together with the E box motif, were similarly examined, it was established that this
fragment was inactive in FleLa and PC 12 cells but could support reporter gene
expression in DRG cultures. This indicated the presence of a second repressor
element associated with nonneuronal cells which was acting to repress the previously
identified AP1/CRE enhancer element in PC 12 and HeLa cell lines (Paterson et al.,
1995c).
Recently, clonal cell lines RINm5F (McGregor et al., 1992) and NF2C cells
(Whitehead and Joseph, 1994) have been found to express endogenous PPT-A and
support expression of the PPT-A promoter (Fiskerstrand et al., 1999). The RINm5F
cells have been derived from a rat pancreatic tumour and NF2C cells were generated
from a transgenic rat in which a temperature-sensitive SV40 LT antigen is expressed
under the control of the neurofilament light-chain promoter (Kilty et al., 1999).
These cell lines allowed functional analysis of putative regulatory elements in the
promoter and the identification of a novel repressor domain lying 3' of the major
transcriptional start site (Fiskerstrand et al., 1999). Cells were transfected with
reporter constructs containing PPT-A promoter fragments driving the luciferase
reporter gene. Comparison of plasmids containing promoter fragments -865+447 and
-865+92 showed that sequences located between +92 and +447 were exerting
negative regulatory effects in both cell lines and DRG neurons (Fiskerstrand et al.,
1999). This effect was shown to be due to sequences located between base pairs
+367 to +396 as mutation of this site relieved repression of the -865+447 promoter
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fragment. This region has been characterised as having the potential for forming
multiple DNA binding complexes and contains binding sites for transcription factors
Oct-1 and NFk-B (Mendelson and Quinn, 1995; Mendelson et al., 1998; Fiskerstrand
et al., 2000). Mutation of the octamer binding site in this region was not associated
with loss of protein binding but in functional studies did result in alleviation of
repression (Fiskerstrand et al., 2000). Therefore loss of repression following
mutation of this octamer binding site is not correlated with loss of octamer binding to
this region.
1.2.3.2 Activation of the PPT-A promoter
Under specific circumstances, the PPT-A promoter fragment -865+92 can be
active in PC 12 cells. Following forskolin treatment in combination with potassium
evoked depolarisation, promoter activity was observed (Morrison et al., 1994b).
Forskolin acts to induce members of the cAMP response element binding family of
transcription factors (CREB) (Montiminy et al., 1986) whereas depolarisation causes
the induction of members of the API family of transcription factors (Bartel et al.,
1989). The induction of the PPT-A promoter by forskolin and potassium evoked
depolarisation in PC 12 cells was thought to be associated with the presence of an E
box motif located between nucleotides -67 to -47. When this region was mutated,
expression in PC 12 cells was no longer observed (Paterson et al., 1995b). DNasel
footprinting had previously identified protein complexes binding to this element
(Mendelson et al., 1995; Mendelson and Quinn, 1995) and it was shown to bind the
bHLH transcription factors USF and max (Paterson et al., 1995b). In addition,
constructs containing this fragment -67 to -47 could drive reporter gene expression
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in HeLa and PC 12 cells (Mendelson et al., 1995). When this construct was used for
transfection of HeLa and PC 12 cells and exposed to TPA and NGF treatment
respectively, promoter activity was increased. When it was microinjected into DRG
neurons, NGF had no effect on the activity. As previously stated, this was thought to
be due to the overlap of signal transduction pathways activated by the process of
microinjection in addition to NGF.
The region spanning nucleotides -345 to -308 was shown to contain two API
sites adjacent to an E box binding consensus. The API sites in this region were
shown to bind a complex that was recognised by antibodies to c-fos/fra. When these
three elements were analysed individually and together, they were shown to behave
differently. When the individual API elements were linked to a heterologous
promoter to drive reporter gene expression no activity was observed in PC 12 cells.
However high levels of activity were observed when all three elements were
provided together, indicating that these elements may act synergistically to regulate
PPT-A promoter activity (Paterson et al., 1995c).
Another octamer binding site located 5' of the major transcriptional start site
(situated -567 to -546) has been shown to be important for positively regulating the
PPT-A promoter. Mutation of this site resulted in both loss of promoter activity in
reporter gene analysis and loss of protein binding in EMSA, confirming enhancer
function of this 5' octamermotif (Fiskerstrand et al., 2000). This 5' octamer binding
element is bound by the same classes of transcription factors as the 3' octamer motif
described previously (section 1.2.3.1, Fiskerstrand et al., 1999) and it is thought
these domains may act synergistically to regulate PPT gene expression. As described
in section 1.2.2.3, octamer binding proteins have been implicated in the regulation of
25
neuron-specific gene expression and in mediating the effects ofNGF on sensory
neuron gene expression (Wood et al., 1992).
DNA binding studies have identified other potential regulatory elements,
however functional analysis of these specific elements has not yet been performed.
These include the identification of purine-rich motifs located between nucleotides
-284 to -264, -576 to -546 and -779 to -775 (Quinn et al., 1995; Mendelson and
Quinn, 1992; Quinn and McAllister, 1993). The region spanning -779 to -775 has
been shown to specifically interact with AP2, Spl, a sequence specific single-
stranded DNA binding protein and other complexes (Quinn et al., 1995). These
elements may serve as binding sites for AP2, Spl or other zinc finger containing
proteins in neurons. In addition to the three E box motif described previously, a
further three E box motifs have been identified 3' of the transcription start site on the
PPT-A promoter. These are located at nucleotides +61 to +66, +69 to +74 and +181
to +186 (Mendelson and Quinn, 1995). Functional analysis of these E box motifs is
still required to determine if these are important elements in regulating PPT-A
promoter activity.
1.2.3.3 Stimulus inducibilitv of the PPT-A promoter
Transcription factors stimulate or repress gene expression in response to
extracellular stimuli delivered to the cell membrane by, for example, hormones,
neurotransmitters or growth factors. The mechanisms that link the cell membrane to
the nucleus involve the activation of signal transduction pathways in which the final
step involves the activation or binding of transcription factors to specific DNA
elements on the gene promoter (figure 1.5). NGF is known to increase PPT-A mRNA
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and SP expression levels in DRG neurons (Lindsay and Harmar, 1989; Vedder et al.,
1993; Mulderry, 1994; Jiang and Smith; 1995; Leslie et al., 1995; Otten and Lorez,
1983) and therefore is likely to regulate SP expression at the levels of transcription.
The PPT-A promoter is known to contain putative binding sites for transcription
factors that are also induced in response to NGF. Factors include API, CREB,
octamer binding proteins and the bHLH families of proteins, which have been shown
to be regulated by NGF (Curran and Franza, 1988; Curran and Morgan, 1985; Ginty
et al., 1994; Milbrandt, 1986; Quinn, 1991; Wood et al., 1992 and Mendelson et al.,
1992). The bovine PPT-A promoter region has been shown to contain elements that
can mediate the effect ofNGF in PC12 and F11 cell lines (Gilchrist et al., 1991a,
1991b and 1992). Comparison of the 5' flanking region of the rat PPT-A gene with
that of the bovine and human shows that the sequences are highly similar between
base pairs -750 and +1 but diverge considerably upstream of -750 (Chapman et al.,
1993). It might be expected that the sequences essential for neuron-specific and
inducible expression are located within this conserved region.
Recently, using adeno-associated virus (AAV) as a tool for transduction of
cultured DRG neurons, it was shown that exogenous NGF induced expression of the
PPT-A promoter (Harrison et al., 1999). In addition to NGF, other growth factors
have been implicated in regulating neuropeptide levels in DRG neurons. Like NGF,
they may be acting at the level of transcription and therefore may be capable of
regulating PPT-A promoter activity. The growth factors that can regulate DRG
phenotype and may have a role in mediating plasticity of the PPT-A gene in DRG


















Figure 1.5: Signal regulated transcription factors mediate changes in gene expression within the neuron.
Changes in gene expression are controlled by signal-regulated transcription factors (TF) which include
ligand-activated TFs of the steroid hormone family, post-translationally activated TFs e.g. CREB family
and transcriptionally activated TFs e.g. c-fos, c-jun.
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1.3 Dorsal root ganglia (DRG) neurons and neurotrophins
Cultures of DRG neurons are commonly used for investigating sensory
neuron physiology and neuronal plasticity. However interpretation of the data can be
difficult due to the heterogenous nature and complexity of the DRG. Cultures
obtained from DRG could represent more than 25 diverse populations that are
specialised to generate a variety of sensory events (Petruska et al., 2000). During
development different populations are dependent on different growth factors and
these are essential for the generation of neuronal heterogeneity. Although adult
DRGs do not require these neurotrophins for survival, they do seem to require them
for the continuous maintenance ofmature phenotypic characteristics (Crowley et al.,
1994; Conover et al., 1995; Sendtner et al., 1996). To understand the role of growth
factors and neurotrophins in adult sensory neurons, DRG neurons have been
extensively studied and various populations classified according to morphology,
anatomical location and electrophysiological and biochemical properties (Lawson,
1992). In particular, neurotrophic molecules influence distinct but overlapping
subsets of neurons and populations are defined by differences in their responsiveness
to these growth factors (Snider, 1994). Neuronal growth factors play an important
role in influencing neuronal phenotypes and therefore in conducting sensory
information. They function by binding and activating specific receptor tyrosine
kinases. This then triggers a cascade of events that culminates in specific
programmes of gene expression and cellular responses. This section will first briefly
summarise the neurotrophins that have been associated with sensory neurons and
regulating PPT-A expression (table 1.1). Subsequently, different neuronal
populations of the DRG will be discussed since this is relevant to the regulation of
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tachykinins in DRG neurons. Different populations of sensory neurons contain
different neurotrophin receptors and therefore neuropeptide expression may be
differentially regulated between these cell populations.
1.3.1 Neurotrophic factors and their receptors
The neurotrophin family of neuronal growth factors includes nerve growth
factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and
neurotrophin- 4/5 (NT-4/5). Neurotrophins trigger a variety of biological responses
including enhanced neurite outgrowth (Cohen et al., 1994; Segal et al., 1995),
changes in electrophysiological properties of neurons (Kalman et al., 1989; Levine et
al., 1995) and alterations in neuronal cell fate (Sieber-Blum, 1991).
Neurotrophins are produced by target tissues and, upon their release, bind to
specific receptors located on the surface of peripheral axons. Each neurotrophin is
capable of interacting independently with the widely distributed low affinity receptor
p75 and specific Trk receptor kinases. The Trk receptors display neurotrophin
selectivity with the TrkA, TrkB and TrkC tyrosine kinases serving as the receptors
for NGF, BDNF and NT-3 respectively, and TrkA and TrkB can also act as receptors
for NT-3 and NT-4/5. P75 is thought to modulate the sensitivity of cells to different
neurotrophins (Chao and Flempstead, 1995), however in the absence of Trk
receptors, neurotrophins binding p75 can lead to cell death (Meldolesi et al., 2000).
NGF is the prototypic neurotrophin therefore its mode of action and resulting
effects have been extensively studied (figure 1.6) (for review see Segal and
Greenberg, 1996). It is known that dimeric NGF molecules bind to TrkA and causes
the formation of TrkA dimers (Jing et al., 1992). This in turn results in internalisation
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and the receptors are transported to the soma. In addition, cross-linking leads to
phosphorylation of the TrkA molecules, which catalyses the formation of large
signalling complexes through the recruitment of cytosolic and membrane associated
protiens (Heldin, 1995). The final step of this cascade involves phosphorylation of
transcription factors that will act directly or indirectly to regulate gene expression
(Stephens et al., 1994). As stated previously NGF is important for neuropeptide
plasticity in DRG neurons and can increase SP expression. This effect is mediated, at
least in part by regulatory elements located on the PPT-A proximal promoter and loss
ofNGF as in axotomy is thought to account for the characteristic decrease in SP
expression following nerve injury.
Neurotrophin glial cell-derived neurotrophic factor (GNDF) has been shown
to alter sensory neuron phenotype. GDNF is a member of a novel family of trophic
factors that also include neurturin, persephin and artemin and can exert notable
trophic influences on dopaminergic neurons (Tornac et al., 1995), motor neurons
(Henderson et al., 1994; Yan et al., 1995) and sensory neurons (Matheson et al.,
1996). Members of the GDNF family exert their effects via a unique multicomponent
receptor complex. This consists of Ret, a tyrosine kinase receptor acting as a signal
transducing domain, in combination with a member of the GFRa family of the
glycosyl-phosphatidyl-inositol-linked GDNF-family receptors (GFRas), acting as a
ligand binding domain (Airaksinen et al., 1999; Durbec et al., 1996; Treanor et al.,
1996).
Immunocytochemistry has identified the presence ofGDNF in DRG sensory
neurons (Hostelge et al., 1998) and GDNF mRNA has been shown to be rapidly up-
regulated in DRG neurons, satellite cells, and in Schwann cells following nerve
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transection (Hammarberg et al., 1996; Bar et al., 1998; Kashiba et al., 1998; Hoke et
al., 2000). GDNF is thought to have a role in normal and injured adult peripheral
nerves. Recently it has been shown that SP levels are increased in cultured DRG
neurons following treatment with exogenous GDNF (Adler, 1999; Ogun-Muyiwa et
al., 1999). It is therefore thought that GDNF, like NGF, might regulate PPT-A
expression at the level of transcription.
In addition to the NGF and GDNF related families of neurotrophins, other
molecules are known to exert trophic effects on DRG and are involved in regulation
of PPT-A gene expression. These include members of the neuropoeitic group of
cytokines, leukemia inhibitory factor (LIF), interleukin-6 (IL-6) and ciliary-derived
neurotrophic factor (CNTF). These proteins have multiple actions on cells of the
nervous system. These include promoting the survival of some neurons (Pennica et
al., 1995; Stahl and Yancopoulos, 1994) and regulating neuropeptide expression in
cultured sympathetic neurons (Nawa et al., 1991; Zigmond and Sun, 1997; Fann and
Paterson, 1994). In addition, LIF is thought to function as a lesion-induced factor
involved in the cell body reaction to axotomy in the sympathetic nervous system
(Sun et al., 1994; Zigmond et al., 1996).
These molecules have been grouped as a family due to partially overlapping
biological activities and are defined by their binding to the common receptor motif
gpl30 transmembrane glycoprotein. Two gpl30 molecules form part of the IL-6
receptor, and one molecule together with another transmembrane glyoprotein termed
the LIF receptor beta subunit (LIFRP) are components of the receptors for LIF and
CNTF. The CNTF and IL-6 receptors are additionally comprised of alpha subunits:
CNTFRa and IL-6Ra (Horton et al., 1998). The LIF, IL-6 and CNTF receptors are
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constitutively associated with the members of the Jak-Tyk family of tyrosine kinases
(Stahl et al., 1994). The first step of the CNTF signalling pathway involves binding
of CNTF to the a-receptor subunit, which promotes association and dimerisation of
two P-receptor subunits. This results in activation of the associated Jak tyrosine
kinases and propagation of the CNTF signal.
LIF and CNTF have overlapping effects (Ip and Yancopoulos, 1992) and in
some cases can elicit similar biological responses to the NGF-related family of
neurotrophins (Mitsumoto et al., 1994), suggesting that the neurotrophin and
cytokine signalling pathways may interact synergistically or may act to antagonise
the effects of neurotrophins. LIF is thought to play a role in regulating neuropeptide
levels in sensory neurons following axotomy and may be an important regulator of
PPT-A gene expression.
Growth factor family Members Receptor
NGF related neurotrophins NGF, BDNF, NT-3, NT-4/5 Trk tryrosine kinases and p75
GDNF-related neurotrophins GDNF, neurturin, persephin,
artemin
Ret tyrosine kinase (signal
transducing domain) plus
member of the GFRa family
(ligand binding domain)
Neuropoeitic cytokines LIF, IL-6, CNTF gp 130 transmembrane
glyoprotein together with
specific receptor subunits for
each factor
Table 1.1: Summary of growth factor families and their receptors that may be involved in the
regulation of PPT-A expression.
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Figure 1,6: Trk signalling pathways. NGF binds to two trk molecules, causing the formation
of a homodimer, which in turn permits each molecule to phosphorylate tyrosine residues on its
partner. Phosphorylation of specific tyrosine residues creates signal binding sites for PI-3 kinase,
PLC-y and She, recruitment of these proteins into a complex and initiation of a signaling cascade.
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1.3.2 Sensory neurons of the DRG
Sensory neurons of the DRG have been broadly divided into two main groups
based on cell body size, termed small diameter dark and large light diameter
population of neurons (table 1.2) (Lawson, 1992; 1996). These groups convey
different types of sensory information. The large diameter neurons are myelinated (A
fibres) and are thought to function as proprioceptors and mechanoreceptors. They
posses cell diameters of greater than 30 pm and can be labelled using antibodies
against the high molecular weight neurofilament protein (NF-H) (Averill et al., 1995;
Molliver et al., 1995). This group comprise 15-20% of all DRG neurons and all
express the NT-3 receptor TrkC (Wright and Snider, 1995).
Small neurons have a cell body diameter of less than 30 pm and are
unmyelinated (C fibres). These are thought to function as nociceptors and can
simplistically be further divided into two groups, those that express neuropeptides
and the non-peptidergic expressing neurons. The peptide containing population
express substance P (SP) and calcitonin gene related peptide (CGRP). These possess
the NGF receptor TrkA and therefore the peptide content of these cells can vary in
response to NGF.
The other subpopulation has been shown to switch its neurotrophin
requirement postnatally from NGF to GDNF (Molliver and Snider, 1997; Molliver et
al., 1997; Bennett et al., 1996; 1998a). Neurons of this group are neurochemically
distinct from the population ofNGF responsive neurons as they do not express
CGRP and SP. This population can be labelled selectively by the isolectin B-4 (IB-4)
and express the enzyme thiamine monophosphatase (TMP) (Averill et al., 1995;
Molliver et al,. 1995, 1997). Virtually all IB4 labelled cells express Ret and GFR-a,
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the receptors for GDNF. (Bennett et al., 1998b). C-ret, the functional receptor for
GDNF, was also found to be present on some of larger, non-nociceptive A fibres
(Flonda et al., 1999).
These three groups define broadly the populations of sensory neurons.
However the situation is much more complex and co-expression studies have
revealed the potential for overlapping populations of marker molecules. In particular,
some studies report that distinct populations express only one Trk receptor (Mu et
al., 1993; Kashiba et al., 1995; Wright and Snider, 1995) whereas others report more
than one Trk receptor to be present in a single neuron (McMahon et al., 1994;
Karchewski et al., 1999). It is believed that the presence of multiple neurotrophin
receptors on a sensory neuron allows it to respond to a variety of neurotrophins. This
exposes the potential for convergent or divergent signalling pathways. In addition,
expression of growth factor receptors can be altered in response to nerve damage
(Krekoski et al., 1996; Cho et al., 1996; Narita et al., 2000) and arthritis (Pezet et al.,
2001) illustrating the complexity and plasticity of these growth factors associated
with DRG neurons.
Properties Class of DRG neuron
1 2 3




Neurotrophin Receptors TrkC mainly





Growth factor responsive BDNF and NT-3 NGF GDNF
Markers Neurofilament CGRP/SP IB-4
Table 1.2: Summary of the broadly defined populations of DRG neurons.
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1.4 Use of adeno-associated virus to investigate transcriptional
regulation of the PPT-A promoter
The studies outlined in section 1.2 have revealed a great deal about the
factors that may be involved in regulating PPT-A promoter activity, however as
discussed previously functional analysis has been difficult. The recent discovery of
cell lines which support the expression of reporter gene constructs directed by the
PPT-A promoter should prove to be a useful tool for investigating PPT-A
transcriptional regulation. However, there is still difficulty with studying promoter
activity in DRG neurons and as described in section 1.2.3, experiments have revealed
there may be differences between the activity of regulatory elements in DRG neurons
and cell lines. Previous experiments investigating promoter activity in DRG neurons
employed the technique ofmicroinjection of plasmid DNA into DRG neurons. This
is extremely time-consuming, laborious and allows the analysis of only a small
number of neurons. In addition, Quinn et al. (2000) suggested that the process of
microinjection might activate stress signal transduction pathways, which may
overlap with those activated by NGF and other growth factors. Recently our group
has used AAV for gene transfer into DRG neurons. These experiments have revealed
that the PPT-A promoter fragment -865 to +92 contains regulatory elements that can
be induced by NGF when the promoter is delivered as a recombinant AAV (rAAV)
particle (Harrison et al., 1999). This result was in stark contrast to the microinjection
data and therefore this model system will be suitable for investigating the effect of
other growth factors described in section 1.3.1 on the PPT-A promoter, in addition to
defining potential transcription regulatory elements.
Interest in the ability to exploit rAAV vectors for gene therapy and
experimental manipulation of the nervous system has encouraged investigation into
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the unique biology of this virus. Understanding the biology ofAAV has provided the
foundations for many developments ofAAV as a DNA delivery vector. Therefore
the biology ofwild-type AAV (wtAAV) will first be outlined before discussing the
work that has focused on improving the rAAV vector system.
1.4.1 Wild-tvpe adeno-associated virus (wtAAV)
Adeno-associated virus (wtAAV) is a member of the parvoviridae family,
which are among the smallest and structurally simplest of the DNA animal viruses.
Parvoviruses are nonenveloped, icosahedral with linear single-stranded genomes of
4.6 - 6 kb. AAV was initially believed to be a defective virus since co-infection with
a helper virus (usually adenovirus or herpes simplex virus) is necessary for
replication and in helper absence AAV may be maintained latently. The helper
functions required for productive infection have been best characterised for
adenovirus coinfection. With the exception of E2b and E3, all of the adenovirus early
functions (Ela, Elb, E2a and E4) contribute to helper function in cell culture and
effect gene expression, both viral and cellular (Richardson and Westphal, 1981).
Cell damage due to chemical mutagens, ultraviolet irradiation and other
cellular insults can also induce lytic life cycle (Yakinoglu et al., 1988; Yakobson et
al., 1987). Five serotypes ofAAV have been identified, the most characterised being
AAV-2.
1.4.2 AAV genetics
The wtAAV genome is 4.7 kb and consists of two open reading frames
(ORFs), the 5' and 3' ORF (figure 1.7). The 5' ORF encodes four regulatory
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proteins, Reps 78, 68, 52 and 40, which are important for gene expression and DNA
replication. The 3' ORF encodes the capsid proteins, Vpl, Vp2 and Vp3. There are
three promoters: two in the 5'ORF at map positions (mp) 5 and 19 (promoters p5 and
p 19 respectively) and one in the 3' ORF at mp 40 (promoter p40). Spliced and
unspliced transcripts initiated from p5 and p 19 are translated to generate all four Rep
proteins. The capsid proteins are translated from a transcript whose promoter is p40
and are generated as a result of alternative mRNA splicing. Vpl is translated from
the minor species and Vp2 and Vp3 from the more abundant mRNA. Vp3 is
translated from the first in-frame initiator codon in the major mRNA species whereas
Vp2 is initiated from an upstream, in-frame ACG codon (Berns, 1990).
An important feature of the AAV genome is the presence of the 145
nucleotide inverted terminal repeats (ITR). The first 125 bases of these can form a T-
shaped hairpin structure that is composed of two small inverted palindromes, flanked
by a larger palindrome. Like the Rep proteins, the ITRs are involved in every step of
the AAV life cycle: regulation of gene expression, regulation ofDNA replication,
site-specific integration and rescue of the genome from the integrated state (Kotin et
ai, 1992; Xiao et al., 1997).
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Figure 1.7 : Genetic map of AAV. Promoter at map position 5 (p5) initiates a transcript which,
unspliced encodes Rep 78 and spliced encodes Rep 68. Promoter pl9 at map position 19 encodes
a transcript that is translated intact, yielding Rep 52 or spliced, to yield Rep 40. p40 initiates all
three capsid mRNAs.Vpl is produced by an alternative splicing event, Vp2 is produced by the
same spliced event used for Rep proteins (Rep 68 and 40). Utilising the same mRNA as Vp3, Vp2
results from using an alternative ACG start codon (front Berns and Linden, 1995).
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1.4.3 AAV productive infection
In the presence of a helper virus, wtAAV undergoes productive infection
(figure 1.8). The virion penetrates to the nucleus of the cell and the virus genome is
uncoated. Two elements are essential for wtAAV DNA replication, the viral origin of
replication that is located within the 145 base terminal repeats and the rep gene.
Mutation analysis has shown that Rep 78 and 68 proteins are essential for replication
(Labow and Berns, 1988) and regulation ofAAV gene expression (Labow et al.,
1986; Beaton et al., 1989). Rep 68/78 has been shown to possess DNA binding, site-
specific endonuclease and helicase activities (Im and Muzyczka, 1990). It is unclear
what roles the smaller proteins Rep 52 and 40 have, although they are thought to
function in virus assembly (Chejanovsky and Carter, 1989). As noted previously, the
function of adenovirus is also necessary for wtAAV replication. In the absence of
adenovirus, Rep 68/78 is a negative regulator ofwtAAV gene expression.
The palindromic ITR can act to initiate DNA replication by forming a hairpin
primer allowing DNA synthesis by a single-stranded displacement mechanism. This
results in the generation of a double-stranded replicative intermediate that is
covalently joined at one end by this palindromic hairpin (Straus et al., 1976). This
structure is then resolved by nicking of the hairpin on the parental strand by Rep
68/78 directly opposite the 3' terminus. The result of this process is to leave a 3' OH
on the parental strand. This then serves as a primer for synthesis to fill in the gap
region and the hairpin sequence is transferred to the daughter strand and can then act
as a template (for review see Berns, 1990).
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1.4.4 AAV latent infection
Under non-permissive conditions, wtAAV may integrate into the host
genome where it is maintained as a latent provirus (figure 1.8). In humans, the
wtAAV genome will preferentially integrate into the q-arm of chromosome 19 at a
site termed AAVS1 (Kotin et al., 1990, 1992; Samulski et al., 1991). The only
homology between the integrated wtAAV DNA and the flanking cellular sequences
is a 1-5 base overlap at the junction. Like DNA replication the process of integration
requires the ITRs and Rep 68/78 (Balague et al., 1997; Surosky et al., 1997). The
ITRs are essentially the only cA-acting elements necessary for integration, however
in the absence of the Rep proteins wtAAV may integrate randomly at low frequency
(Xiao et al., 1997). The mechanism for wtAAV integration is unclear however
models have been proposed (Lindel et al., 1996; Rizzuto et al., 1999; Tsunoda et al.,
2000). It is thought Rep 68/78 can bind a specific site on the ITR of the wtAAV
genome and the AAVS1 site on host DNA. This initiates a complex process whereby
recombination and integration occurs. In the absence of integration wtAAV genomes
may be maintained as head-to-tail concatamer (Duan et al., 1998). An understanding
of the process of integration and rescue of the wtAAV genome will be extremely
important in the generation of future wtAAV vectors.
42
Figure 1.8: Model for AAV infection. Under non-permissive conditions, AAV integrates into
the q-arm of human chromosome 19, where it remains silent until challenged by a helper virus.
This leads to rescue of the integrated viais from the chromosome and induction of the lytic cycle.
Under permissive conditions (in the presence of helper virus), AAV replicates resulting in host
cell lysis.
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1.4.5 AAV receptors and cell entry
Viral receptors are often involved in defining the host range and specific
tissue tropism of a virus. Recently it has been shown that the cell surface heparin
sulphate proteoglycan (HSPG) serves as the primary attachment receptor for wtAAV
(Summerford and Samulski, 1998). Fibroblast growth factor receptor and av(35
integrin have also been implicated as coreceptors or facilitators (Qing et al., 1999;
Summerford et al., 1999).
The mechanism ofwtAAV entry has been examined and a model for wtAAV
infection of cells proposed. Following binding to heparin sulphate receptors on the
cell surface, wtAAV is internalised by endocytosis. This process is mediated by
clathrin coated pits and the avp5 integrin receptor. Virus particles are then released
into the cytosol and translocated to the nucleus where uncoating, replication and gene
expression occurs (Bartlett et al., 2000). A greater understanding of this early step in
wtAAV infection will be important for understanding transduction of different cell
types.
1.4.6 AAV vectors
There are a number of features that make rAAV vectors both an attractive
tool for both neuron-specific expression studies (in vivo and in vitro) and therapeutic
gene delivery. The safety features associated with this viral vector system are often
highlighted in the hope that rAAV may be clinically beneficial for gene delivery,
particularly the fact that rAAV has never been implicated as the causative agent for
disease in humans (Berns and Bohenzky, 1987).
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The methods employed to generate recombinant virus allow the production of
rAAV particles without the risk ofwild-type helper virus contamination (Samulski et
al., 1989) and eliminates the possibility of an immune response caused by viral gene
expression (Yang et al., 1994, 1995; Xiao et al., 1996; Jooss et al., 1998).
Furthermore, rAAV viral particles are very stable, resistant to many physical and
chemical factors such as various detergents, wide range of pH, certain proteases,
repeated freeze-and-thaw cycles and heat denaturation up to 60 °C (Muzyczka,
1992).
wtAAV can infect both dividing and non-dividing cell types and rAAV
vectors have been shown to transduce a variety of cell types. Delivery and long-tem
expression of rAAV vectors has been shown in lung (Flotte et al., 1994; Halbert et
al., 2000), muscle (Xiao et al., 1996; Fisher et al., 1997; Kessler et al., 1996; Clark et
al., 1997), blood (Flerzog et al., 1999; Snyder et al., 1999), cartilage (Pan et al.,
1999), brain (Bosch et al., 2000; Lo et al., 1999; McCrown et al., 1996; Haberman et
al., 1998; Kaplitt et al., 1994) and the peripheral nervous system (Glatzel et al.,
2000).
This ability of rAAV to introduce foreign genes into neuronal cell types is
particularly important from an experimental point of view, allowing accessibility and
manipulation of the PNS and CNS in vivo. This together with the in vitro
transduction of neurons may now allow investigation of the fundamental questions
regarding neuron specific gene expression.
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1.4.7 AAV vector production
wtAAV has several biological properties that would make it a useful vector
for gene therapy therefore there has been increased effort to develop AAV as a
vector. The standard protocol for the production of rAAV vectors involves transient
transfection of HEK293 (human embryonic kidney) cells with an AAV plasmid
substrate and a helper plasmid (Samulski et al., 1989), followed by subsequent
infection with mutant adenovirus type 5, which lacks the Ela and Elb genes, (figure
1.9). The Ela and Elb genes are essential for replication of adenovirus and therefore
the HEK293 cells have been transformed with the adenovirus genes Ela and Elb to
provide these essential products, limiting the growth of adenovirus to the 293 cells.
Many studies employ the rAAV plasmid pSub201 (Samulski et al., 1989) for
the generation of rAAV vectors. Digestion of this plasmid with Xbal removes the
wtAAV Rep and Cap sequences that are replaced by the desired gene but retains the
wtAAV 145 bp ITRs flanking the gene of choice. These ITRs contain the recognition
signals for DNA replication, packaging and integration of rAAV provirus and the
rescue of integrated genomes. To produce the viral vector, the modified pSub201
plasmid is cotransfected with a helper plasmid containing the wtAAV rep and cap
sequences (deleted from the pSub201 construct). This allows the AAV structural
proteins to be provided in trans. Superinfection with adenovirus allows the
replication of rAAV sequences, and single-stranded DNA molecules are then
encapsulated into rAAV particles. rAAV particles are then released from infected
cells by lysis, helper adenovirus particles are inactivated by heat treatment and rAAV
vectors may be further purified by caesium chloride gradients. In this system the
vector virions are free of contamination by wild-type AAV. Since Rep is required for
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site-specific integration, it is uncertain whether rAAV vectors integrate randomly or
mainly persist as episomes.
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Figure 1.9: Standard protocol for the production of rAAV. 293 cells are co-transfected with rAAV helper
plasmid and the AAV plasmid and are then infected with adenovirus. The AAVhelper plasmid pAAV/Ad
provides the AAV genome in trans resulting in adenovirus and rAAV particle production. Both viruses
are released and adenovirus is then inactivated by heating to 56 °C
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1.4.8 Limitations associated with AAV vectors
Although AAV has many positive attributes, there are some limitations
associated with this virus system. One of the main difficulties associated with rAAV
is the production ofAAV preparations that have high titres, since AAV vectors are
technically difficult to generate due to the lack of well-developed packaging cell
lines. Other problems associated with use ofAAV vectors include the size restraints
associated with this system, as the maximum size of insert that can be used is 5 kb. In
addition, the possibility of site-specific integration may be an important
consideration ifAAV vectors are to be used in gene therapy. However, the expansive
research into the life cycle ofAAV and improvements in AAV production are likely
to overcome many of these drawbacks.
1.4.8.1 Improvements in rAAV production
The standard method for rAAV production described above (section 1.4.7)
has formed the basis for generating rAAV vectors as a tool for both in vitro
experiments and for gene therapy studies, however there are some limitations with
producing rAAV vectors in this way. First, the fact that these preparations are
contaminated with helper virus and must be purified leads to losses in the titre of
rAAV. In addition, contamination with wild type AAV and residual adenovirus has
been observed (Wang et al., 1998; Xiao et al., 1998) and this conventional protocol
does not allow convenient large-scale production of vector particles. Therefore much
research has been carried out to generate a system that overcomes these
complications associated with rAAV production.
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Recently, a production system has been developed which allows the
generation of rAAV in the absence of helper adenovirus (Xiao et al., 1998). A helper
plasmid that contains elements of the adenovirus genome was constructed. This
plasmid incorporates the essential helper genes, but lacks the adenovirus structural
and replication genes, therefore is incapable of producing infectious adenovirus
particles. Cotransfection of this adenovirus plasmid, together with the AAV helper
plasmid and AAV packaging substrate, resulted in the generation of high titre rAAV
particles. This approach has eliminated the possibility of unwanted adenovirus
contamination. Other groups have created similar adenovirus helper plasmids
(Matsushita et al., 1998; Salvetti et al., 1998). In addition, chimeric virus vectors
which have AAV sequences together with adenoviral (Fisher et al., 1996; Grimm et
al,. 1998; Lieber et al., 1999) and HSV (Conway et al., 1999) sequences have been
generated. The presence ofAAV and helper sequences on one plasmid eliminates the
need for the cotransfection of several plamids and therefore results in improved
rAAV production and increased titres.
All of these alternative strategies have increased rAAV titre and decreased
helper virus and wild-type AAV contamination. However, they do not allow the
convenient scaling up of rAAV particles. To do this, the use of producer cell lines
should allow bulk production of rAAV particles by overcoming the dependency on a
transfection step. Initial efforts to develop cell lines containing AAV rep and cap
genes was met with modest success and efficiency was poor with maximum rAAV
yields not exceeding those of the basic protocol (Clark et al., 1995; Tamayose et al.,
1996). Although eliminating the transfection step, these cells rely on the over
expression of viral gene products Rep and Cap, which are toxic to cells. To date one
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successful packaging system has been developed (Inque and Russell, 1998) which is
based on inducible amplification of the integrated helper AAV constructs. Rep/Cap
expressing cell lines have recently been used in conjunction with AAV-adenovirus
hybrid vectors where the hybrid vector is used to deliver the rAAV genome to the
packaging cell line in place of plasmid transfection (Gao et al., 1998; Liu et al.,
1999).
1.4.8.2 Size limitations
rAAV vectors have a limited packaging capacity and transgenes to be
delivered must be less than 5 kb and greater that 4.1 kb. Currently strategies are
being explored to expand the AAV packaging capacity. These include the use of
small promoters or promoter activity derived from the AAV ITR (Flotte et al., 1993;
Haberman et al., 2000) and heterodimerization of separate rAAV vectors.
Heterodimerization of separate rAAV vectors takes advantage of a unique
feature ofwtAAV biology that results in head-to-tail concatenation of viral genomes
during double-stranded conversion (Berns, 1996). Persistence of expression from
rAAV vector occurs at least in part from latent AAV proviral DNA exisiting in head-
to-tail concatamers, whether integrated or in nonintegrated circular form (Muzyczka,
1992; Xiao and Samulski, 1996; Duan et al., 1998). Recently three separate groups
have taken advantage of this inherent wtAAV feature and developed a strategy that
bridges the 5' and 3' segments of a split expression construct through paired rAAV
ITRs (Sun et al., 2000; Yan et al., 2000 and Nakai et al., 2000). This means a larger
candidate gene can be split into two parts and separately packaged into two
individual rAAV vectors increasing the packaging capacity ofAAV to 10 kb.
r
1.4.8.3 Strategies to eliminate the risk of insertional mutagenesis
rAAV vectors can integrate into the host genome, unlike wtAAV, it is not
site-specific, and may therefore carry the risk of insertional mutagenesis. rAAV
vectors have all the cA-elements necessary for integration, which can be carried out
by host factors, but targeting is lost in rep-minus constructs (Yang et al., 1997). The
incorporation of a truncated Rep protein into a rAAV vector has been described
recently, with the restoration of integration at the chromosome 19 site in tissue
culture (Rinaudo et al., 2000).
1.4.8.4 Improvements in rAAV aene transfer
Recent insights into wtAAV biology highlight the three main areas to be
addressed to improve rAAV transuction: rAAV interaction with target receptors,
efficient conversion to a double -stranded template and adequate expression from the
rAAV-transgene construct.
Recently attention has been paid to the tropic nature of each of the five
serotypes ofwtAAV in order to improve transduction. The genomes of each of these
wtAAV serotypes are organised similarly, however there is extensive heterogeneity
within the surface exposed regions of capsid structures between the serotypes. This
suggests that each serotype may have a distinct mechanism of cellular uptake
(Chiorini et al., 1999a; 1999b). Transduction efficiencies between serotypes was
shown to differ between cell lines (Chiorini et al., 1999a; 1999b) and regions of the
mammalian brain (Davidson et al., 2000). The elucidation of the mechanism of tissue
tropism observed for the different wtAAV serotypes will contribute to designing
rAAV-specific targeting vectors.
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Other attempts to produce targeted rAAV vectors have focused on modifying
the natural tropism ofwtAAV by using cross-linked monoclonal antibodies to target
wtAAV to antigens on the surface of non-permissive cells (Bartlett et al., 1999) or by
genetically altering the capsid coding region (Girod et al., 1999, Rabinowitz et al.,
1999).
For efficient expression from rAAV vectors, virus must be converted from
monomer single-stranded genome to double-stranded form and increased transgene
expression levels are associated with the appearance of transgene copies in double-
stranded DNA (Vincent-Lacaze et al., 1999; Miao et al., 1998; Malik et al., 2000).
Recently a mechanism for this conversion has been reported and a cellular Tyr
phosphoprotein has been described which binds AAV ITRs and might regulate
synthesis of the complementary strand (Qing et al., 1998). It is thought that strategies
to augment or accelerate the presentation of double-stranded template for
transcription will increase transduction by rAAV vectors (Monahan and Samulski,
2000). High amounts of the dephosphorylated form of this protein have been shown
to correlate with efficient transduction by rAAV (Qing et al., 1998).
Persistence of expression from rAAV vectors depends on the generation of
AAV concatamers and conversion to high molecular weight (HMW) DNA (Xiao et
al., 1996; Vincent-Lacaze et al., 1999). It is unclear why this is the case but an
understanding of this would be extremely useful for ensuring long-term expression
from rAAV vectors.
Long-term expression of transgenes has been increased by the addition of a
post-transcriptional regulatory element. The woodchuck hepatitis virus
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posttranscriptional regulatory element (WPRE) was shown to enhance the expression
of a GFP reporter gene when delivered by a rAAV vector (Loeb et al., 1999).
1.4.8.5. Improvements in rAAV purification
Improvements in virion purification have also been addressed. Purification of
rAAV was initially performed by centrifugation over CsCl gradients, however this
cumbersome technique yields preparations with a considerable amount of
contaminating non-viral proteins and a high ratio of genome copies verses infectious
units. Given that heparin sulphate proteoglycan is known to serve as the viral
receptor for wtAAV, a heparin sulphate (HS) affinity column was used for rAAV
purification (Clark et al., 1999; Anderson et al., 2000; Auricchio et al., 2001). These
commercially available HS affinity columns can be used to rapidly concentrate and
purify rAAV from crude cell lysate. Other groups have used the technique of high
performance liquid chromatography (HPLC) to successfully purify rAAV vectors
(Zolotukhin et al., 1999; Gao et al., 2000).
1.4.9 Titration of rAAV vectors
Reliable titration of rAAV is crucial for the planning and execution of
preclinical and clinical studies and for the comparison of results between
laboratories. A wide range of rAAV titres has been reported and this is due to
differences between production protocols and how titres are measured and defined.
The titre of rAAV can be determined by semiquantitative PCR (Miller et al., 1994),
quantitative real-time PCR (Sanburn and Cornetta, 1999), Southern blot (Russell et
al, 1994) or by DNA dot blot (Flotte et al., 1995) following DNase digestion of
54
unpackaged rAAV plasmids in vector stocks. These techniques define the number of
virions containing the rAAV virion regardless of infectivity or functionality.
rAAV titres can also be determined by the replication centre assay
(McLaughlin et al., 1988; Yakobson et al., 1987). This technique involves the
infection of cells with rAAV together with wild-type AAV and adenovirus. The
presence ofwtAAV and adenovirus provides the necessary functions for the rAAV
vector DNA to amplify within the cells. The number of cells containing amplified
rAAV is determined by transferring cells onto a nylon membrane and probing with
radiolabelled rAAV-specific DNA. Each dot on the autoradiograph represents one
rAAV infected cell and therefore reflects the number of infectious and replication
competent rAAV particles. This protocol has been modified by Salvetti et al. (1998)
to employ a stable cell line, which expresses AAV Rep and Cap proteins. This means
co-infection with wtAAV is no longer required.
rAAV vectors are also described as the number of transducing particles. This
refers to the titre obtained by rAAV functional assays such as the number ofGFP
positive cells produced by rAAV-GFP virus from the GFP reporter gene expression.
1.4,10 Other defective viral vectors for transduction of neurons
Other than AAV, adenovirus (Ad) and herpes simplex virus (HSV) have been
also used to create recombinant vectors for the transduction of neurons. Like AAV,
Ad and HSV can infect post-mitotic terminally differentiated cells. Retroviruses
require target cells that are undergoing cell division for genome integration and
expression (Miller et al., 1990) therefore neurons cannot be transduced. However,
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recently non-pathogenic retroviral vectors based on lentivirus have been developed
and these have the ability to infect non-dividing cells.
1.4.10.1 Adenovirus (Ad) vectors
Adenovirus is a non-enveloped virus with a genome of 36 kb, which
possesses the ability to infect both dividing and non-dividing cells. The genomic
region El is deleted in adenoviral vectors (for review see Kaplitt and Makimura,
1997). This encodes the main transactivator ofAd gene regulation, therefore deletion
renders Ad-vectors replication deficient. This El region is complemented in trans to
replicate the vector. This is achieved by means of the 293 cell line, which is stably
transformed by the adenovirus El region (Hitt et al., 1995). To allow the insertion of
larger fragments of foreign DNA (up to 35 kb),'gutless' Ad-vectors have been
generated. These contain only the ITRs, which are necessary for DNA replication,
and the encapsidation signal. The other viral proteins are provided in trans by helper
virus (Parks et al., 1996; Parks and Graham, 1997). Once cells are transduced by Ad,
the viral genome exists in an episomal state. Adenovirus vectors can be generated
free of contaminant replication-competent virus at very high titres, and can infect
both dividing and non-dividing cell. The ability to package large amounts ofDNA is
another of the major advantages associated with Ad-vectors, together with the fact
that Ad does not integrate into the host genome therefore avoiding the risk of
insertional mutagenesis. In addition, the biology ofAd virus is well known, there is a
wide range of adenoviral systems available and Ad is easy to manipulate (Hitt et al.,
1995).
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Disadvantages associated with Ad include high immunogenicity, which
elicits inflammation and strong host immune responses to expressed viral antigens
(Barkats et ah, 1998; Kozarsky and Wilson, 1993; Lawrence et ah, 1999), toxicity at
high titres and the inability to sustain long-term expression of transgene. So far, a
maximum of four months has been achieved (Geddes et ah, 1997; Stein et al, 1999).
1.4.10.2 Herpes Simplex virus-1 (HSV-1) vectors
HSV-1 is a double stranded virus with an envelope derived from the host cell
and can form a lytic infection or enter a latent state in neurons. Three types ofHSV-1
vectors are currently in use: amplicons, replication defective and replication
competent vectors (for review see Latchman, 1999; Simonato et ah, 2000). The
amplicons are plasmid derived vectors containing both an HSV and E. coli origin of
replication, together with HSV packaging recognition signals. These plasmids are
grown in E. coli and transfected into cell lines together with an HSV-1 bacterial
artificial chromosome to provide helper functions (Stavropoulos and Strathdee,
1998). The primary advantage of these vectors is that they are easy to construct and
multiple copies of the transgene can be delivered to neurons within each viral capsid,
however the size of transgene is limited to 10 kb.
Replication defective vectors are made ofmutant viruses with deletions in
one or more genes essential for the lytic cycle. These can only grow in
complementing cell lines, which provide the missing function. Deletion of all
immediate early genes prevents virus toxicity for cells at high multiplicity of
infection, which allows the vector to persist in cells for long periods (Marconi et ah,
1996).
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Replication competent vectors are composed of attenuated viruses where
genes that are not essential for replication in cultured cells are mutated or deleted.
The removed genes could be important for the viral cycle in the natural host in vivo
and could contribute to neuropathogenicity (McMenamin et al., 1998). However
these vectors elicit a strong cytotoxic immune response and wild-type reverents arise
with a relatively high frequency during vector preparation and contaminate viral
stocks with replication-competent viruses.
1.4.10.3 Lentivirus vectors
Lentivirus vectors are derived from a group of highly pathogenic retroviruses
which includes the HIV viruses (for review see Lever et al., 1999; Buchschacher and
Wong-Staal, 2000). They have a large cloning capacity of at least 9 kb and are stably
integrated into the genome of target cells. Most of the efforts so far have focused on
the development of efficient vector systems based on the HIV-1 virus. In the current
versions ofHIV-1 based lentivirus vectors, five or six of the nine HIV-1 genes are
eliminated (Zuffrey et al., 1997). The viral particles are generated by transient
transfection of cells with three or four different plasmids. This reduces the risk of
recombination events that may lead to the generation of an infectious, replication-
competent retrovirus (Zuffrey et al., 1997). In addition, these HIV-1 vectors are
psuedotyped with the G envelope protein of the vesicular stomatitis virus (VSV-G)
which allows the vector to infect a broad range of tissues (Dull et al., 1998).
The use of lentivirus vectors raises a number of important safety issues that would
have to be solved before these vectors could be considered for routine use and for
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clinical application. In addition, the biology and the mechanism of pathogenesis of
lentiviruses are unclear, making this a difficult system to work with.
1.5 Summary
The aim of this study was to investigate transcriptional regulation of the PPT-A
gene promoter in cultured DRG neurons. This was achieved by using rAAV vectors
for the transduction of DRG neurons. DRG cultures are highly heterogenous and the
modulation of different neuronal populations and PPT-A gene expression by
individual growth factors is an extremely complex area. Therefore the cell types that
are present in DRG cultures was initially established to ensure these cultures would
be a suitable model system for these studies. As described in section 1.4.8, improved
methods for the generation of rAAV vectors has been the focus ofmuch research.
Using certain reagents that became available over the course of this thesis, AAV
vector production was first optimised to a standard suitable for the routine infection
of DRG cultures. This allowed the cell types that were transduced by rAAV to be
established before investigating transcriptional regulation of the PPT-A promoter.
Functional analysis of the PPT-A promoter was achieved by generating a series of
AAV vectors, which contained different fragments of the PPT-A promoter driving
the luciferase reporter gene. The activity of these deletion constructs was examined
in both cultured DRG neurons from adult and neonate rats. In addition, the effect of
growth factors on the PPT-A promoter fragment (spanning nucleotides -865 to +92)
was examined in adult DRG neurons. It was hoped that these experiments would lead
to a greater understanding of tissue specific and inducible expression of the PPT-A
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promoter in DRG neurons and generate an appropriate model system for future
studies in this area.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Materials
2.1.1 Commonly used solutions and reagents
6 x agarose gel loading buffer 0.25% (w/v) bromophenol blue, 0.25% (w/v)
Xylene cyanol, 1 mM EDTA, 30% glycerol.
TAE ImM EDTA, 0.04 M Tris-acetate
TE 10 mM Tris-HCl (pH 8.0), 1 mM EDTA.
TN 20 mM Tris-HCl, 150 mM NaCl.
L-Broth 10g/l tryptone, 5g/l yeast extract, 5g/l NaCl.
L-Agar
L-Agar plates
L-broth to which 1% bacto-agar was added.
L-agar was autoclaved and left to cool to room
temperature. Ampicillin was added to the agar
at a final concentration of 0.1 mg/ml before
pouring into plates and leaving to set at room
temperature. Once set, plates were used or
stored at 4 °C for upto two weeks.
Amplicillin A stock of ampicillin was made up at 100
mg/ml and stored at -20 °C.
SOC medium L-broth plus 10 mM glucose, 10 mM MgS04,
20 mM MgCl2.
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PBS 137 mM NaCl, 0.2 M NaH2P04.H20,
0.02 M EDTA (pH 7.4).
Collagenase/dispase Stocks of collagenase/dispase were made up at
1.25% in PBS and stored at -20 °C
Poly-D-ornithine Stocks were made up at 10 mg/ml in 0.15 M
borate buffer and stored at -20 °C
2.1.2 Plasmids
A series of plasmids have been constructed from previous studies in this
laboratory (table 2.1). These have either been used for the generation of subsequent




pGl-pPPTcDNA Protein coding regions of cDNA encoding P-PPT
cloned into BamHI site ofpGEMl (Promega)
MacDonald et al.,
1988
pSnaBl-stuffer 3277 bp Hindlll-SnaBI(blunt) fragment ofMHV-68
cloned with 464bp EcoRV(blunt)-SalI fragment from
pATT153 (described in Sambrook et al., 1989) into
Hindlll-Sall backbone of pG13 basic (Promega)
Harrison et al.,
1999
pSub201 Infectious clone ofAAV type 2 DNA Samulski et al.,
1987; 1989
pG13-865+447-LUC 1362 bp KpnI-Hindlll fragment (encoding -865 to
+447 of the rPPT gene relative to trasncriptional start




pG13-865+92-LUC 993 bp KpnI-Hindlll fragment (encoding -865 to +92
of the rPPT gene relative to the major transcriptional




pG13-47+92-LUC 190 bp KpnI-Hindlll fragment (encoding -47 to +92
of the rPPT gene relative to the major transcriptional







Corresponds to the luciferase plasmids described
above except luciferase ORF (Ncol-Xbal) of the
pG13 plasids was replaced by an EGFP ORF (Ncol-
Xbal) from pEGFP-N 1 (Clonetech)
Generated by Dr.
P. Harrison
pG13-CMV-LUC 877 bp Bglll-Hindlll fragment of pCDNA3
(InVitrogen) carrying the CMV promoter cloned into
the Bglll-Hindlll sites of pG13basic (Promega)
Generated by Dr.
P. Harrison




pVL30 PPT promoter spanning base pairs -671 to 92 driving
CAT reporter gene
From Dr. J. Quinn
pVL31 PPT promoter spanning base pairs -484 to +92
driving CAT reporter gene. This was originally
described as promoter fragment —^431 +92.
From Dr. J. Quinn
pVL32 PPT promoter spanning base pairs -271 to +92
driving CAT reporter gene This was originally
described as promoter region spanning -345 +92.
From Dr. J. Quinn
p22mut Mutant PPT promoter spanning base pairs -865+92
driving the CAT reporter gene in which BamElI











Recombinant AAV plasmid, which contains the
corresponding promoter and reporter described
above. Promoter and reporter DNA fragment were
first inserted into pSnaBlstuffer plasmids to
introduce extra DNA, then inserted into the Xbal
sites ofplasmid pSub201 to replace AAV genome.
Harrison et al.,
1999
Table 2.1: Series of plasmids provided for the purpose of this study.
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2.2 Methods
2.2.1 Agarose gel electrophoresis
1% (w/v) agarose (Ultrapure agarose, GibcoBRL) was used to separate DNA
fragments 7 kb to 0.5 kb and 2% agarose used to separate DNA fragments 0.5 kb to
0.1 kb. Either 100 ml or 25 ml 1 x TAE agarose gels containing 0.3 pg/ml ethidium
bromide were used and placed in the appropriate gel electrophoresis apparatus
(Hybaid Easi-E cast midi and mini gel electrophoresis equipment). A sufficient
amount of 1 x TAE buffer was used to cover the gel. Samples were loaded in loading
buffer and gels usually electrophoresed at 60 mV for as long as required to achieve
separation ofDNA fragments. DNA fragments were visualised using a long wave
UV transilluminator.
2.2.2 Cloning and DNA techniques
2.2.2.1 Restriction enzyme digests
Typically, restriction digest reactions were carried out using 1 unit of
restiction enzyme (NEB) per lpg ofDNA, 1 x reaction buffer (as specified by the
manufacturer), 100 pg/ml BSA and dH20 to the required volume. Reaction mixtures
were incubated at 37 °C for 1 h. Digested DNA was visualised after agarose gel
electrophoresis (section 2.2.1.). 0.2 - 0.5 pg ofDNA was usually used for diagnostic
digestions in a reaction volume of 20 pi. 1 - 1.5 pg DNA in a final volume of 50 pi
was used in restriction enzyme digests for subcloning purposes.
DNA molecular weight markers used were 1 kb marker (GibcoBRL; 15615-
616) which gave 23 fragment sizes ranging from 75 bp to 1.2 kb [75, 134, 154, 201,
64
220, 298, 344, 396, 506, 517, 1018, 1636, 2036, 3056, 4072, 5090, 6108, 7126, 8144,
9162, 10180, 11198, 12216 bp]. X Hindlll/EcoRI DNA marker (GibcoBRL; 15612-
013) was also used. Fragments ranged from 0.5 to 21 kb [125, 564, 831, 947, 1375,
1584, 1904, 2027, 3530, 4268, 4973, 5148, 21226 bp],
2.2.2.2 DNA ligation
Ligation reactions were carried out using 1 unit ofT4 DNA ligase (Roche;
481220), 1 x ligation buffer (0.05 M Tris-Cl, pH 7.6, 10 mM MgCl2, 10 mM
dithiothreitol, 50 pg/ml BSA) and a 1:3 molar ratio of vector DNA:insert DNA (10 -
50 ng DNA), in a final volume of 10 pi. Ligation reactions were incubated at
14 °C for 16 h.
2.2.2.3 Purification of DNA from agarose gels
Digested DNA products were run on an agarose gel (section 2.2.1) for the
appropriate time required to separate the DNA fragments. After visualising on the
UV transilluminator, gel slices containing the DNA fragments of interest were
excised using a clean scalpel blade. Gel slices were placed in a 1.5 ml eppendorf and
purified using the QIAEXII gel extraction kit (Qiagen) according to manufacturers
instructions. Briefly, gel slices were incubated in 800 pi Buffer QX1 and 15 pi of
QIAEXII suspension and heated at 56 °C for 10 min to dissolve the agarose gel.
This solution was then vortexed and centrifuged at 10000 rpm for 30 sec. The
supernatant was removed and the suspension containing the DNA fragment was
washed twice with Buffer PE. The DNA was then eluted from the QIAEXII
suspension by resuspending it in 20-50 pi of TE. This was then centrifuged at 10000
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rpmn for 30 sec and the supernatant containing the DNA fragment was transferred to
a fresh eppendorf tube.
2.2.2.4 Production of blunt-ended DNA fragments
Following gel extraction, DNA fragments were treated with Klenow enzyme
(NEB) to fill in the recessed 3' termini created by restriction enzyme digestion.
Typically, 3 units of klenow enzyme per 100 ng ofDNA was used, together with 33
pM dNTPs, 1 x klenow buffer (0.05 M Tris-Cl, pH 7.6, 0.01 M MgCl2) and dH20 to
the required final volume. Reaction mixtures were incubated at 25 °C for 15 min,
then klenow was heat inactivated by incubating at 75 °C for 20 min.
2.2.2.5 Transformation of competent Escherichia coli (E.coli)
Commercially bought INVaF One Shot™(InVitrogen) competent cells were
used for all transformations. Cells were thawed on ice and 2 pi 0.5M p-
mercatoethanol added to each 50 pi aliquot of cells. 1-5 pi or 10 ng of ligation
reaction was added directly to the cells, mixed by stirring gently and incubated on ice
for 30 min. Cells were heat shocked for 30 sec at 42 °C and placed on ice for 2 min.
200 pi SOC medium was added to each vial and cells shaken horizontally at 37 °C
for 1 h at 200 rpm. The entire transformation mix was spread on LB agar plates
containing 100 pg/ml ampicillin or kanamycin. Plates were inverted and placed in a
37 °C incubator for approximately 18 h. Colonies that grew on the selective media
were picked for mini-prep analysis.
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2.2.2.6 Mini-prep analysis of transformed E. coli colonies
Single bacterial colonies were picked from freshly transformed plates,
inoculated into 5 ml of LB containing the appropriate selective agent and grown for
12 - 16 h. Mini-prep DNA was prepared using QIAprep spin miniprep kit (Qiagen),
according to manufacturers instructions. The Qiagen plasmid protocols are based on
a modified alkaline lysis procedure, followed by binding of plasmid DNA to a
Qiagen anion-exchange resin under the appropriate low salt and pH conditions.
RNA, protein and low molecular weight impurities are then removed by a medium-
salt wash.
Briefly, bacterial cells were harvested by centrifuging at 5000 rpm for 2 min
and resuspended in 250 pi Buffer PI. 250 pi Buffer P2 was then added, followed by
the addition of 350 pi Buffer N3. The solution was then centrifuged for 10 min and
the supernatant applied to a QIAprep colummn. This was centrifuged at 10,000 rpm
for 30 sec and the flow-through discarded. The QIAprep spin column was washed by
addition of 750 pi buffer PE, followed by centrifugation at 10,000 rpm for 30 sec and
the flow-through discarded. The QIAprep column was then placed in a clean 1.5 ml
microfuge tube and DNA was eluted by the addition of 50 pi Buffer EB (10 mM
Tris-CL, pH 8.5) and centrifugation at 10,000 rpm for 1 min.
2.2.2.7 Large scale preparation of plasmid DNA
Single bacterial colonies were picked from freshly streaked selective plates
and inoculated in 5 ml LB medium containing the appropriate selective antibiotic.
Bacterial cultures were incubated at 37 °C for 8 - 12 h with vigorous shaking and
then added to 100 or 250 ml LB selective medium, depending on whether the
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plasmid was high or low copy number and grown at 37 °C for 16 h. DNA was then
prepared using the QIAfilter maxi prep kit (Qiagen), according to instructions. The
theory and process is similar to that of Qiagen miniprep DNA preparations described
above (section 2.2.2.6) but on a larger scale and following elution, maxi-prep
plasmid DNA is concentrated by isopropanol precipitation and purified by ethanol
wash.
2.2.2.8 Polymerase chain reaction (PCR)
PCR reactions were carried out using 10 ng of template DNA, 100 ng of each
oligonucleotide, 200 pM dATP, dCTP, dGTP and dTTP, 2 units of Taq polymerase
(Roche; 1647679) and 1 x PCR buffer (50 mM KC1, 10 mM Tris-Hcl, pH 8.3, 1.5
mM MgCb, 0.01% gelatin). Typically, 40 cycles of PCR (30 s 94 °C, 30 s 60 °C, 1
min 72 °C) were performed and polymerisation was continued for a further 5 min at
72 °C at the end of the last cycle.
2.2.2.9 DNA sequencing
All DNA sequencing of plasmid DNA was carried out by Mr. Ian Bennet by
automated sequencing using a LI-COR DNA sequencer model 4000C (MXG-
Biotech).
2.2.3 rAAV plasmid contruction: rPPT promoter constructs
2.2.3.1 PPT deletion constructs
rAAV plasmids containing varying lengths of the PPT promoter driving the
luciferase reporter gene were used in this study. Plamids pSub201-865+447-LUC,
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pSub201-865+92-LUC and pSub201-47+92-LUC were a gift from Dr. Patrick
Harrison and the other deletion constructs pSub201-671+92-LUC, pSub201-484+92-
LUC and pSub201-270+92-LUC were generated as follows. pSub201-270+92-LUC
(originally described as incorporating promoter fragment -345+92, however was
found to actually span -270 to +92 bp) was produced by three cloning steps. The
BamHI-Hindlll PPT-A 362 bp promoter fragment spanning base pairs-270+92 from
plasmid pVL32 (from Dr. J. Quinn) was inserted into the Bglll-Hindlll sites of
pGL3basic (Promega) to create plasmid pG13-270+92-LUC. pG13-270+92-LUC was
subsequently digested with Mlul-H3 and this 400 bp DNA fragment ligated to the
Mlul-H3 backbone ofpSnaBl-60mut-LUC (section 2.2.3.2) to generate pSnaBl-
270+92-LUC. Finally, pSnaBl-270+92-LUC was digested with Nhel and this 4.3 kb
fragment was inserted into pSub201-XbaI backbone to replace the AAV genome.
pSub201-484+92-LUC (originally described as incorporating promoter
fragment -431+92, however was found to actually span -484 to +92 bp) and
pSub201-671+92-LUC were generated in exactly same way as pSub201-270+92-
LUC described above. The promoter fragment -484+92 was obtained from plasmid
pVL31 and fragment -671+92 from pVL30 (both from Dr. J. Quinn).
2.2.3.2 PPT mutant constructs
Plasmid pSub201-60mut-LUC was generated by a number of steps. The PPT
promoter fragment spanning base pairs -865+92, which contains a mutation at base
pair -60 (E box sited disrupted by the insertion of oligonucleotide containing a
BamHI site) was removed from plasmid p22mut (Paterson et al., 1995b) by digestion
with Sail and Hindlll. This fragment was ligated to the Xhol-Hindlll digested
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backbone of pGL3basic (Promega) to generate plasmid pGL3-60mut-LUC. The
Mlul-Hindlll 2.9 kb fragment from pGL3-60mut-LUC containing the PPT promoter
and luciferase reporter gene was inserted into the Mlul-Xhol digested pSnaBlstuffer
backbone. This resulting plasmid, termed pSnaBl-60mut-LUC was then digested
with Nhel and the 4.65 kb fragment ligated to pSub201-XbaI backbone to generate
pSub201-60mut-LUC.
2.2.4 rAAV plasmid construction: PPT cDNA expression constructs
2.2.4.1 Generation of plasmids pSub201-CMV-pPPT/pSub201-865+92-PPT
Plasmid pSub201-CMV-PPPT was produced in order to generate a
recombinant AAV vector expressing PPT cDNA and therefore gene products SP and
NKA. This required 3 separate cloning steps: The Hind III -EcoRI (blunt) 560 bp
P-PPT cDNA fragment from plasmid pGl-P-PPT (gift from Dr. G. McGregor),
which has been previously described (MacDonald et al., 1988), was inserted into the
Hindlll-Xbal (blunt) backbone of plasmid pGL3-CMV-LUC. The resulting plasmid,
pGL3-CMV-pPPT was digested with NotI and Eco47III and ligated to the NotI- Nsil
(blunt) digested plasmid pSnaBl-stuffer. Finally, pSub201 was digested with Xbal to
remove the entire AAV genome, leaving only the terminal repeats. The CMV-PPPT
cassette containing stuffer DNA was isolated from pSnaBl-CMV-pPPT by digestion
with Nhel and inserted into the Xbal digested pSub201, generating plasmid
pSub201 -CMV-pPPT.
Plasmid pSub201-865+92-PPT was produced in the same way as pSub201-
CMV-PPT as described above except plasmid pG13-865+92-LUC was used in the
70
initial step whereby the PPT cDNA replaced the luciferase ORF. Subsequent steps
were as described above for pSub201-CMV-PPT production.
2.2.4.2 Amplification of pSub201-CMV-(3PPT by PCR for generation of
pSub201- CMV-f3PPTAexon 3
Two separate PCR reactions were carried out to amplify the regions upstream
and downstream of PPPT cDNA. Oligonucleotides (synthesised by MWG biotech)
for PCR reaction (1) were 5' GGT CTA TAT AAG CAG AGC TCT C 3' (termed
cdnamutl: corresponding to a region in the CMV promoter in plasmid pSub201-
CMV-pPPT, upstream ofPPT cDNA) and 5' C AAA GGG CTC ATG CAT TGC
CT 3' (termed cdnamut2: corresponding to region in exon 3- base pairs 159 to 138 of
PPT cDNA. The highlighted bases have been introduced to allow the incorporation
of an Nsil site).
PCR reaction (2) employed oligonucleotides 5' T GGA TTA ATG CAT AAA
CGG GAT G 3' (cdnamut3: complementary to region at exon3/intron3 boundary,
base pairs 200 to 220 of PPT cDNA sequence. Highlighted bases will incorporate an
Nsil site into the sequence), and oligonucleotide 5' TCC CTC TGC CAG TTA CTC
CT 3' (cdnamut4: complementary to region in stuffer fragment of pSub201-CMV-
PPPT, approximately 1.5 kb downstream of PPT cDNA).
Both reactions contained 10 ng of plasmid pSub201-CMV-pPPT and PCR was
carried out as described in section 2.2.2.8. PCR products (1) and (2) were analysed
by 2% and 1% agarose gels, respectively (section 2.2.1). Amplification of PPT
fragment (1) using primers cdnamutl and cdnamut2 resulted in a 450 bp product, and
PPT fragment (2) using primers 3 and 4 produced a 1.7 kb fragment.
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2.2.4.3 Cloning of PCR fragments (11 and (2) for the generation of pSub201
-CMV-PPTAexon3 and pSub201-865+92-PPTAexon3
PCR products PPT (1) and (2) (section 2.2.4.2) were cleaved with Nsil,
agarose gel extracted (section 2.2.2.3) and ligated to the TA cloning vector pCRII
(InVitrogen) (section 2.2.2.2). This involved a '3-way' ligation whereby PCR
products PPT (1) and (2) ligated at the Nsil site and the A overhangs 5' and 3' in PCR
products (1) and (2) respectively, allowed insertion into the TA cloning vector pCRII
(InVitrogen). The resulting plasmid, pCRII-pPPTAexon3 contained the PPT cDNA
sequence which lacked exon 3. This was confirmed by restriction digestion (section
2.2.1) and sequence analysis (section 2.2.2.9).
PCRII-PPPT cDNA was then digested with Hindlll-Fsel and the mutated PPT
cDNA fragment was inserted into Hindlll-Fsel digested plasmids pSub201-CMV-
PPPT and pSub201-865+92-pPPT backbone to replace wild-type sequence. The
presence of the mutant sequence was confirmed by restriction enzyme digest analysis
(section 2.2.2.1). Plasmids were termed pSub201-CMV-pPPTAexon3 and pSub201-
865+92-pPPTAexon3.
2.2.5 Determination of functional expression from AAV-CMV/-865+92-
PPTcDNA particles
2.2.5.1 RNA extraction
Before constructs pSub201-CMV-pPPT and pSub201-865+92-pPPT were
used for the generation of iAAV particles, it was necessary to ensure that they were
functional and expressing PPT mRNA. BHK cells were transfected with plasmids
pSub201 -CMV-pPPT and pSub201-865+92-pPPT (section 2.2.6.2) and RT-PCR
performed. Total RNA was isolated from cells using RNAazol B (Biogenesis). Cells
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were washed once with PBS and 0.5 ml of RNAazol was added per 35 mm dish
containing approximately 0.5 - 1 x 106 cells. The cell lysate was resuspended by
passing through a pipette several times and transferring to a 1.5 ml eppendorf. 100 pi
of chloroform was added per 1 ml of homogenate, samples were shaken vigorously
and centrifuged at 12,000 rpm for 15 min at 4 °C. The aqueous layer was transferred
into a fresh eppendorf and an equal volume of isopropanol was added. Samples were
centrifuged at 12,000 rpm for 15 min at 4 °C and the supernatant removed. The RNA
pellet was washed with 75% ethanol and centrifuged at 8000 rpm for 8 min at 4 °C.
The pellet was dissolved in 160 pi ImM EDTA and ethanol precipitated: 40 pi of 1
M NaCl was added together with 200 pi of 100% ethanol. Samples were incubated at
-20 °C for at least 2 h. Samples were then centrifuged at 8,000 rpm for 20 min at 4
°C and RNA pellets resuspended in 20 pi 1 mM EDTA.
2.2.5.2 Reverse transcription-PCR
Single-stranded cDNA was produced using the Promega reverse transcription
system, containing oligo (dT) primers which allows amplification of poly (A) mRNA
only. Each reaction mix contained 5 mM MgCl2, 1 x reverse transcription buffer, 1
mM each dNTP, 1 unit/pl Recombinant Rnasin Ribonuclease inhibitor, 15 units/pl
AMV reverse transcriptase, 0.5 pg oligo(dT)15 primer per 1 pg ofRNA and 2 pg
RNA. Samples were incubated at 42 °C for 30 min, then heated at 99 °C for 5 min to
inactivate the enzyme. This was followed by a 5 min incubation at 4 °C. The cDNA
reaction was suitable to use directly in PCR reactions. Each PCR reaction contained
20 pi (< 1 pg of first-strand cDNA reaction), 2 mM MgCh (with contribution from
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first-strand cDNA synthesis reaction), 1 x reverse transcription buffer, 200 pM
dNTPs (contributed from reverse transcription reaction) and 50 pmol of each primer
PPTprl (5' AGAATTCAACATGAAAATCCTCGTG 3') and PPTpr2 (5'
ATCTCCATCTGTGTCATGGAGAT 3'). These primers correspond to regions in
exon 2 and exon 7 of the PPT cDNA, respectively. PCR reactions were performed as
described in section 2.2.2.8.
2,2.5.3 Determination of SP protein expression from AAV-CMV-PPT cDNA
AAV-CMV-PPTcDNA was generated from plasmid pSub201-CMV-PPT by
Genethon (section 2.2.9.7). Cultured adult DRG neurons were grown on 9 mm
6 6 7
coverslips and infected with 0, 1x10 ,5x10 and 1x10 infectious virus particles of
rAAV-CMV-PPT (section 2.2.9.1). Seven days post-infection cells were fixed with
4% paraformaldehyde at RT for 10 min and immunostained for SP expression
(section 2.2.7).
2.2.6 Cell culture techniques
2.2.6.1 Cell culture growth medium
Human 293 cells (originally derived from human embryonic kidney cells
transformed with adenovirus type 5 Ela and Elb genes) were a gift from Dr. P.
Harrison (Cellular Physiology Research Unit, University College Cork, Cork,
Ireland). HeLa human cervical carcinoma cells were obtained from Dr. K. Chapman
(Dept. Molecular Medicine, MRC, University ofEdinburgh, UK) and HeLaRC
(derived from HeLa cells transformed with the AAV rep and cap genes) from Dr. P.
Moullier (University ofNantes, France). These cells were maintained in minimum
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essential medium (MEM) containing Earle's salts (GibcoBRL) supplemented with
nonessential amino acids (NEAA) (GibcoBRL), 50 units penicillin and 50 pg/ml
streptomycin and 10% foetal calf serum (FCS). Baby hamster kidney (BHK) cells
were obtained from Miss D. Allan (Dept. Vet. Pathology, University of Edinburgh,
UK) and grown in GMEM (Glasgow's modified Eagle's medium) supplemented
with 10% new born calf serum (NBCS), 10% tryptose phosphate (GibcoBRL), 2 mM
L-Glutamine, 50 units/ml pennicillin and 50 pg/ml streptomycin. All cell types were
maintained at 37 °C in a 10%CO2/air atmosphere.
2.2.6.2 Transfection of BHK cells
BHK cells were transfected by electroporation in normal growth medium
supplemented with 0.5% NBCS using EquiBio EasyjectPlus gene pulser apparatus.
Approximately 0.5-lxl06 cells, together with 10 pg ofDNA construct were
electroporated at 600 V/ 1050 pF. Each electroporation was then plated on a 35 mm
tissue cultures dish. Cells were harvested 48 h post-transfection.
2.2.6.3 Transfection of 293 cells
For the purpose of determining the optimal method for transfection of 293
cells, several techniques were performed. In each case, cells were seeded out at
approximately 3 x 105 cells per well in 6 well tissue culture dishes, 24 h prior to
transfection. In all protocols described below, cells were harvested 48 h post-
transfection.
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2.2.6.3.1 Polvethylenamine (PEI) mediated transfection
Different ratios of a 10 mM monomer solution of polyethylenamine (PEI)
(Aldrich; 40,872-7) (Boussif et al., 1995) and DNA were used for the transfection of
293 cells as the correct ratio is crucial for efficient transfection. 4pg and 8 pg of
pSub201-CMV-LUC were diluted in 50 pi 150 mM NaCl. Increasing amounts (2, 6,
10, 15 pi) of PEI were also dissolved in 50 pi 150mM. 50 pi DNA was added to 50
pi PEI and incubated at RT for 10 min. 1.5 ml fresh medium was added to each well
and the DNA/PEI mix was added dropwise to the cells. Fresh medium was added 2 h
after transfection.
2.2.6.3.2 Calcium phosphate-mediated transfection
Cells were transfected by calcium phosphate (Sambrook et al., 1989) as
follows. Increasing amounts of plasmid pSub201-CMV-LUC (1, 2.5, 5 and 10 pg)
were dissolved in a total volume of 1 lOpl TE. 110 pi DNA was added to 125 pi HBS
buffer (50 mM HEPES, 280 mM NaCl, and 1.5 mM Na2HPC>4, pH7.12) and mixed
well. 15.5 pi 2.5 M CaCb was then slowly added to the DNA/HBS mixture whilst
vortexing gently. This was incubated at RT for 30 min before adding dropwise to the
cells. After 6 h of transfection, the medium was replaced with complete medium.
2.2.6.3.3. Effectene reagent- mediated transfection
Cells were transfected using Effectene reagent (Qiagen) according to the
manufacturer's instructions. To determine the optimal conditions for transfection by
Effectene, 0.5 pg and 1 pg pSub201-CMV-LUC were added to buffer EB to a total
volume of 100 pi. 4 and 8 pi enhancer reagent was added to 0.5 and 1 pg DNA
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respectively (the ratio ofDNA:enhancer must be 1:8), vortexed and incubated at RT
for 5 min. Effectene reagent was then added to the DNA/enhancer mix and vortexed.
Different amounts of Effectene (2.5, 5, 12.5 and 25 pi) were added to both 0.5 and 1
pg DNA to establish the optimal ratio ofDNA:Effectene. The DNA/Effectene mix
was incubated at RT for 10 min. 1.5 ml fresh medium was added to the cells and 0.5
ml medium was added to the DNA/Effectene complex before it was added dropwise
to the cells.
2.2.6.3.4 Transfection of 293 cells for rAAV production
For the production of rAAV particles, 293 cells were transfected using
Effectene transfection reagent (Qiagen) (section 2.2.6.3.3) in 90mm tissue culture
plates and the reagents were scaled up accordingly. Generally, 2.5 x 106 cells in 90
mm tissue-culture dishes were transfected with 6 pg of total DNA using 48 pi
enhancer and 75 pi Effectene reagents as described above. 7 ml of fresh medium was
added to the cells and 3 ml of medium added to the DNA/Effectene mix before
addition to the cells.
2.2.7 Preparation of primary neuronal cultures
2.2.7.1 Adult dorsal root ganglion neurons
Dorsal root ganglia (DRG) with attached roots were dissected from Wistar
Albino rats (4-6 weeks) and collected in PBS. Ganglia were freed of connective
tissue and nerve roots and each ganglia cut into approximately 4 pieces. Ganglia
were treated with 0.125% collagenase /dispase (Roche; 269-638) for 2 h at 37 °C.
Dissociation of neurons was obtaining by resuspending ganglia approximately 15
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times using a 1 ml pipette and allowing the undissociated ganglia to fall to the
bottom of the tube. The supernatant containing dissociated ganglia was transferred to
fresh tube. This process was repeated as many times as necessary. Neurons were
centrifuged for 1000 rpm 2 min, resuspended in F-14 medium (GRH Biosciences)
containing 10% FCS and plated onto poly-D-ornithine (0.5 mg/ml in 0.15 M borate
buffer (Sigma; P8638) coated 35 mm tissue culture dish. After 15 hours, the non-
neuronal cells are firmly attached to the dish, while the neurons only weakly adhere.
The following day, culture medium was carefully removed and neurons dislodged
from the plate and collected in a 15 ml conical tube. Cells were centrifuged at 1000
rpm for 2 min and the cell pellet resuspended in F-14 medium containing 10% FCS
and 100 ng/ml NGF (7S, Promega). Cells were plated on poly-D-ornithine and
laminin (1 mg/ml Roche; 23017-015) coated 9 mm coverslips. 2 days after culturing
cells were maintained in F-14 medium containing 2% FCS and medium was changed
every 3-4 days.
2.2.7.2 Neonate dorsal root ganglion neurons
Dorsal root ganglia were removed from 1 day old pups (Wistar Albino) and
collected in PBS. Ganglia were freed of roots and treated with 0.125%
collagenase/dispase for 45 min at 37 °C. Ganglia were washed 3 times with PBS and
then 3 times with medium solution 1 (Dulbecco's Modified Eagles Medium
containing 200 mM L-glutamine, 1% penicillin/streptomycin and 10% FCS). DRG
neurons were triturated by passing the ganglia through a 21G syringe needle 8 times
and then passing through a 23G needle until cells are fully dispersed. The cell
suspension was then passed through a 40 pm cell strainer (Falcon) and centrifuged
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1000 rpm 2 min. The cell pellet was resuspended in medium containing 100 ng/ml
NGF and 2.5 pM Cytosine Arabinoside (Sigma; C1768) and plated onto poly-L-
lysine and laminin coated coverslips. 48 hours after plating, cells were replaced with
medium solution 2 (DMEM containing L-glutamine, penicillin/streptomycin, 1%
FCS and 1 x N-2 supplement (Gibco; 17502-048). Cytosine arabinoside is a selective
inhibitor ofDNA synthesis and N-2 supplement allows the maintenance of rat
primary neurons in mass culture.
2.2.8 Immunostaining of cultured DRG neurons
Cells were fixed by incubating with 4% paraformaldehyde for 15 min at RT.
Cells were washed 5 times in PBS and then incubated for 10 min at RT in PBS
containing 0.2% triton-X. Cells were again washed several times with PBS and then
incubated with block solution (PBS containing 20% normal goats serum) for 30 min
at RT. Cells were then incubated at 4 °C overnight in primary antibody.
Rabbit anti-SP antibody (Penninsula laboratories) was used at a working
dilution of 1:20,000 in block solution and detected using a 1:200 working dilution of
goat anti-rabbit IgG (10 pg/ml; Vector laboratories). Mouse anti-neurofilament
antibodies (monoclonal anti-neurofilament 200, clone N52, Sigma) was used at a
working dilution of 1:400 of antibody solutions provided (no details of SP and NF
antibody concentrations were provided) and was detected by biotinylated goat anti-
mouse IgG (used at 1:200 working dilution, 5 pg/ml, Vector). For IB-4 analysis of
DRG neurons cultures were incubated with biotinylated IB-4 (Sigma) at a working
dilution of 1:500 (0.4 pg/ml). In most cases, staining was visualised using Vector
Alkaline Phosphatase Substrate kit I (Vector laboratories SK-5100).
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After overnight incubations with primary antibodies, cultures were washed
with PBS 5 times and incubated with secondary biotinylated antibody for 1 h at RT.
Cells were then washed several times with PBS and incubated with Vectastain ABC-
AP (Vector laboratories) complex for 30 min. The ABC-AP complex was made
according to manufacturer's instructions. These ABC-AP kits contain a special form
of Avidin DH and biotinylated alkaline phosphatase H. To make up the ABC
complex, 1 drop of reagent A and 1 drop of reagent B were added to 5 ml buffer (10
mM sodium phosphate, pH7.5, 0.9% PBS). This was mixed well and incubated at RT
for 30 min before adding to the cells. Cells were again washed several times with
PBS and the colour reaction developed as follow.
The alkaline phosphatase substrate working solution was prepared according
to manufacturers instructions: To 5 ml lOOmM tris-HCl, pH 8.2-8.5, 2 drops of
reagent 1 was added and mixed well. Then 2 drops of reagent 2 was added and mixed
well and 2 drops of reagent 3 was added and mixed well. This was added
immediately to the cells. The colour was developed for approximately 20 mins
before it was stopped by the addition of tap water.
Cells were then counterstained for 5 seconds in haematoxylin, washed in
Scotts water and then in tap water and mounted using aqueous mount (Aquamount





Both wild-type adenovirus type 2 and mutant adenovirus type 5 varient
AE1A/E1B were produced by the following method. 60 - 80% confluent 293 cells in
175 cm2 tissue-culture flask were infected with virus at a multiplicity of infection
(moi) of 1 in growth medium supplemented with 2% FCS and incubated at 37 °C for
1 h to allow viral adherence. Normal growth medium (containing 10% FCS) was
then added and infected cells were incubated at 37 °C for 4 - 7 days until cytopathic
effects were observed. Cells were then harvested and centrifuged at 1000 rpm for 5
min. The supernatant was removed and cell pellet resuspended in TE buffer. Cells
were freeze-thawed three times and spun at 1000 rpm for 4 min to remove cell
debris. The supernatant containing adenovirus was transferred to a fresh eppendorf
and stored in 50 pi aliquots at - 70 °C.
2.2.9.2 Titration of adenovirus
Both wild-type adenovirus type 2 and mutant adenovirus type 5 titres were
established by end point dilution. Cells were seeded out in 96 well plates at
approximately 30% confluency. The following day, adenovirus stock was diluted in
medium from 10~6 through to 10"H. 100 pi of each dilution was added to 10 wells and
incubated for 16 h before changing the medium. Medium was then changed every 3
days and the number of viral plaques at each dilution counted 6 to 8 days post¬
infection. The method ofReed and Meunch was used to calculate TCIDso/ml and
virus titre pfu/ml (Revah et ai, 1996) (section 2.2.9.3).
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2.2.9.3 Reed and Muench method to calculate TCIDsn/ml
The 50% infectious dose (TCID50 or tissue culture 50% infectious dose) is calculated
using mathematical anaylsis of the data. The Reed and Muench method was used to
determine adenovirus titre after counting plaques generated by various dilutions of
adenovirus stocks as described above (section 2.2.9.2). The resulting adenovirus
titres are expressed as plaque forming units per ml (pfu/ml).
_ (% ofwells infected at dilution above 50% - 50%).1 ~ ' (% ofwells infected at dilution above
50% - % wells infected at dilution below)
_- „ . , . . „ Jog total dilution above 50% - (I x log h)
50% endpoint titre =10 5 B
Where I = Interpolated value of the 50% endpoint (or proportionate distance)
h = dilution factor
Example of the method ofReed and Meunch to calculate titre:
If a titration gave 9/10 positive wells (90%) at the 10~8 dilution and above, 3/10
(30%) at the 10"9 dilution and 0/10 at the 10"10 dilution then:
_ (90% - 50%) _ 401 - /(90%-30%) ~ '60 = °-67
50% endpoint titre = 10"'
- (0.67 x 1)
50% endoint titre = 108'67
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This represents the number of infectious doses per unit volume therefore if only
100 pi of virus was added to each well, this must be multiplied by 10 to give a final
value of 109'67TCID50/ml.
1 TCID is approximately equal to 0.7 plaque forming units (pfu) and therefore can
define titre as pfu/ml.
2.2.9.4 Preparation of rAAV
In these studies rAAV was initially generated using AAV helper plasmid
(pXX2) and AAV plasmid (pSub201) together with adenovirus mutant to provide
helper functions. Later plasmid pXX6-80 (Xiao et al., 1998) was used in place of
adenovirus.
2.2.9.4.1 Generation of rAAV using mutant adenovirus as helper
90 mm tissue culture dishes containing 50 - 80% confluent HEK293 cells
were transfected with 4 pg AAV plasmid and 2 pg pXX2 using Effectene
transfection reagent (section 2.2.6.3.4). 6 h post-transfection, cells were infected with
adenovirus mutant in medium containing 2% FCS (section 2.2.9.1) at approximate
moi of 10. 1 h after adenovirus infection, medium was replaced with complete
medium and cells were incubated for approximately 48-72 hours. Cells were
harvested when a cytopathic effect was apparent (when all cells looked rounded and
infected but still attached to plates). Cells were centrifuged for 4 min at 2000 rpm
and cell pellet resuspended in 1 ml TN. Cells were then subjected to 3 rounds of
freeze-thawing and then centrifuged at 2000 rpm for 4 min. The supernatant was
collected in a fresh tube and heated at 56 °C for 45 min to inactivate adenovirus. This
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was then centrifuged at 2000 rpm for 2 min and the supernatant collected in fresh
tube. rAAV preps were stored in 50pl aliquots at -70 °C.
2.2.9.4.2 Generation of rAAV using pXX6-80 as helper
293 cells, approximately 80% confluent were transfected by Effectene
transfection reagent (section 2.2.6.3.4) with 1 pg AAV plasmid (pSub201), 2 pg
pXX2 and 3 pg pXX6-80 (Xiao et al., 1998). 72 h post-transfection, cells were
harvested by resuspending at 2000 rpm for 4 min and cell pellet resuspended in 1 ml
TN (100 mM Tris-HCl, pH 7.5, 150 mM NaCl). Cells were then freeze-thawed three
times and centrifuged at 2000 rpm for 4 min. rAAV preparations were aliquoted and
stored at -70 °C.
2.2.9.5 Optimisation of rAAV production
To determine the optimal reagents for rAAV production, rAAV titres were
compared when AAV was generated using AAV helper plasmid pAAV/Ad
compared with pXX2. Production of rAAV was also compared when adenovirus and
plasmid pXX6-80 provided helper functions and when different ratios of these
plasmids were used. In all experiments, pSub201-CMV-LUC was used to generate
rAAV-CMV-LUC. Approximatley 2.5 x 105 293 cells per well were seeded in 6 well
plates 20 h prior to transfection and transfected using PEI (section 2.2.6.3.1) and
harvested 48 h post-transfection.
In the first set of experiments, production of rAAV-CMV-LUC was
investigated when pAAV/Ad and mutant adenovirus are used. The amount of
pSub201-CMV-LUV and pAAV/Ad used was varied. Ratios of 1:3, 3:1 and 1:1 jag
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ofpSub201-CMV-LUC:pAAV/Ad were compared. A similar experiment was carried
out in which pXX2 was used as the AAV helper plasmid. Cells were transfected
using PEI at the appropriate DNA:PEI ratio as described in section 2.2.6.3.1. Briefly,
4 pg total DNA was diluted in 50 pi 150 mM NaCl and 2 pi PEI was diluted in 50 pi
150 mM NaCl. These were mixed together and incubated at RT for 10 min before
adding to the cells and fresh medium was added 2 h post-transfection. 6 h post-
transfection, cells were infected with mutant adenovirus as follows. The medium was
removed and replaced with 500 pi growth medium containing 2% FCS and
adenovirus at a moi of 10. This was incubated for 1 h before 2 ml complete medium
(containing 10% FCS) was added to the cells.
A third experiment investigated AAV production when plasmid pXX6-80 is
employed. Varying ratios of plasmids were compared: 0.8: 0.8: 2.4, 0.8:1.6:2.4,
0.8:0.8:4.8 and 0.8:1.6:4.8 pg of pSub201-CMV-LUC: pXX2: pXX6-80
respectively were used for transfection of 293 cells by PEI as described above. Cells
were harvested 72 h post-transfection by centrifuging at 2000 rpm for 4 min. The cell
pellet was resuspended in 250 pi TN and cells were subjected to three rounds of
freeze-thawing and the supernatants processed as described in section 2.2.8.3. rAAV
preparations were then titred by the modified replication centre assay (section
2.2.9.6).
?.? 9.6 Titration of rAAV particles
rAAV titres were determined by the modified replication centre assay
(Salvetti et al., 1998). HeLaRC cells were seeded at approximately 3 x 106 cells per
24 well plate. The following day, cells were infected with varying concentrations of
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the rAAV samples, diluted 10~2, 10~3,10~4, 10"5 and 10~6 in 100 pi Optimem (GibCo),
together with wild-type adenovirus type 2 at an moi of 20 in 100 pi Optimem. Cells
were incubated 37 °C for 2 h then 1 ml complete medium was added to the infected
cells. Cells were harvested 30 h post-infection and cell pellet resuspended in 4 ml
versene. Cells were then applied to nylon membrane filters (Schleicher and Schuell,
1- 414112) using dot-blot apparatus and left to air dry. Membrane filters were
washed once in 0.5M NaOH/1.5M NaCl for 5 min and twice in 1 MTris pH7.2 x
SSC 5 min and left to air-dry overnight. The following day filters were baked at 80
°C for 30 min and washed in pre-hybridisation buffer (50% formaldehyde, 5 x SSC,
5 x denhardts, 100 mM NaH^PO^ 17 mM SDS) for 2 h.
To probe for AAV particles, DNA fragments containing the luciferase ORF
was 32P labelled using 'Ready-to-go'™ DNA labelling beads (Amersham pharmacia
biotech) according to manufacturers instructions. Approximately 25-50 ng DNA was
made up to a final volume of 45 pi in dH^O and denatured by heating for 3 min at 99
°C. It was then placed immediately on ice for 2 min and centrifuged briefly. The
denatured DNA was then added to the DNA labelling beads (contain labelling beads,
buffer, dATP, dGTP, dTTP, klenow fragments ofDNA polymerase, random
nucleotides) and resuspended. 50 pCi [a-32P] dCTP was added to the DNA/bead mix
and incubated at 37 °C 30 min. The labelled DNA was then isolated from free probe
by using Probe-Quant™ G-50 microcolumns (Amersham pharmacia biotech)
according to manufacturers instructions. Briefly, 32P-DNA was added to the column
and centrifuged at 2000 rpm for 1 min. The flow-through was then boiled for 2 min
and placed on ice. 100 pi prehybridisation buffer was added to the 32P-labelled DNA
and this was incubated with the filters overnight at 37 °C.
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2.2.9.7 Generation of rAAV vectors by Genethon
Genethon is a charitable organisation that provides researchers with batches
of vectors, reagents and technical assistance for those working in the field of virus
vectors and gene therapy. Plasmids pSub201-CMV-PPT, pSub201-CMV-
PPTAexon3, pSub201-CMV-GFP and pSub201-PPT-GFP were send to Genethon for
generation into rAAV particles. rAAV vectors were generated using a three plamsid
protocol to avoid use of adenovirus to provide helper functions. This resulted in the
production of clean, high titre rAAV prepartions that are free from contaminating
adenovirus. Following rAAV production, rAAV stocks are purified by two CsCl
gradients and titred.
2.2.10 Transduction of DRG cultures by rAAV
2.2.10.1 Infection of DRG cultures by rAAV
DRG cultures were grown on 9 mm glass coverslips. Coverslips containing
cells for infection were transferred into a well of a 48 well culture dish. The rAAV
was then added to the cells in a total volume of 150 pi F-14 containing 10% FCS.
The following day the medium was removed and 250 pi fresh medium was added.
2.2.10.2 Growth factor induction
For growth factor experiments, the medium ofDRG cultures was replaced 24
to 48 h after neurons were plated on coverslips, with F14 containing 10% FCS only.
Cells were incubated for at least 24 h before infecting with the rAAV (section
2.2.10.1). Upon infection, rAAV was added in F14 medium containing 10% FCS + /-
growth factor. Cells were maintained in medium containing the growth factor for the
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duration of infection time. Growth factors used were 100 ng/ml 7s NGF (mouse
recombinant, Promega), 25 ng/ml LIF (mouse recombinant, Sigma, L5158), 25 ng/ml
BDNF (human recombinant, Sigma B3795), GDNF (rat recombinant, Sigma G1401),
50 ng/ml CNTF (rat recombinant, Sigma C3960) and IL-6 (mouse recombinant,
Sigma 19646).
2.2.10.3 Detection of luciferase expressing rAAV vectors: luciferase assays
Luciferase activity was determined using the Promega Luciferase assay kit
according to manufacturers instructions. For DRG exepriments, cultures that were
infected with rAAV as described in section 2.2.10.1 were harvested and assayed as
follows. Cultures in 48 well plates were washed gently with PBS and 70 pi of
reporter lysis buffer was added to the cells. Cells were incubated in lysis buffer for
15 min and the lysate transferred to a fresh eppendorf. Samples were freeze-thawed,
vortexed briefly, centrifuged at 10,000 rpm for 1 min and the supernatant transferred
to a fresh eppendorf. 40 pi of lysate was mixed with 200 pi of luciferase assay buffer
and luciferase activity measured using a luminoskan RT luminometer.
For cell culture that had been transfected with pSub201-CMV-LUC (section
2.2.6.3), after washing with PBS, 250 pi of 1 x lysis buffer was added to each well of
the 6 well tissue culture dishes. The cell lysate was treated as described above for
DRG cell lysates. To assay for luciferase activity, 1 pi of lysate was first diluted in
50 pi of lysis buffer and then 20 pi of diluted lysate was mixed with 100 pi of
luciferase assay buffer.
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2.2,10.4 Detection of GFP expressing rAAV vectors
Following infection of DRG cultures with AAV-PPT-GFP or AAV-CMV-
GFP, GFP expression could be detected by fluorescent microscopy. In most cases,
cells were fixed and subject to ABC immunostaining. Cells were fixed, washed and
blocked as in section 2.2.7 and then incubated overnight with 0.1 pg/ml mouse anti-
GFP (Molecular probes). Cells were washed and incubated for 2 h with goat anti-
mouse biotinylated secondary antibody and stained using ABC-AP and Vector red
kit as described in section 2.2.7. In some experiments GFP antibodies were
visualised by Vector SG substrate kit and Elite ABC kit. The Elite ABC kit contains
Avidin DH and biotinylated horseradish peroxidase H reagents, which form
complexes for immunoperoxidase staining. Elite ABC complex was made according
to manufacturer's instructions: 2 drops of reagent A was added to 5 ml buffer and
mixed well. 2 drops of reagent B was then added and mixed well. To prepare vector
SG colour reaction, 3 drops of Chromogen was added to 5 ml PBS and mixed well.
This was followed by the addition of 3 drops of hydrogen peroxidase solution.
Colour reactions were developed for approximately 5 min and stopped by the
addition of tap water.
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CHAPTER 3: TRANSDUCTION OF DRG NEURONS BY AAV VECTORS
3.1 Introduction
The aim of this study was to optimise the production of recombinant AAV
(rAAV) vectors to a standard suitable for the routine transduction of cultured DRG
neurons to investigate PPT-A promoter regulation in sensory neurons. Previous work
in this laboratory had employed rAAV technology for transfection ofDRG neurons
to investigate stimulus inducibility of the PPT promoter (Harrison et al., 1999).
However the techniques available for generating rAAV vectors have since improved
and many questions regarding rAAV infection ofDRG neurons remain to be
answered. To address these issues, the protocol for generating rAAV vectors was
optimised to increase rAAV vector titres and eliminate the need for adenovirus
helper function. Subsequently, the conditions necessary for rAAV infection ofDRG
cultures and the DRG cell populations that support reporter gene expression from
rAAV vectors were also addressed.
3.2 Optimisation of rAAV production
Over the course of this thesis the technology for generating rAAV has rapidly
improved, allowing high titre preparations that are pure and free of adenovirus
contamination (section 1.4.8.1). The original protocol (figure 3.1) for the production
of rAAV particles involves the transient transfection of 293 cells with a rAAV
packaging substrate and helper plasmid. Subsequently superinfection with mutant
adenovirus provides the essential proteins for AAV replication and packaging
(Samulski et al., 1989). The AAV packaging substrate retains only the 145 bp
inverted terminal repeats (ITR) flanking the gene of choice and the AAV structural
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proteins are provided in trans by cotransfection of the AAV packaging substrate with
a helper plasmid containing only the AAV rep and cap genes. In the presence of
adenovirus infection, expression of the AAV rep and cap genes occur. This allows
replication of rAAV sequences and single-stranded DNA molecules to be
encapsulated into AAV capsid structures. This method generates both rAAV
particles and adenovirus therefore rAAV is subsequently isolated by inactivation of
adenovirus (section 1.4.7; figure 3.1).
This method has several limitations as it can be technically difficult and
inefficient, it can be difficult to achieve high titres and there is the possibility that
residual adenovirus may contaminate stocks. Therefore focus has been on improving
AAV production (section 1.4.8). One area has been the development of packaging
cell lines, which express the AAV rep and cap genes, to allow large scale production
(Holscher et al., 1994, Tamayose et al., 1996, Inque and Russell, 1998). Other
groups have generated improved AAV helper plasmids, in which the AAV genes
essential for DNA replication are down-regulated, to increase rAAV titres (Xiao et
al., 1998). To eliminate the possibility of adenovirus contamination, adenovirus-
AAV helper plasmids have been generated (Collaco et al., 1999; Matsushita et al.,
1998; Grimm et al., 1998) which carry both essential adenovirus and AAV helper
function. In addition, an adenovirus plasmid has been generated which is incapable
of producing infectious adenovirus particles but can provide all the necessary helper
functions for rAAV replication (Xiao et al., 1998; section 1.4.8.1).
As many of these reagents have become available over the course of this
study we were able to take advantage of these to improve and optimise the conditions
for generating rAAV in this laboratory. The work presented here employs the
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adenovirus helper plasmid described by Xiao et al. (1998) in place ofmutant
adenovirus to improve rAAV titres and also avoid adenovirus contamination.
Initially in this laboratory the original protocol employing mutant adenovirus
was used for the generation ofAAV particles (figure 3.1). This therefore involved
the transfection of 293 cells by electroporation with the helper plasmid pAAV/Ad
together with pSub201 plasmids (AAV packaging substrate), followed by infection
with mutant adenovirus (Samulski et al., 1989). However, transfection of 293 cells
by electroporation generally caused high amounts of cell death and was thought to be
quite an inefficient method for transfection, resulting in low titre rAAV preparations.
The first step in this optimisation process was therefore to improve the transfection
efficiency of 293 cells. Consequently, production of rAAV using the standard
method described was compared to protocols that employed plasmids pXX2 and
pXX6-80 (Xiao et al., 1998) instead ofAAV helper plasmid pAAV/Ad and
adenovirus respectively. Plasmid pXX2 is an improved AAV helper plasmid and
plasmid pXX6-80 carries the genes essential for adenovirus helper functions. Over
the course of this study these two important reagents came available and were shown
by Xiao et al. (1998) to be more effective in generating high titre rAAV that is free
of contaminating adenovirus.
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Figure 3.1: Standard protocol for the production of rAAV. 293 cells are transfected
with rAAV helper plasmid and the AAV plasmid and are then infected with adenovirus.
The AAV helper plasmid pAAV/Ad provides the AAV genome in trans resulting in
adenovirus and rAAV particles production. Both viruses are released and adenovirus
is then inactivated by heating to 56 °C.
93
3.2.1 Transfection of 293 cells
To determine the most effective method for transfection of 293 cells, cells
were transfected with plasmid pSub201-CMV-LUC by calcium phosphate,
polyethylenimine and Effectene reagent (Qiagen) (section 2.2.6.3). In all
experiments, 2.5 x 106 293 cells were seeded out approximately 20 h prior to
transfection in 6 well tissue culture dishes and were approximately 70 - 80%
confluent on the day of use. Cells were harvested 48 hours post-transfection and
lysed extracts assayed for luciferase activity (section 2.2.10.3).
3.2.1.1 Effectene (Qiagen) reagent-mediated transfection
Effectene transfection reagent is a non-liposomal highly branched lipid
molecule that works in conjunction with a DNA-condensing enhancer. The first step
in Effectene mediated transfection is incubation ofDNA with the enhancer reagent to
condense the DNA. Effectene reagent is then added to this complex and the DNA-
Effectene complex is added directly to the cells. The DNA:Effectene complex
requires a slight positive charge in order to bind efficiently to the negatively charged
cell surface molecules and successfully transfect cells. It was therefore necessary to
optimise the amount ofDNA and Effectene reagent used since the overall charge of
the Effectene DNA complex is determined by the ratio of Effectene to DNA-
enhancer mix (section 2.2.6.3.3). 0.5 pg DNA was used together with 2.5, 5, 12.5
and 25 pi Effectene to give DNA (pg):Effectene (pi) ratios of 1:5, 1:10, 1:25 and
1:50 respectively. 1 pg DNA was also used together with 2.5, 5, 12.5 and 25 pi
Effectene to give ratios of 1:2.5, 1: 5, 1:12.5 and 1:25 respectively. It was found that
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1 pg DNA used in combination with 25 fj.1 Effectene reagent reproducibly resulted in
the highest transfection effciencies (table 3.1).
3.2.1.2 Polyethvlenimine-mediated transfection
Polyethylenimine (PEI) molecules are highly positively charged and when
added to DNA, form microprecipitates that are absorbed by the cells by endocytosis
(Boussif et al., 1995). To investigate transfection efficiency of 293 cells by PEI,
different ratios ofDNA:PEI were also tested (section 2.2.6.1). Both 4 pg and 8 pg
DNA was each used in combination with 2, 6, 10 and 15 pi 10 mM PEI. 4 pg of
DNA together with 2 pi of PEI (DNA:PEI ratio of 1:05) resulted in the highest
luciferase values (table 3.2). Increased ratios ofDNA:PEI was observed to be toxic
to the cells and resulted in reduced transfection efficiencies. This suggested that
DNA:PEI ratios are critical for achieving efficient transfection.
3.2.1.3 Calcium phosphate-mediated transfection
Calcium phosphate-mediated transfection (section 2.2.6.3.2) is the most
commonly used method for transfection of 293 cells for the production ofAAV,
particularly when large scale preparations are generated as this technique is
inexpensive and relatively efficient. An exact pH is essential for efficient transfection
and pH 7.12 was found to be critical. The amount ofDNA that was optimal for the
formation of calcium phosphate-DNA coprecipitates at pH 7.12 was determined.
Increasing amounts ofDNA in a total volume of 110 pi were added together with
125 pi 2 x HBS pH 7.12. 15.5 pi 2.5 mM calcium chloride was then added to the
DNA/HBS mix, which was then incubated with the cells in 6 well culture dishes. 1,
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2.5, 5 and 10 jag DNA was compared and it was found that 1 pg DNA achieved the
highest transfection efficiency (table 3.3).
3.2.1.4 Comparison of transfection procedures
PEI-mediated transfection resulted in the highest luciferase values when a
DNA:PEI ratio of 1:0.5 was used (tables 3.1 to 3.3). Increasing amounts of PEI were
observed to be highly toxic to the cells. Table 3.2 shows there is a 6 fold reduction in
transfection efficiency when a DNA:PEI ratio of 1:1.5 was used, indicating that the
DNA:PEI is crucial for effective transfection.
Effectene reagent-mediated transfection was shown to provide high
transfection efficiencies as measured by luciferase activity and was the most
effective method of transfection (table 3.1). Unlike PEI mediated transfection, a large
variation in transfection efficiency was not observed between the different
DNA:transfection reagent ratios when Effectene reagent was employed. In addition,
toxicity to the 293 cells was not apparent and high levels of transfection are
achievable despite using much lower quantities ofDNA. To achieve these high
transfection efficiencies only 1 pg DNA was required, whereas to achieve equivalent
luciferase values by PEI mediated transfection, it was necessary to use 4 pg DNA.
This was an important consideration as difficulty was encountered in achieving high
yields of adenovirus helper plasmid pXX6-80 from plasmid preparations.
Subsequently, Effectene transfection reagent at a DNA:Effectene ratio of 1:25 has
been the method of choice for transfection of 293 cells for the production of rAAV.
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Amount of Amount of Ratio DNA: Luciferase Protein cone. Luciferase
DNA (pg) Effectene (pi) Effectene reading (pg/ml) activity/pg
protein
0.5 2.5 1:5 1406 270 260
5 1:10 3761 275 684
12.5 1:25 2445 260 470
25 1:50 3448 505 341
1 2.5 1:2.5 1157 270 214
5 1:5 4438 340 653
12.5 1:12.5 8182 270 1515
25 1:25 10213 300 1702
Table 3.1: Luciferase values of cell extract of 293 cells transfected with pSub201-CMV-LUC by
Effectene transfection reagent. To assay, cell extract was diluted 1:50, then 20 pi cell extract was
added to 100 pi luciferase assay buffer.
Amount of Amount of Ratio Luciferase Protein conc. Luciferase
DNA (pg) PEI (pi) DNA:PEI reading (pg/ml) activity/pg
protein
4 2 1:0.5 12454 330 1887
6 1:1.5 1909 250 382
10 1:2.5 1134 280 203
15 1.3.75 75 120 31
8 2 1:0.25 8539 270 1581
6 1:0.75 1294 250 259
10 1:1.25 789 150 263
15 1.1.9 590 130 227
Table 3.2: Luciferase values of cell extract of 293 cells transfected with pSub201-CMV-LUC by
polyethylenimine. To assay, cell extract was diluted 1:50, then 20 pi cell extract was added to 100 pi
luciferase assay buffer.
Amount ofDNA (pg) Luciferase Protein conc. (pg/ml) Luciferase activity/pg
reading protein
1 1532 270 284
2.5 149 210 35
5 390 300 65
10 30 250 6
Table 3.3: Luciferase values of cell extract of 293 cells transfected with pSub201-CMV-LUC by
calcium phosphate method . To assay, cell extract was diluted 1:50, then 20 pi cell extract was added
to 100 pi luciferase assay buffer.
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3.2.2. Production of rAAV vectors
To address the issue of improving rAAV yield and producing stocks, which
are completely free of helper adenovirus, plasmids pXX2 and pXX6-80 generated by
Xiao et al. (1998) were utilised (figure 3.2). pXX2 is an AAV helper plasmid which
was designed to specifically increase rAAV titres. In comparison to the original
packaging plasmid pAAV/Ad, pXX2 has attenuated synthesis ofAAV Rep78/68
proteins and an additional p5 promoter downstream of the AAV Cap open reading
frame. AAV Rep 78/68 is essential for DNA replication however unregulated
overexpression is known to inhibit rAAV production, therefore reduction of
Rep78/68 expression by attenuated translation initiation has resulted in much higher
AAV yields (Li et al., 1997). Deletion of the p5 promoter results in down-regulation
of promoters pi 9 and p40 (Pereira et al., 1997), which allow transcription of genes
coding for Rep52/40 and the capsid proteins. It was therefore thought that the
additional p5 promoter would increase the expression ofRep 52/40 and the capsid
proteins. Rep 52/40 is important for AAV single-stranded formation, which is part of
the packaging process (Chejanovsky and Carter, 1989), and the capsid proteins are
required for virus assembly. The collective effects of these helper plasmid changes
were shown to result in higher rAAV yields (Xiao et al., 1998).
A number of adenovirus genes, including El a, Elb, E2a, E4 and VA genes
are necessary for helper function (Berns, 1996). pXX6-80 contains only the E2a, E4
and VA genes and is capable of propagating rAAV in the presence ofAAV rep and
cap genes in 293 cells. These cells provide the missing adenovirus Ela and Elb
genes, which are essential for replication. pXX6-80 is defective for adenovirus
replication and the ability to produce adenovirus structural proteins, however as it
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can still provide helper function, rAAV vectors will be free of adenovirus
contamination.
To optimise the conditions for generating rAAV using these reagents, rAAV
stocks were made using the packaging plasmids pAAV/Ad or pXX2 together with
adenovirus as helper. The titres of these rAAV preparations were then compared to
rAAV stocks that were generated when pXX6-80 was employed instead of
adenovirus. AAV packaging substrate pSub201-CMV-LUC was used for producing
rAAV-CMV-LUC stocks in all experiments and different ratios of pSub201-CMV-
LUC: AAV helper plasmid was also compared. Figure 3.2 shows the plasmids used
for this study and figure 3.3 summarises the conditions of each experiment.
For these initial optimisation experiments PEI was utilised as it is inexpensive
and achieves efficient transfection of 293 cells. Cells were seeded out 20 h prior to
transfection in 6 well tissue culture dishes and were approximately 80% confluent on
day of use. Cells were transfected with plasmids by PEI-mediated transfection as
described in section 3.2.1.2. (see section 2.2.9.5 for a more detailed description).
When adenovirus was used as helper, cells were infected 2 h post transfection and
harvested approximately 48 h following infection, when cytopathic effects were
apparent. However when pXX6-80 was co-transfected with pXX2 and pSub201-
CMV-LUC, cells were harvested 72 h post-transfection. Harvested cells were lysed
by three cycles of freeze thawing, cell debris was removed and adenovirus was heat
inactivated when present (section 2.2.9.5). HeLaRC cells were then infected with
varying concentrations of the rAAV preparations and the titres determined by the
modified replication centre assay (section 2.2.9.6).
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The highest titres of rAAV were obtained when pXX2 and pXX6-80 were
used to prepare stocks (table 3.5) compared to those rAAV preparations generated
when pAAV/Ad helper or pXX2 was utilised together with adenovirus (table 3.4).
Specifically, the greatest titres were achieved when plasmids pSub201-CMV-LUC,
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Figure 3.2: Plasmids used for rAAV optimisation experiments. (A) AAV vector pSub201-CMV
-LUC contains the CMV promoter driving the luciferase reporter gene and stuffer DNA flanked
by the AAV ITRs. This superfluous DNA is neccesary to ensure fragment is similar in length to
the AAV genome (4.5 kb) for successful packaging. (B) AAV helper plasmid pXX2 differs from
pAAV/Ad in that it has a mutation in the start codon of rep78/68 gene which reduces Rep78/68
synthesis. It also has an additional p5 promoter downstream of cap gene. (C) Ad helper plasmid
compared to Ad DNA sequences shows that only the sequences VA, E2A and E4 essential for
supplying AAV helper function are retained. E1A and E1B are also essential but are complemented

















Figure 3.3: Experiments performed for the optimisation of rAAV production. All cells were
transfected with pSub201-CMV-LUC, in addition to (A) pAAV/Ad followed by infection with
adenovirus, (B) pXX2 followed by infection with adenovirus and (C) pXX2 together with pXX6-80.
Different ratios of pSub201 -CMV-LUC to AAV helper plasmids were also examined.
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Table 3.4: Titres of rAAV-CMV-LUC generated when AAV helper plasmids pAAV/Ad
or pXX2 are used in conjunction with adenovirus. Different ratios of pSub-CMV-LUC: AAV









Table 3.5: Titres of rAAV-CMV-LUC generated when the three plasmid
system (Xiao et al. ,1998) is used. Different ratios of pSub201-CMV-
LUC: pXX2:pXX6-80 were also compared.
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3.2.3 Summary of optimisation experiments
Initially in the laboratory, rAAV stocks were generated using the original
protocol described by Samulski et al. (1989) (section 1.4.7). rAAV is now generated
by transfecting 293 cells with plasmids pSub201, pXX2 and pXX6-80 at a ratio of
1:2:3. Transfection is achieved using Effectene transfection reagent at a
DNA:Effectene ratio of 1:25. Cells are harvested at 72 hours post-transfection and
rAAV stocks titred (figure 3.4). Although it later became apparent that it may be
necessary to further purify this lysate further (chapter 4), it was believed at the time
this work was performed that this crude cell lysate should be suitable for experiments
involving infection of cultured DRG neurons. This method of rAAV production
avoids contamination of stocks by adenovirus and adenovirus cytotoxic proteins.
This is an important consideration, as it is known that high amounts of contaminating
adenovirus are toxic to the cultured DRGs (Revah et al., 1996). In addition, the
presence of contaminating adenovirus may influence results when studying PPT-A
promoter regulation (see chapter 4).
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Figure 3.4: Optimised protocol for the production of rAAV vectors. 293 cells are transfected with
AAV vector, AAV helper pXX2 and Ad plasmid pXX6 at a ratio of 1:2:3 pg DNA respectively.
Cells are transfected using Effectene transfection reagent and harvested 72 h post-transfection.
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3.3 Generation of DRG neuronal cultures
Cultures of DRG neurons were obtained from both neonate (section 2.2.7.2) and
adult rats (section 2.2.7.1) for use in this study. DRG were removed from all spinal
levels of the animals. To achieve cultures that were enriched for neuronal cell
populations, adult neuronal preparations had an additional pre-plating step. The
dissociated DRG were plated onto 0.5 mg/ml poly-D-ornithine coated plates
overnight to allow the non-neuronal cells to adhere tightly while the neurons only
loosely adhered. The neurons were washed off and then plated onto polyornithine
and laminin coated coverslips (figure 3.5). Only preparations from adult DRG were
treated in this way as adult rats appear to be surrounded by excessive connective
tissue, which is difficult to remove and therefore increases the likelihood of
contaminating the cell culture with epithelial and other nonneuronal cells. If
necessary, cultures were treated with arabinose cytosine to limit the growth of
nonneuronal cells. Arabinose cytosine disrupts DNA synthesis and therefore dividing
cells are specifically killed. The significant growth of nonneuronal cells is
particularly a problem for rAAV transduction experiments as cells must be
maintained in culture for 7 days post-infection as this time scale is required for gene
expression from AAV vectors (Afione et al., 1999; personal observations).
Since this model of cultured DRG neurons was used in all subsequent studies, it
was necessary to establish the cell types that are generated and survive in culture
when DRG are processed in this way.
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3.3.1 Neurofilament. IB4 and SP immunostainina of adult rat DRG cultures
As described in section 1.3, sensory neurons can be divided into three broad
subgroups that are associated with specific neuronal functions and are responsive to
distinct growth factors. It was therefore important to determine if each of the
populations were present in these DRG cultures. Briefly, the large cell diameter (> 30
pm) population make up 30% of DRG neurons and can be identified using antibodies
to neurofilament. The other two groups, the peptidergic and non-peptidergic
populations have small cell diameters (< 30 pm) and make up 40 and 30% of DRG
neurons respectively. The peptide containing group can be identified by using
antibodies against the neuropeptide substance P whereas the non-peptidergic group
possess cell surface glycoconjugates which can be identified by binding isolectin IB4
(Lewin, 1992). It is important to note that these percentages represent the normal
state of DRG cells and under certain circumstances, such as inflammation and nerve
damage the expression of these markers may change (Hokfelt et al., 1994).
Neurofilament (NF), substance P (SP) and IB4 immunostaining was analysed
individually in cultured DRG neurons (section 2.2.8). In control experiments the
primary antibody was omitted. Figure 3.6 shows that the NF marker was associated
with the perikarya, dendrites, and axons of neuronal populations that are large in cell
body diameter. IB4 immunostaining was mainly observed in the cell bodies of
neurons that are small diameter (figure 3.7) and antibodies against SP (figure 3.8)
showed staining in the cell bodies of small diameter neurons, together with a number
of cells that may be medium sized diameter.
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coated coverslips (9 per rat)
Figure 3.5: Generation of cultured DRG neurons. Dorsal root ganglia (DRG) are removed
from all levels of the spinal cord and treated with collagenase to digest. Ganglia are
mechanically dissociated to achieve single-cells and subsequently plated on coated coverslips.
Neurons from adult rats undergo a pre-plating step to eliminate nonneuronal cells.
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Figure 3.6: Neurofilament immunostaining of adult DRG cultures. Cells stained for NF are pink
and (a) and (b) show both large and medium sized neurons are positive for NF.
Scale = (a) 50 pm and (b) 25 pm.
Figure 3.7: IB4 immunostaining of adult DRG cultures. A population of small cell neurons
were positive for IB4 (red arrows) and are shown in both (a) and (b). Blue arrows highlight the
large neurons which have not been IB4 labelled and the green arrow in (b) shows that some
small neurons were not 1B4 positive. Cells counterstained with haematoxylin are blue in colour.
Scale = 25 pm.
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Figure 3.8: Adult DRG cultures immunostained for SP. Cells expressing SP are highlighted
with the red arrows as expression is quite low and it difficult to distinguish SP positive cells
from counterstained cells. Staining was mainly associated with small diameter cells (c) and (d)
although staining was also observed in some medium neurons (b). For control experiments. SP
antibody was omitted (a). Scale = 25 pm.
3.3.2 Discussion
These experiments show that the DRG cultures generated for these studies
are highly heterogenous and immunostaining for SP, NF and IB-4 has identified
different populations of DRG. This expression pattern is consistent with the
consensus that the DRG is composed of three broad populations of neurons (Lawson,
1992) and these cultures contain members of each of the neurochemically defined
populations of DRG cells. This is therefore a suitable model for investigating the
transduction of sensory neurons by AAV. Furthermore, these experiments provide
the basis for determining which neuronal populations support expression of the PPT-
A promoter and will allow subsequent promoter regulation studies. Since it is known
that these different populations are responsive to different stimuli, the promoter
activity could be examined in individual cell populations in response to a variety of
conditions and growth factors. Recently the technique of biolistic firing (also called
particle-mediated transfection) into organotypic cultures has been employed for
investigating PPT-A promoter regulation in cortical brain slices. This technique
enabled plasmid constructs, containing the PPT-A promoter driving the GFP reporter
gene, to be introduced into neurons and confocal microscopy was used to quantify
single cell immunofluoresence (Walker et al., 2000). This method of particle-
mediated transfection can therefore enable analysis of neuronal gene promoters
within single neurons in real time. Similar analysis using the AAV model for
investigating PPT-A promoter regulation could provide invaluable information about
expression of the PPT-A gene in DRG neurons.
Ill
3.4 Infection of DRG neurons with rAAV
It has been previously established that AAV can transduce cultured DRG
neurons. DRG cultures were infected with rAAV vectors that contained the CMV or
PPT promoter driving the luciferase reporter gene. Cultures were subsequently
harvested and assayed for luciferase activity (Harrison et al., 1999). However, this
method does not allow the transduction efficiency to be established or to determine
what cell populations are transduced in DRG cultures.
To address these queries, rAAV particles that contain the CMV or PPT
(spanning base pairs -865+92) promoter driving the GFP reporter gene were used to
infect the cultured DRGs. These preparations termed AAV-CMV-GFP and AAV-
PPT-GFP were used to investigate which cell types support PPT promoter activity
and therefore express GFP. Neurons were identified by their characteristic
morphology and nonneuronal cells appeared to be either broad flattened or small
spindel shaped cells. DRG cultures were initially infected with 2.5x106 particles of
AAV-CMV-GFP and AAV-PPT-GFP (section 2.2.10.1). Approximately 7 days post¬
infection, GFP expression was observed. The number of cells expressing GFP and
the intensity was greater in those cultures transduced by AAV-CMV-GFP compared
to those infected with AAV-PPT-GFP. Figure 3.9 shows GFP expression 7 days
post-infection ofDRGs with AAV-CMV-GFP, however the fluorescent microscope
and photography equipment available was not sensitive enough to capture the images
of those cells expressing PPT-GFP therefore it was decided to use antibodies to
detect GFP.
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Figure 3.9: GFP expression in cultured adult ORG neurons. Cells were infected with rAAV-CMV-
GFP and 7 days post infection GFP expression was observed. Both neuronal and nonneuronal cells were
GFP positive. Neurons are identified by their characteristic morphology (red arrows) and nonneuronal
cells are highlighted by the blue arrows.
3.4.1 Dose dependent transfer of GFP gene expression
Cultures of adult DRGs containing both neuronal and nonneuronal cells were
infected with increasing concentrations of AAV-CMV-GFP and AAV-PPT-GFP.
The Gene Therapy Services unit at Genethon generated the rAAV preparations for
these studies (section 2.2.9.7). This service produced extremely pure, high titre
rAAV stocks that could not be feasibly generated in this laboratory and therefore
allowed high doses of rAAV to be used for infection. In addition, these Genethon
samples could be used as standard for comparison with our own rAAV preparation.
Approximately 500-1000 adult DRG neurons were grown on 9 mm
coverslips (section 2.2.7.2) and 0, 4.5 x 105, 1.8 x 106, 4.5 x 106 and 9 x 106
infectious particles of AAV-CMV-GFP were used for infection of these cultures
(section 2.2.10.1). Maximum GFP expression was observed 7 days after infection.
Cells were fixed and subject to GFP immunostaining (section 2.2.10.4). In all
infections both neurons and nonneuronal cells expressed GFP and the efficiency of
gene transfer to neurons was related to the concentration of virus (figure 3.10). Cells
infected with 4.5 x 105 particles showed very low levels of expression (figure 3.10
B). The cell numbers expressing GFP was also quite low in those infected with 1.8 x
106 particles (figure 3.10 C and D). When 4.5 x 106 particles were used there is a
marked increase in the number of positive cells and almost all neurons and
nonneuronal cells appear to be stained for GFP (figure 3.10 E, F and G). In these
circumstances the transduction efficiency of cell types in the cultures cannot be
specifically defined, as it is highly likely that the number of nonneuronal cells
increased with cell growth throughout the time course of the experiment. However, it
is clear that transduction efficiency of neurons is almost 100% when 4.5 x 106
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particles were used for infection. In addition, GFP expression and the intensity of
staining is greater in neurons than in the noneuronal cells. When 9 x 106 particles are
used (figure 3.9 H, I and J) there is not a marked difference compared to those
cultures infected with 4.5 x 106 particles. This suggests that future experiments
should employ at least 4.5 x 106 particles to achieve infection of all neurons in a
typical 9 mm coverslip culture (approximately 500-1000 neurons). Therefore, this
can be calculated at 4.5x103 rAAV infectious particles per neuron. Although this
appears to be a very high number of virus particles per cell, it is important to
remember that the method by which rAAV particles are usually titred (replication
centre assay) does not always relate specifically to the number of transcriptionally
active rAAV particles. Rather it describes the number of replication competent
rAAV particles, which can often be 100 fold higher than the number of actual
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Figure 3.10: Adult DRG infected with increasing concentrations ofAAV-CMV-GFP and
immunostained for GFP 7 days post infection. Cells positive for GFP are pink in colour,
and were infected with no virus (A), 4.5 x 105 particles (B), 1.8 x 106 particles, (C) (D),
4.5 x 106 particles (E) (F) (G) and 9 x 106 particles (H), (I) (J). Scale = 50 pm 10 x mag (A),
(C), (D), (E), (F), (FI) and (I); 25 pm 25 x mag (B), (G) and (J).
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3.4.2 Population of neurons which support PPT promoter activity
Adult DRG cultures were infected with increasing concentrations ofAAV-
PPT-GFP (which were also generated by Genethon) as described above. Again 0, 4.5
x 105, 1.8 x 10b, 4.5 x 106 and 9 x 106 infectious particles were used to infect
approximately 500-1000 DRG neurons on 9 mm coverslips. GFP expression was
observed 7 days post-infection and cultures were immunostained for GFP expression
(section 2.2.10.4).
GFP expression driven by the PPT promoter was observed in neurons and
nonneuronal cells (figure 3.11). When 4.5 x 105 infectious particles was used for
infection, only a small number of cells were GFP positive (data not shown). When
the amount of virus was increased to 1.8xl06, an increase in GFP expression was
observed, although expression from the AAV-PPT-GFP infected cells was low
compared to those cultures infected with an equivalent number of AAV-CMV-GFP
particles (figure 3.11 A, B). Infection with 4.5 x 106 and 9 x 106 infectious particles
of AAV-PPT-GFP resulted in approximately 30 to 50 GFP positive cells per
coverslip and those infected with 9 x 106 infectious particles showed more intense
staining (figure 3.11 C-H). The proportion ofGFP expressing cells is much less
(approximately 10% expression) than those cultures infected with AAV-CMV-GFP
(almost 100% expression; compare figures 3.10 and 3.11). Cells infected with 4.5 x
106 and 9 x 106 infectious particles ofAAV-CMV-GFP reach a saturation point
whereby all cells were expressing GFP. This suggests that all the neurons have been
transduced by AAV-PPT-GFP but only a proportion of these cells supported GFP
expression driven by the PPT promoter. Efficiency of gene transfer to DRG neurons
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Figure 3.11: Adult DRG infected with increasing concentrations ofAAV-PPT-GFP and
immunostained for GFP 7 days post-infection. Cells positive for GFP are pink in colour and were
infected with 1.8xl06 particles (a), (b), 4.5xl06 particles (c), (d), 9xl06 particles (e), (f), (g) and
no virus (h). Scale = 25 pm 25 x mag (a)-(f) and (h); 50 pm 10 x mag (g).
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3.4.3 Discussion
This study has demonstrated AAV-mediated gene transfer to cultured DRG
neurons by both AAV-CMV-GFP and AAV-PPT-GFP vectors. It has defined several
of the parameters that may be important for efficient transduction and the cell
populations that are transduced by AAV. In addition, this study has implicated the
cell types that might support reporter gene expression when the PPT promoter is
utilised.
It was found that both AAV-CMV-GFP and AAV-PPT-GFP express GFP in
both neurons and nonneuronal cell types. The number ofGFP positive neurons
increased as a greater number ofAAV-CMV-GFP virus particles were added and
when 4.5 x 106 infectious particles ofAAV-CMV-GFP was used for infection,
approximately all neurons were expressing GFP. This indicates a dose-dependent
pattern ofAAV mediated gene expression, with the possibility of reaching a
maximum of 100% efficiency at high doses ofAAV.
Cultures infected with AAV-PPT-GFP showed less expression both in the
number and intensity of GFP positive cells. Since similar doses ofAAV-CMV-GFP
showed 100% transduction efficiency, it may be the case that all neurons were
transduced by AAV-PPT-GFP but only a limited population of cells in culture
support expression of the PPT promoter therefore PPT promoter expression is
restricted compared to the CMV promoter. To determine if this may be the case, it
would be necessary to confirm the presence of viral DNA in the cells.
The PPT promoter has been described as supporting neuron specific reporter
gene expression when delivered as a rAAV vector to DRG cultures (Harrison et al.,
1999). In this study by Harrison et al., expression of the luciferase reporter gene was
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detected in DRG cultures but not in clonal cell lines however, this assay did not
allow the PPT expression to be visualised directly. In another study, analysis of PPT
promoter activity in DRG neurons was performed by microinjection of plasmid DNA
(containing the PPT promoter driving the (3-galactosidase reporter) directly into
neurons (Mulderry et al., 1993). This study did allow the DRG neurons expressing
the PPT promoter to be identified but did not investigate PPT expression in cell
populations other than the microinjected neurons. In agreement with the work
presented here, Mulderry et al. did find that expression was restricted to only a small
percentage of the neurons injected. In addition, Mulderry et al. revealed that
expression of the PPT constructs was not selective for DRG neurons containing
immunoreactive SP. This indicated that the promoter can support expression in
neuronal cells that do not always express the endogenous PPT gene. To test cell type-
specificity of expression ofPPT constructs, Mulderry et al. also injected the PPT
constructs into nonneuronal cells ofDRG cultures and low levels of PPT promoter
activity was observed.
This is the first study performed that examines PPT promoter activity directly
in all cell populations of cultured DRG neurons. When DRG cultures were infected
with AAV-PPT-GFP, the PPT promoter can support expression in some nonneuronal
cells. Analysis of plasmids containing this promoter fragment driving the GFP
reporter gene in cortical brain slices also observed GFP expression in nonneuronal
cell populations (Walker et al., 2000). PPT gene expression in the noneuronal
population of cells is known to occur and astrocytes can express SP (Too et al., 1994;
Lin, 1995).
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Therefore the work presented here suggested that the PPT promoter is active
in nonneuronal cells and this has been previously observed (Mulderry et al., 1993;
Walker et al., 2000). An extremely important consideration, which may account for
these observations, is that the presence of such high copy numbers ofAAV vectors
or plasmid DNA containing the PPT promoter in nonneuronal cells might act to
overcome repression of the PPT-A promoter. For example, plasmids containing the
PPT promoter do not normally support reporter gene expression in PC 12 cell lines
(Mendelson et al., 1995). However, when this reporter construct was cotransfected
into PC 12 cells together with a plasmid containing multiple copies of the postulated
repressor binding site, expression of the PPT promoter was observed (Mendelson et
al., 1995). Therefore the presence ofmultiple copies of the repressor binding site
acted to titrate the repressor from the reporter gene allowing the PPT promoter to
support reporter gene expression.
Together this work provides extremely important information about the
infection ofDRG neurons with AAV. This is important if this virus vector is to be
used in the study of investigating transcriptional regulation of the PPT promoter and
other neuron-specific genes. Furthermore, these studies have formed the basis for
future experiments to define specifically the cell populations that can support
expression of the PPT-A promoter. This could be achieved by performing
immunostaining of infected cells to identify the specific cell types that are expressing
GFP and will ultimately lead to a greater understanding of the PPT-A gene
regulation.
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CHAPTER 4: REGULATION OF THE PPT-A PROMOTER IN CULTURED
DRG NEURONS
4.1 Introduction
The aim of this study was to investigate the transcriptional regulation of the
PPT-A promoter in cultured DRG neurons. DNA binding studies have allowed
models of transcriptional regulation of the PPT-A promoter to be proposed (section
1.2.3) and these can be tested by the introduction of reporter gene constructs into
DRG neurons in culture or clonal cells lines. However functional analysis of the
PPT-A promoter has been greatly hindered due to the lack of clonal cells lines that
express endogenous PPT-A or support reporter gene expression driven by the PPT-A
promoter, together with the difficulties associated with transfection ofDRG neurons.
This study set out to overcome these problems associated with functional analysis of
the PPT-A promoter in DRG neurons. This was achieved by using rAAV as a vector
for transduction ofDRG neurons. Regulation of the promoter was investigated in two
ways. Firstly, expression of promoter constructs that contained varying lengths of the
PPT-A promoter was analysed. It was hoped that these studies would define
functional elements involved in PPT-A promoter activity in cultured sensory
neurons. Secondly, the effect of growth factors on the PPT-A promoter was studied.
Plasticity ofPPT-A gene expression is an established occurrence and expression is
induced or repressed by a variety of stimuli (Hokfelt et al., 1994). It was therefore
hoped that these studies would provide insight into PPT-A gene regulation and the
signal transduction pathways involved in mediating these effects.
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4.2 Regulation of PPT-A promoter activity: Deletion analysis
4.2.1 Background
As previously stated functional analysis of the PPT-A promoter has been
greatly hindered. Initial functional studies employed the technique ofmicroinjection
of plasmid DNA into cultured DRG neurons. Only a small number of studies have
been carried out in this way as this procedure is extremely time consuming and
allows the analysis of only a small number of neurons (section 1.2.3). Studies have
also focused on the role of individual promoter elements in cultured DRG neurons
and HeLa and PC 12 cell lines. These cell lines cannot support the expression of the
entire PPT-A proximal promoter due the presence of a dominant repressor (section
1.2.3). Subsequently isolated promoter elements were linked to heterologous
promoters to drive reporter gene expression (section 1.2.3). These studies have
determined whether specific motifs have the potential to be activator or repressor
elements, allowing models of promoter regulation to be proposed. However it is not
clear if these sites have the same function in isolation as they do when in context of
the entire promoter. It is likely that transcription factor binding sites may be
differentially regulated in cultured DRG neurons compared to cell lines such as HeLa
and PC 12 that do not express endogenous PPT-A. More recently, two cell lines
expressing endogenous PPT-A have been used for functional analysis ofPPT-A
promoter and have established transcription factor binding sites that are involved in
transcription of the proximal promoter (Fiskerstand et al., 1999). The use of these
cell lines allow potential transcriptional mechanisms to be deciphered before
performing analysis in DRG neurons, in which only a small number of experiments
are feasible. However it is important to appreciate that the plasticity of the PPT-A
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expression in DRG neurons means that regulation of the PPT-A gene could differ
between cell lines that express endogenous PPT and the DRG neurons. PPT-A
expression is regulated differently between different neuronal types, for example
sensory and sympathetic neurons (Rao et al., 1993), and even within populations of
sensory neurons, PPT-A expression is differentially regulated (Verge et al., 1995).
Consequently, the factors involved in modulating expression of the PPT-A gene are
extremely complex. This study set out to investigate the regulation of the PPT-A
gene expression in cultured adult and neonate rat DRG neurons. Neurons were
transduced by infection with AAV recombinant virus particles containing 5'and 3'
flanking DNA sequences linked to the luciferase reporter gene to study promoter
expression. In addition, the role of a specific 'E box motif in PPT gene expression
was also investigated in adult DRG neurons. Previous functional studies in PC 12 and
HeLa cells have implicated this element as an important regulator ofPPT-A
promoter activity.
4.2.2 Results
Previous work has shown that high levels of reporter gene activity is directed
by promoter fragment -865 to +92 (relative to the transcriptional start site) and the
majority of putative response elements of interest are contained in this proximal
promoter fragment (section 1.2.3). To identify regulatory regions within this span of
the PPT-A promoter, pSub201 -derived constructs were generated that contained
different lengths of the 5'-end of the PPT promoter driving luciferase as a reporter
gene (section 2.2.3.1). In addition a construct containing the promoter fragment
spanning base pairs -865 to +447 was generated, as the region spanning +92 to +447
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has been shown during the course of this thesis to contain important transcription
factor binding sites (Fiskerstrand et al., 2000). These constructs were then used for
the generation of recombinant AAV vectors (section 2.2.9.4) and the resulting
vectors were termed AAV-865+447-LUC, AAV-865+92-LUC, AAV-671+92-LUC,
AAV-484+92-LUC and AAV-47+92-LUC (figure 4.1). Unless otherwise stated, all
rAAV preparations were generated using the three-plasmid optimised protocol
described in section 3.2. Cultured DRG neurons from both adult and neonate rats
were infected with these AAV vectors (section 2.2.10.1). The infected cells were
maintained in culture for 7 days and then harvested by lysis. The cell extracts were
then assayed for luciferase activity (section 2.2.10.3). All experiments were
performed in the presence ofNGF to allow equivalent comparison of promoter
activity in DRGs from adult and neonate rats. Although cultured adult DRGs can be
maintained in the absence of growth factors, neonate DRG cultures require NGF for
survival (Lindsay, 1988).
4.2.2.1 Activity of PPT-A promoter constructs in adult DRG cultures
Due to the limited cell numbers obtained in generating adult DRG cultures,
only a maximum of three promoter fragments could be compared in any one
experiment. Therefore numerous experiments were carried out to compare the
activities of different promoter fragments in each adult DRG experiment (table 4.1).
To get a broad understanding ofPPT-A promoter expression, the activities of two
promoter fragments were compared. In particular, each promoter fragment activity
was related to that of the minimum promoter fragment -47+92 (table 4.2 and figure
4.2).
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AAV-865+447-LUC showed the highest expression levels (100%) (table 4.1)
and promoter activity was induced an average of 60 fold compared to the minimum
promoter fragment AAV-47+92-LUC (table 4.2). Expression was reduced 2 fold
(50%) when the PPT-A promoter sequence was deleted to create fragment -865 to
+92 compared to -865+447. Levels of expression from the -865+92 construct were
approximately 30 fold greater than the minimum promoter fragment therefore
showed 50% more activity than -47+92 (table 4.2). Further 5' deletions beyond
-865+92 to leave fragments -671+92 or -484+92 caused a further reduction in
expression (table 4.1). Promoter fragment -671+92 and -484+92 directed equivalent
levels of expression (approximately 10%) (table 4.1), showing an average 6 fold
increase in promoter activity compared to the minimum promoter fragment (table
4.2). These results are summarised in figure 4.2.
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Figure 4.1: AAV recombinant virus generated for PPT-A promoter analysis. Figure shows AAV
vectors containing the different promoter fragments driving the luciferase reporter gene. Important
features of these AAV vectors are also shown including the ITRs and the stuffer fragment necessary
to ensure transgene size is equal to that of AAV genome. These AAV vectors were used for infection
of cultured DRGs from both adult and neonate rats.
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Expt Promoter
-865+447 -865+92 -671+92 -484+92 -47+92
1 - 2.38710.220 0.49310.144 0.40110.062 -
2 - - - 0.0481 0.0131
3 1.069+0.482 0.53210.298 0.0221 - -
Luciferase
4 - 41.6815.04 - 12.5611.298 1.5910.219
values 5 - 18.6613.88 - 4.81810.855 0.41110.026
6 32.46±18.92 3.80710.342 - - 0.2810.047
7 30.15±19.67 19.3411.408 - - 0.910.086
8 26.02±5.702 10.6411.405 - - 0.8410.298
9 - 3.02511.162 0.42710.120 - 0.36110.126
10 58.83±6.675 35.8313.567 - - 1.38410.011
11 142.6131.68 83.219.175 - - 1.3610.195
12 - 0.18010.058 0.04110.012 - -
13 - - 0.85910.403 0.57510.125 0.27610.104
14 - - 1.18810.618 1.75610.573 0.13210.04
15 - - 0.32710.003 0.58510.016 0.06510.018
16 0.85210.196 - 0.00410.002 - -
17 0.27610.078 - - 0.00410.001 -
18 0.06110.019 - - 0.00710.001 -
Table 4.1: Expression of PPT-A promoter vectors in adult DRG neurons. DRG cultures from adult
rats were infected with AAV vectors containing the PPT-A promoter fragments -865+447, -865+92, -
671+92, -484+92 and -47+92. Cells were maintained in medium + 100 ng/ml NGF for 7 days and
then harvested and assayed for luciferase activity. The luciferase values shown are represented as












Figure 4.2: Expression of PPT-A promoter vectors in adult DRG cultures. DRG cultures
were infected with AAV vectors containing the PPT-A promoter fragments -865+447, -865+92,
-671+92, -484+92 and -47+92. Cells were maintained in medium + 100 ng/ml NGF for 7 days and
then harvested and assayed for luciferase activity. Results are represented as fold increase induced
by promoter fragments compared to expression from the minimum promoter -47+92. Data is
expressed as mean + SEM from three to eight independent experiments, whereby each experiment
incorporated triplicate wells.
-865+447 -865+92 -671+92 -484+92
Promoter fragment
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Expt Luciferase values Fold increase over
Promoter minimum
-865+447 -47+92
1 32.46 ± 18.92 0.28 ±0.047 116
2 30.15 ± 19.67 0.9 ±0.086 33.3
3 26.02 + 5.702 0.84 ±0.297 31.0
4
58.83 ±6.675 1.384 ±0.113
42.5
5
142.6 ±31.68 1.36 ±0.196
105
-865+92 -47+92
1 41.48 ±5.04 1.59 ±0.068 26.1
2 18.66 ±3.88 0.411 ±0.025 45.4
3 3.807 ±0.341 0.28 ± 0.049 13.6
4


















1 0.859 ±0.403 0.276 ±0.104 3.1
2 1.188 ± 0.618 0.132 ±0.094 9.0
3 0.327 ±0.003 0.065 ±0.018 4.8
-484+92 -47+92
1 12.56 ± 1.490 1.590 ±0.219 7.9
2 4.818 ± 0.977 0.411 ±0.026 13.4
3 0.575 ±0.150 0.276 ±0.103 2.1
4
1.756 ±0.573 0.132 ±0.040 13.3
5
0.585 ±0.016 0.065 ±0.018
9.0
Table 4.2: Comparison of promoter fragment activity to minimum promoter -47+92
in adult DRG cultures. Results from table 4.1 are represented as fold increase over the
minimum promoter. That is the increase in expression induced by promoter fragments
-865+447, -865+92, -671+92 and -484+92 compared with expression from promoter
-47+92.
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4.2.2.2 Activity of PPT-A promoter constructs in neonate DRG cultures
When the rAAV promoter vectors were analysed in neonate DRG cultures it
was possible to compare a greater number of promoter fragments in one experiment.
A greater number of neurons can be generated from neonate DRGs, which survive in
culture. In addition, several animals can be used to produce one set of cultures for
each experiment. Six separate experiments were performed in which expression from
vectors AAV-865+92-LUC, AAV-484+92-LUC and AAV-47+92-LUC, were
compared (table 4.3). In addition, four experiments included AAV-865+447-LUC
and two experiments included AAV-671+92-LUC for comparison (table 4.3).
When the activity of promoter fragment -865+447 was examined, it was
found to be approximately equal to that of -865+92. Both fragments showed the
greatest promoter acvtivity being approximately 15 fold greater than the minimum
promoter activity. Fragments -865+447 and -865+92 can therefore be described as
possessing 100% promoter activity (table 4.4; figure 4.3). When sequences were
removed to leave fragments -671+92 and -484+92, a large reduction in expression
was observed. Promoter fragments -671+92 and -484+92 directed equivalent levels
of reporter gene expression (table 4.3) and the activity of fragment -484+92 was
approximately 50% (2 fold) less than that of the minimum promoter fragment. The
increase and decrease in promoter activities over the minimum promoter are
summarised in figure 4.3.
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Expt Promoter
-865+447 -865+92 -671+92 -484+92 -47+92
Luciferase
values
1 365+19.16 276148.24 - 9.110.933 16.1610.382
2 213.5± 13.13 109.9114.68 - 5.76310.049 11.5710.174
3 59.09111.92 63.9+3.286 5.00711.751 4.60511.826 -
4 162.8147.04 150.214.017 9.17510.787 7.24414.849 27.85111.20
5 766611323 22.2812.415 - 0.51310.041 0.81910.042
6 999170.65 14.65+3.805 - 0.55110.076 1.48110.110
Table 4.3: Expression of PPT-A promoter vectors in neonate DRG neurons. DRG cultures from
neonate rats were infected with AAV vectors containing the PPT-A promoter fragments -865+447,
-865+92, -671+92, -484+92 and -47+92. Cells were maintained in medium + NGF for 7 days and then
harvested and assayed for luciferase activity. The luciferase values shown are represented as mean and














-865+447 -865+92 -671+92 -484+92
Promoter fragment
Figure 4.3: Expression of PPT-A promoter vectors in neonate DRG cultures. DRG cultures
were infected with AAV vectors containing the PPT-A promoter fragments -865+447, -865+92,
-671+92, -484+92 and -47+92. Cells were maintained in medium + 100 ng/ml NGF for 7 days and
then harvested and assayed for luciferase activity. Results are represented as fold increase induced
by promoter fragments compared to expression from the minimum promoter -47+92. Data is
expressed as mean ± SEM from three to five independent experiments, whereby each experiment
incorporated triplicate wells, with the exception of * which was performed only once in triplicate.
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1 365±19.16 16.16+0.382 22.6
2 213.5+13.13 11.57+0.174 18.4
3 162.8+47.04 27.85+11.20 5.8
-865+92 -47+92
1 276+48.24 16.16+0.382 17.1
2 109.9±14.68 11.57+0.174 9.4








1 9.175±0.787 27.85+11.20 3.0(D)
-484+92 -47+92
1 9.1±0.933 16.16+0.382 1.8(D)
2 5.763±0.049 11.57+0.174 2.0 (D)
3 7.244+4.849 27.85+11.20 3.8 (D)
4




Table 4.4: Comparison ofpromoter fragment activity to minimum promoter -47+92
in neonate DRG cultures. Results from table 4.3 are represented as fold increase over
minimum promoter. That is the increase in expression induced by promoter fragments




This study set out to identify the important regulatory elements within the
PPT-A promoter. A series of rAAV vectors were generated that contained different
PPT-A promoter fragments and were used to infect cultured DRG neurons from both
adult and neonate rats. Analysis of the PPT promoter deletion fragments revealed
differences between regulation of the promoter in DRGs from adult and neonate rats.
These results are summarised in figures 4.4 and 4.5. In adult DRGs, the promoter
fragment -865+447 directed the highest levels of luciferase reporter gene expression,
followed by fragment -865+92. There is a reduction in -671+92 promoter activity
when compared with -865+92 and there appears to be no apparent difference in
fragments -671+92 and -484+92 promoter activities. These results suggest that the
region of promoter between base pairs -865 and -671 is important for directing high
levels of promoter activity and that the region between -671 and -484 does not
contain enhancer elements functioning in these cultures. Additional enhancer
elements important for promoter regulation may be located between -484 and -47 as
removal of this sequence again results in reduced expression and the region lying
between +92 and +447 may contain further enhancer elements.
In neonate cultures, the promoter fragment spanning -865+447 directed
equivalent expression levels to fragment -865+92 and therefore gave no evidence of
functional elements between base pairs +92 and +447. When the PPT-A flanking
sequence was deleted to leave base pairs -671+92, expression levels were decreased
and further 5' deletions to create fragment -484+92 did not alter expression. Together
these results suggest that the region between -865 and -671 may contain elements,
which can act as enhancer motifs in neonate cultures. The region spanning -671 to
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-484 does not contain additional elements. This expression associated with the
-484+92 promoter fragment is also less than that of the minimum promoter. This
suggests the presence of potential silencer sequences in this region spanning
-484 to -47 in neonates.
In conclusion, the results show that although some domains may have similar
functions, expression of the PPT-A promoter may be differentially regulated between
adult and neonate DRG neurons. In particular, these studies have shown the presence
of potential repressor elements between -484 and -47 that is not present in adult DRG
neurons. Furthermore, potential activator elements between +92 and +447 were
identified in adult DRG cultures, which were not similarly observed in neonate
cultures. These putative regulatory regions are summarised in figure 4.7.
It is thought that endogenous PPT-A gene expression differs between adult
and neonate sensory neurons and this could be reflected in promoter expression. A
number of elements could be involved in this differential expression. Examination of
the nucleotide sequence of this promoter fragment reveals a number of putative
transcription factor binding sites (figure 4.6) and a number of these sites have been
shown to bind transcription factors (section 1.2.3, figure 4.7). In both neonate and
adult DRGs the promoter spanning base pairs -865 to +92 can drive high levels of
reporter gene expression and this could, in part, be attributed to the enhancer activity
shown to be associated with the region spanning -865 to -671. This region is known
to contain sequences that are bound by multiple double and single stranded DNA
binding proteins including Spl, AP2, hnRNPK and others (section 1.4.1). The
convergence of these transcription factors to this region suggests a complex interplay
between them in the regulation of the PPT-A promoter (Quinn et al., 1995). AP2
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expression in sensory neurons has been correlated with increased levels of PPT
expression in an animal model of arthritis (Donaldson et al., 1993). This previously
identified AP2 site may have a role in induction ofPPT-A promoter expression in
adult DRG cultures in the presence ofNGF.
The sequence between -671 and -484 does not appear to contain enhancer or
silencer elements in either neonates or adult. This region has been shown to contain
an octamer transcription factor binding site at base pairs -669 to -662 and has been
shown to bind members of the family of octamer binding proteins (Mendelson et al.,
1998; Fiskerstrand et al., 2000). Some of these proteins are found to have restricted
expression within the nervous system (Rosenfeld et al., 1991) and it is known that
transcription factor Oct-2 is expressed in DRG neurons and is under the control of
NGF (Wood et al., 1992). This element has previously been shown to have enhancer
function in clonal cell line NF2C as mutation of this site resulted in loss of function
and was associated with loss of protein binding in EMSAs (Fiskerstrand et al.,
2000). The function of this 5' octamer site has not been investigated in DRGs
previously and results presented here suggest that this is not acting as an enhancer in
adult or neonate DRG neurons, however under certain conditions this element may
play an important role in promoter inducibility. This conclusion has been drawn from
the assumption that this octamer site is active in this promoter fragment. It may be
the case that transcription factors binding to this site has been lost in the creation of
this deletion fragment since the octamer binding site is located only 4 base pairs
away from the 5' end of promoter fragment -671+92. In addition, activity of factors
binding this region of the promoter may depend on them acting synergistically with
elements out with this promoter fragment in order to exert an effect.
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The presence of another octamer site located 3' of the transcriptional start site
at base pairs + 372 to +389, has also been shown to be functionally important in the
NF2C and RINm5F clonal cell lines and DRG cultures. This 3' octamer site was
found to repress promoter activity (Fiskerstrand et al., 1999). The results presented
here suggest that the region spanning +92 to +447 may actually possess enhancer
activity in adult DRG cultures. However, there are fundamental differences in the
experimental procedures between these studies. Apart from the obvious method of
transfection ofDRG neurons, the work presented here was performed in the presence
ofNGF and this was not the case for the microinjection studies performed by
Fiskerstrand et al. (1999). As stated earlier, NGF is essential for neonate DRG
survival and therefore all experiments were performed in the presence ofNGF so that
promoter activity in adult and neonate cultures could be compared. The presence of
NGF is likely to cause the induction of different transcription factors and therefore
influence the results obtained. Mulderry et al. (1993) also found the region between
+92 and +447 to possess enhancer activity. Plasmids containing promoter fragments
spanning -3356 to +92 and -3356 to +447 driving the lacZ reporter gene were
microinjected into adult DRG cultures and assayed for P-galactosidase activity. The
latter fragment was found to be approximately 2 to 3 fold more active than the
fragment -3356 to +92. In accordance with the work presented here, Mulderry et al.
performed all experiments in the presence ofNGF. NGF can activate both PPT-A
expression and a variety of transcription factors. These include API and cAMP
responsive element binding protein (CREB), the octamer binding proteins and the
basic helix-loop-helix proteins (bHLH) (section 1.2.2.). In addition to the octamer
binding site, this region spanning +92 to +447 has also been shown to contain a
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potential binding site (termed E box motif) for the bHLH family of transcription
factors (section 1.2.2). Together these elements may be important for this observed
induction in promoter activity in adult DRG neurons.
The region between -484 and -47 may contain transcriptional regulatory
motifs that can function as enhancer elements in adult DRG cultures. In neonate
DRG neurons there is some evidence for these sequences being moderate repressors
of promoter activity. This region contains several APl-CRE-like elements and E box
motifs. The functional consequence of binding to an API site can be either
enhancement or repression of transcription (Quinn et al., 1989; Takimoto et al.,
1989). API- and CRE-like elements have been shown to function synergistically
with other promoter elements to work as a tissue specific enhancer or repressor (Chu
et al., 1991; Hyman et al., 1989; Leonard et al., 1992; Zhang and Young, 1991). The
API transcription factor complex consists of dimeric protein complexes composed of
members of the c-jun and c-fos family of molecules. Members of the API family of
transcription factors can also dimerise with members of the cAMP responsive
element binding proteins to bind both API and CRE consensus sequences (section
1.2.2.2). API and CRE elements often act synergistically to regulate gene
expression. These elements could therefore act as potential cA-regulatory elements
through which a vast range of stimuli could act and these elements could contribute
to the differences in promoter activity seen in adult and neonate sensory neurons.
Growth factors, inflammation, steroids and cocaine have been shown to regulate
expression of these proteins directly (Bartel et al., 1989; Hope et al., 1992; Moratalla
et al., 1993, Quinn, 1991; Spiro et al., 1993). Similarly the E motifs located in this
region may also contribute to enhancer or repressor activity. As stated above, E box
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elements are recognised and bound by the bHLH family of proteins. Like members
of the API and CRE families, these bHLH proteins form homo- or heterodimer
complexes with certain other members of the family (section 1.2.2.1). Specific bHLH
factors are expressed by neurons in addition to constitutive factors (Johnson et al.,
1992) and are also involved in tissue specific gene expression (Ball et al., 1992;
Murre et al., 1989a; Therrien and Drouin, 1993).
There are many potential factors, which can act to mediate expression of the
PPT promoter. Functional determination of important transcriptional regulators is a
complex process. The work described here has contributed to the delineation of
potential regions of the PPT-A promoter that are important for regulation ofPPT-A
expression. It has provided the basis for future studies to define the specific elements
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Figure 4.4: Summary of promoter results in cultured DRGs from neonate and adult DRG. Figure
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Figure 4.5: Differential regulation of the PPT-A promoter in cultured adult and neonate DRGs.
Figure shows (A) the fold increase or decrease of promoter fragment expression over the minimum
promoter in both adult (i) and neonate (ii) DRGs. These results reveal the differences in promoter
activity in adult and neonates and the (B) possibility that different enhancer and repressor elements
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Figure 4.6: Sequence of promoter fragment spanning -865+447 base pairs. Nucleotides also -671,
-484, -47 and +92 highlighted to indicate where sequence of each promoter fragment would start and
finish. The positions of transcription factor binding sites are shown.
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Figure 4.7: Diagram of transcription factor interactions with the PPT-A promoter.
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4.3 Regulation of PPT-A promoter activity: E box mutant studies
4.3.1 Background
This study set out to investigate the role of the 'E box motif located between
-67 and -47 base pairs of the proximal PPT-A promoter. Previous work addressing
the function of this site has found that it may be important for the transcriptional
regulation of the PPT-A promoter. When this sequence is linked to a heterologous
promoter it has been shown to drive high levels of the reporter gene expression in
PC12 and HeLa cell lines (Mendelson et al., 1995) and in DRG neurons (Paterson et
al., 1995a). NGF induced the activity of this same reporter gene construct in
transfected PC 12 cells but this induction of expression was not observed in
microinjected DRG neurons (Paterson et al., 1995a). The activity of the PPT
promoter fragment -865+92 in PC 12 cells was compared to a mutated version of
this same promoter fragment, in which the -60 E box site was disrupted. Following
forskolin-potassium evoked depolarisation the mutant construct showed much lower
reporter gene expression compared to the wild-type promoter. Under basal
conditions, the PPT-A promoter is inactive in PC 12 cells, however the combined
stimuli of forskolin and depolarisation, is necessary to achieve expression of the
PPT-A promoter. Depolarisation induces members of the API family of transcription
factors (Bartel et al., 1989) and forskolin induces members of the cAMP response
element binding (CREB) family of transcription factors (Montminy et al., 1986). E
box motifs are recognised by the basic helix-loop-helix family (bHLH) of
transcription factors, specifically members Max and USF (Paterson et al., 1995b).
Members of these three families of transcription factors are known to heterodimerise
with other family members to allow inducible and tissue-specific gene expression
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and can be induced in response to NGF (section 1.2.2.1). It is possible this element
may be important for the regulation of the PPT promoter and may have role in
mediating the response to NGF and other growth factors.
The activity of this -60 mutant promoter fragment has not yet been
investigated in DRG neurons. The activities of the promoter fragments -865+92 and
-60 mutant were compared together with the minimum promoter fragment -47+92 in
DRG neurons that were maintained it the presence or absence ofNGF. This was to
determine if this site is important for regulating the proximal promoter in DRG
neurons and if it has a role in the NGF response associated with this proximal
promoter.
4.3.2 Results
To address the role of the E box binding motif spanning base pairs -47 to -67
of the rPPT-A promoter, recombinant AAV vectors were generated that contained a
mutant version of the PPT promoter fragment -865+92, driving the luciferase
reporter gene (AAV-60mut-LUC) (section 2.2.3.2). The mutant promoter fragment
termed -60mut contained the insertion of a 10 bp oligonucleotide at nucleotide -60,
and has been previously described to disrupt PPT-A promoter activity (Paterson et
al., 1995a; 1995b). This was compared with the vectors containing the wild-type
promoter fragment -865+92 (AAV-865+92-LUC) and the minimum PPT promoter
fragment spanning base pairs -47+92 (AAV-47+92-LUC). These rAAV particles,
AAV-865+92-LUC, AAV-60mut-LUC and AAV-47+92-LUC, were used to infect
DRG neuronal cultures from adult rats and were subsequently maintained in the
presence or absence of 100 ng/ml mouse recombinant 7S NGF (section 2.2.10.1). 7
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days following infection, DRG cultures were harvested, assayed for luciferase
activity and the activity of each promoter compared (section 2.2.10.3). Each
experiment was carried out four times each time in triplicate.
It was found that the promoter activity of fragment -865+92 was equal to that
of the -60mut promoter fragment in cultures which had been maintained in NGF for
the duration of the infection period (table 4.5). The activity of both these fragments
being approximately 4 to 11 times greater than that of the minimum promoter (table
4.5).
In the absence ofNGF it was found that the activity of fragment -60mut was
approximately 8 fold greater than that of fragment -865+92 and approximately 16 to
47 times greater than the activity of the minimum promoter (table 4.6). When the
promoter activity of fragment -865+92 was compared to the minimal promoter in the
absence ofNGF it is only 2.6 to 9 times greater than —47+92 promoter activity (table
4.6). These results, summarised in figures 4.8 and 4.9 suggest that disruption of this
E box motif at -60 base pairs resulted in a higher level of promoter activity in DRG
cells in the absence of NGF when compared to the minimum promoter activity.
To determine whether the -60mut promoter activity was decreased in the
presence ofNGF, cultured DRG neurons were infected with AAV-60mut-LUC and
maintained in the presence or absence ofNGF. In a separate study, cultured DRG
neurons were infected with AAV -865+92 and also maintained in the presence or
absence ofNGF. 7 days post-infection, cells were lysed and cell extracts assayed for
luciferase activity. Table 4.7 shows that in the presence ofNGF, luciferase values of
those cells infected with AAV-60mut-FUC are lower than in the absence ofNGF and
therefore promoter activity is slightly repressed (ranging from 1.5 to 4 fold). In
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contrast, in the presence ofNGF the activity of AAV-865+92-LUC is increased
(ranging from 2.5 to 7.8 fold) compared to untreated samples (table 4.8).
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Expt Luciferase activity Fold incr.




1 0.952 ±0.137 0.744 ±0.188 0.152 ± 0.013 6.3 4.9
2 0.403 ±0.151 0.348 ± 0.090 0.035 ±0.004 11.5 9.9
3 10.54 ±2.726 20.03 ± 0.976 1.85 ±0.461 5.7 10.8
4 2.899 ± 1.202 2.394 ±0.548 0.631 ±0.071 4.6 3.8
Table 4.5: Comparison of promoter fragments -865+92, -60mut and -47+92 in the presence of
NGF. Adult DRG cultures were infected AAV vectors containing the PPT promoters -865+92, -
60mut and -47+92 (minimal promoter). Cells were maintained in medium + NGF for 7 days and then
harvested and assayed for luciferase activity. The luciferase values are represented as mean and std.
error of triplicate wells for each sample. Fold increase represents the increase in expression induced
by fragments -865+92 and -60mut compared to expression from minimal promoter -47+92.
Expt Luciferase activity Fold incr.




1 2.265 ±0.732 16.75 ±2.129 0.852 ±0.202 2.7 19.7
2 4.941 ± 1.114 25.80 ±3.524 0.550 ±0.034 9.0 46.9
3 3.845 ± 1.193 28.14 ±6.572 - - -
4 1.298 ±0.783 8.297 ±2.866 0.508 ±0.186 2.6 16.3
Table 4.6: Comparison of promoter fragments -865+92, -60mut and -47+92 in the absence of NGF.
Adult DRG cultures were infected AAV vectors containing the PPT promoters -865+92, -60mut and
-47+92 (minimal promoter). Cells were maintained in medium only for 7 days and then harvested and
assayed for luciferase activity. The luciferase values are represented as mean and std. error of
triplicate wells for each sample. Fold increase represents the increase in expression induced by
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Figure 4.8: Comparison of promoter PPT-A promoter fragments -865+92 and -60mut in the
presence or absence ofNGF. DRG cultures were infected with AAV vectors containing the PPT-A
promoter fragments -865+92, -60mut and -47+92. Cells were maintained in medium +/- 100 ng/ml
NGF for 7 days and then harvested and assayed for luciferase activity. Results are represented as fold
increase induced by promoter fragments compared to expression from the minimum promoter
-47+92. Data is expressed as mean + SEM from three or four independent experiments, whereby
each experiment incorporated triplicate wells.
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Expt Luciferase activity -60mut Fold deer. NGF treated
over untreated
- NGF +NGF
1 1.270 0.348 3.6
2 0.718 0.418 1.7
3 0.089 0.047 1.9
4 42.81 27.99 1.5
5 17.85 6.288 2.8
Table 4.7: Promoter activity of-60mut in the presence or absence of NGF. Adult DRG cultures were
infected with AAV vectors containing the PPT promoter -60mut driving the luciferase reporter gene
and maintained in the presence or absence of 100 ng/ml NGF. Cells were harvested and assayed for
luciferase activity 7 days post-infection. Luciferase values are given as mean and std. error of
triplicate wells for each sample. Fold decrease represents the reduction in expression induced by NGF
treatment compared to untreated samples.
Expt Luciferase activity -865+92 Fold incr. NGF treated
over untreated
-NGF + NGF
1 0.015 ±0.010 0.066 ±0.019 4.4
2 2.975 ±0.019 7.463 ±1.791 2.5
3 6.245 ± 1.165 46.68 ±2.032 7.8
4 10.93 ±5.979 51.08 ± 13.56 4.7
Table 4.8: Promoter activity of-865+92 in the presence or absence ofNGF. Adult DRG cultures
were infected with AAV vectors containing the PPT promoter (-865+92) driving the luciferase
reporter gene and maintained in the presence or absence of 100 ng/ml NGF. Cells were harvested and
assayed for luciferase activity 7 days post-infection. Luciferase values are given as mean and std. error
of triplicate wells for each sample. Fold increase represents the increase in expression induced by the
addition ofNGF compared to untreated samples.
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4.3.3 Discussion
The aim of this study was to investigate the function of one of the E boxes in
the PPT-A promoter in DRG neurons. Adult DRG neurons were infected with AAV
vectors containing the PPT-A promoter -865+92 and a mutant version of this
promoter termed -60mut. This mutant contained a disruption in the E box motif,
which spans base pairs -47 to -67 of the PPT promoter. The activities of these
constructs were compared both in neuronal cultures that were maintained in medium
only and those that were maintained in medium containing NGF. It was found that
when NGF is absent, the -60mut construct has greater activity than that of -865+92
(table 4.5). Following NGF treatment, -865+92 and -60mut promoter fragments
possessed equal activities (table 4.6). Further experiments examined the effect of
NGF on each of the promoter fragments (table 4.7 and 4.8). The activity of the
-60mut fragment was greater in the absence ofNGF than in the presence. The
opposite effect was observed for -865+92 promoter activity, whereby promoter
activity was increased in the presence of NGF.
These results confirm that this E box site may play an important role in the
regulation of the PPT-A proximal promoter. It has been previously suggested that
this site might be involved in NGF induction of the PPT-A gene. The results
presented here indicate this E box motifmay have a regulatory role that is associated
with the basal levels of promoter expression. It can be hypothesised that in DRG
neurons in the absence of NGF, the PPT-A proximal promoter activity is normally
repressed by the presence of factors binding this E box motif (figure 4.10). These
studies provide no clear evidence to support a role for this E box motif in the NGF
induction of the PPT-A promoter. In the presence ofNGF, the fold increase over the
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minimum promoter is 3.8 to 10.8 and in the absence of NGF, it is 16.3 to 49.9,
therefore the -60 mutant fragment is more active in the absence ofNGF than in the
presence. In addition, when the -60mut fragment was compared in the presence or
absence ofNGF, untreated samples did have greater luciferase activity than those
that were NGF treated. It can be hypothesised that NGF might mediate its effect by
relieving repression of this E box site that was observed under basal conditions. If
this is the case, induction by NGF of this -60mut promoter may not have been
observed under these experimental conditions since the creation of this mutation has
relieved repression under both basal and NGF treated conditions and therefore may
mask the normal effect ofNGF. Similarly it can be hypothesised that NGF may
mediate its effect by activating transcription factors that bind elements on the PPT-A
promoter other than this E box motif. Further experiments would need to be
performed before any conclusions could be drawn regarding the role of this E box in
NGF induction of the PPT-A promoter (figure 4.10).
Previous work has shown that this E box site can function as a transcriptional
activator in microinjected DRG neurons and PC12 cells (Paterson et al., 1995a;
1995b). This work by Paterson et al. looked at the E box activity in DRG neurons in
isolation. In addition activity of the disrupted E box in context of entire promoter was
examined in PC 12 cells, following forskolin and potassium depolarisation. The use
of different cell types and induction conditions are bound to influence the precise
repertoire of transcription factors present and this is likely to modulate the function
of the PPT-A E box. As previously stated E box motifs are bound by the bHEH
family of transcription factors. These can form homo- or hetero-dimers with different
member of the bHLH family and with members of other transcription factor families
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(section 1.2.2.1). Furthermore, the specificity of binding to the E box may involve
recognition of flanking sequences in addition to the core binding motif therefore
looking at the E box fragment in isolation may give different results to those
generated in the context of the entire promoter. Therefore the flexibility of
interaction between transcription factors may facilitate whether this E box motif is to
function as an activator or repressor, facilitating tissue-specific and inducible PPT-A
gene expression.
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Figure 4. 9: Summary of PPT-A promoter -865+92 and mutant version -60mut activity in the
presence or absence ofNGF. Figure shows the E box sequence in the wild-type promoter fragment
(red) and the mutant version (original sequence shown in red and 10 bp oligonucleotide is shown
in black).
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Figure 4.10: Hypothesis for the role ofE box motif in regulation of the PPT-A promoter. It is thought
that the -60 E box motif is repressed under normal conditions (a). It is unclear whether it is involved
in the induction of PPT-A promoter activity by NGF treatment. NGF induction may be due to the
activation of transcription factors acting on promoter elements other than the E box
motif (b). It is possible that this E box site is activated in response to NGF and other stimuli (c).
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4.4 Effect of Growth factors on the PPT-A proximal promoter
4.4.1 Background
The aim of this study was to determine if the PPT-A proximal promoter is
responsive to a variety of growth factors in cultured DRG neurons. The PPT gene is
regulated directly and indirectly by a variety of stimuli including steroids, cocaine,
inflammation and peripheral axotomy (section 1.1.3). In addition, members of the
neurotrophin family and other growth factors are thought to influence regulation of
the PPT-A gene. Little is known about the effect of neurotrophic factors other than
nerve growth factor (NGF) on PPT-A gene expression in DRG neurons. NGF can
regulate PPT mRNA levels in DRG neurons in culture and in vivo (section 1.1.3).
However, other growth factors and members of the NGF-related neurotrophin family
have also been implicated in regulating SP expression in sensory neurons (Mulderry,
1994). If these factors play a role in influencing neuropeptide levels in DRG neurons,
it is possible that regulation is at the level of transcription of the PPT-A gene.
Sequence analysis of the PPT-A gene showed the presence ofmany putative
transcription factor binding sites which may have a role in mediating the effects of
these stimuli (section 1.2.2). Furthermore, DNA binding studies showed the majority
of important regulatory elements reside in the proximal promoter region spanning
nucleotides -865 to +447 (section 1.2.3). This PPT-A promoter fragment has
previously been shown to be NGF responsive in cultured DRG neurons when
delivered as a rAAV particle and therefore must contain regulatory elements that can
mediate the effect ofNGF (Harrison et al., 1999). It was thought that this promoter
fragment -865+92 may contain regulatory elements that can act to mediate the effect
of other growth factors. The effects of growth factors nerve growth factor (NGF),
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brain derived neurotrophic (BDNF) and glial cell-derived neurotrophic factor
(GDNF), together with cytokines leukemia inhibitory factor (LIF) and interleukin-6
(IL-6), on PPT-A promoter activity was examined. These factors were chosen
because they have all been implicated in regulating neuronal phenotypes and have
been associated with distinct populations ofDRG neurons.
NGF and BDNF are both members of the neurotrophin family of growth
factors (section 1.3.1). Although adult sensory neurons do not require neurotrophins
for their continued survival, the neurotrophins are required for the continued
maintenance of particular mature phenotypic characteristics, including peptide
content and physiologic responsiveness. Neurotrophins also play a role in the
regulation of neuronal growth, and particularly in growth or regeneration as a
response to injury (Segal and Greenberg, 1996). NGF is known to have an important
role in adult sensory neuron function, particularly nociception (Lewin and Mendell,
1993). BDNF is also required for neuronal plasticity and is thought to have
nociceptive function distinct from that ofNGF in adult DRG neurons (Thompson et
al., 1999; Kerr et al., 1999; Shu and Mendell, 1999).
In addition to the neurotrophins, several other proteins are thought to
influence phenotypic characteristics. LIF and IL-6 are members of the neuropoietic
cytokine family. These cytokines have been shown to influence the survival and
differentiation of various neuronal subpopulations in the central and peripheral
nervous system (Fann and Patterson, 1994; Sendtner et al., 1994; Stahl and
Yancopoulos, 1994; Pennica et al., 1995; Horton et al., 1998). LIF and IL-6 may
play a regulatory role in the interaction between the nervous and immune systems
and both LIF and IL-6 are thought to be involved in altering neuropeptide phenotype
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in adult sensory neurons following nerve injury (Corness et al., 1996; Sun and
Zigmond, 1996a; 1996b; Thompson et al., 1998).
GDNF is member of the transforming growth factor p (TGFP) superfamily
and is known to play an important role in the development and survival of
dopaminergic neurons (Poulsen et al., 1994; Beck et al., 1995; Bowankamp et al.,
1995). GDNF has been shown to be associated with sensory neurons (Holstege et al.,
1998; Bennet et al., 1998b; Kashiba et al., 1998) and induce SP expression in DRG
cultures (Adler, 1998).
4.4.2 Results
To determine if these growth factors can directly regulate the PPT-A
promoter, DRG were dissected from adult rats and the neurons cultured (section
2.2.7.1). In the initial stages of producing these cultured DRGs, cells were plated out
in medium containing NGF to promote neurite outgrowth. Routinely after 24-48
hours, medim containing exogenous NGF was removed and cells were maintained in
medium containing no growth factors for at least 24 hours (section 2.2.10.2). AAV
vectors that contained the PPT-A promoter spanning base pairs -865+92 driving the
luciferase reporter gene (termed AAV-865+92-LUC) was used to infect DRG
neurons (section 2.2.10.1). The infected neurons were subsequently maintained in the
presence or absence of each particular growth factor for 7 days. DRG cultures were
harvested and assayed for luciferase reporter gene product activity (section 2.2.10.3).
It was important in these experiments to ensure that results obtained are due to the
growth factor acting specifically on the promoter construct and not due to variations
in neuronal survival. Adult DRGs have been reported to survive in culture
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independently of added neurotrophic factors (Lindsay, 1988) therefore the effect of
trophic factors on promoter activity should be uncomplicated by cell survival effects.
However, to eliminate any possible effect on survival, the effect of growth factors on
the CMV promoter was also examined. This also eliminates the possibility that any
response observed is due to artefacts associated with virus genome structure.
Accordingly DRGs were also separately infected with AAV vectors containing the
CMV promoter driving the luciferase reporter gene (termed AAV-CMV-LUC). This
process is shown in figure 4.11.
Another important aspect associated with these experiments is that there is a
high degree of variability in promoter activity both between and sometimes within
experiments. In addition, only a small number of samples are available for analysis in
each experiment and a relatively small number of cells make up each sample. These
factors together make variation appear large and also mean that statistical or
quantitative analysis cannot be performed. However, trends in induction or
repression of promoter activity can be investigated and reveal important information
about the regulation of the PPT-A promoter. Due to these constraints it was decided
that if a growth factor resulted in a 2 fold or greater increase or decrease in luciferase
activity, it could be described as having an effect on the PPT-A promoter. In addition
the concentrations of exogenous growth factor employed by these experiments were
similar to those that have been used in the literature to induce endogenous PPT-A
gene expression (NGF: Lindsay and Harmer, 1989; GDNF: Adler, 1998; CNTF,







Leukaemia inhibitory factor (LIF)
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Figure 4.11: Stimulus inducibility of the PPT-A promoter: Summary of growth
factor experiments. Cultured DRG were infected with AAV vectors containing
the PPT-A proximal promoter driving the luciferase reporter gene
(AAV-865+92-LUC). Infected cultures were subsequently maintained in medium
+/- growth factor (GF). Separate DRG cultures were also infected with AAV vectors
containing the CMV promoter driving luciferase (AAV-CMV-LUC). This
ensured any effect observed was due to GFs acting specifically on promoter.
The effects of a variety of growth factors were studied.
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4.4.2.1 Effect of NGF
The effect of 100 ng/ml of exogenous mouse recombinant 7S NGF on the
PPT-A promoter was investigated. Table 4.9 shows the mean values of each
experiment when AAV-865+92-LUC infected DRG cultures were treated with NGF
or untreated. This experiment was performed four times, each time in triplicate. In
each experiment, NGF treated cells displayed increased luciferase values compared
to cells in which exogenous NGF was absent, suggesting the induction of PPT
promoter activity by NGF. Induction ranges from 2.5 fold to 7.8 fold. NGF did not
influence levels of luciferase activity in those cells infected with AAV-CMV-LUC
(table 4.14).
4.4.2.2 Effect of GDNF
The effect of 25 ng/ml rat recombinant GDNF on the PPT-A promoter was
examined four times in triplicate. Table 4.10 shows the mean values of each
experiment. Cultures infected with AAV-865+92-LUC and maintained in GDNF
showed greater luciferase values. This increase ranged from 2.4 to 4.4 fold compared
to cells, which were not treated with GDNF, implying GDNF may be acting to
induce PPT promoter activity. When the same experiment was performed on cells
infected with AAV-CMV-LUC, GDNF did not affect luciferase values (table 4.14)
4.4.2.3 Effect of BDNF
The effect of 50 ng/ml human recombinant BDNF on the PPT-A -865+92
promoter fragment in DRG cultures was examined in four separate experiments
(table 4.11). It was found that in those cells treated with BDNF, luciferase values
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were 1.6 to 2.7 times greater than those cells that in which exogenous BDNF was
absent. It is unclear ifBDNF is acting to significantly induce promoter activity.
4.4.2.4 Effect of LIF and LIF+NGF
To examine the effect of LIF alone and NGF together with LIF, infected
neuronal cultures were maintained in medium containing no growth factor, medium
containing LIF alone and medium containing LIF and NGF together. This
experiment was performed six times each in triplicate (table 4.12). When cells were
maintained in the presence of 25 ng/ml mouse recombinant LIF only luciferase
values were reduced by 2 to 4 fold compared to cells in which LIF was absent. When
cells were maintained in both 25 ng/ml LIF and 100 ng/ml mouse recombinant 7S
NGF, the results were much more variable. In experiments 2 and 6, the addition of
NGF and LIF together showed increased luciferase activity (3.5 and 3 fold)
compared to untreated. Flowever, in experiments 3 and 4, a clear reduction in
luciferase activity was observed (2.6 to 5.4 fold) and in experiments 1 and 5, no real
effect on luciferase values was observed when NGF and LIF were added. These
results suggest that LIF can act to repress PPT promoter activity, however it is
unclear what action NGF and LIF are having on the promoter when provided
together.
4.4.2.5 Effect of IL-6
The effect of IL-6 on PPT-A promoter activity was examined three times, each in
quadruplicate. Cultures infected with AAV-865+92-LUC were maintained in the
presence or absence of 25 ng/ml mouse recombinant IL-6 and the mean luciferase
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values obtained for each experiment are shown in table 4.13. In experiments 1 and 2,
IL-6 does not appear to be influencing luciferase activity, however in experiment 3
there is a 6 fold increase in luciferase activity in IL-6 treated samples compared to
cells maintained in the absence of IL-6. Again, it is unclear if IL-6 is significantly
acting to influence the PPT-A promoter.
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Experiment Luciferase values
-NGF + NGF Fold incr. NGF treated
over untreated
1 0.015 + 0.010 0.06610.019 4.4
2 2.975 10.019 7.4631 1.791 2.5
3 6.2451 1.165 46.6812.032 7.8
4 10.9315.979 51.08113.56 4.7
Table 4.9: Effect of NGF on the PPT-A promoter. Adult DRG cultures were infected with AAV
vectors containing the PPT promoter (-865+92) driving the luciferase reporter gene and maintained in
the presence or absence of 100 ng/ml NGF. Cells were harvested and assayed for luciferase activity 7
days post-infection. Luciferase values are given as mean and std. error of triplicate wells for each
sample. Fold increase represents the increase in expression induced by the addition ofNGF compared
to cells that were maintained in the absence ofNGF (untreated).
Experiment Luciferase values
-GDNF + GDNF Fold incr. GDNF
treated over untreated
1 33.01 14.43 144.3 151.09 4.4
2 16.8217.03 64.4716.31 3.8
3 2.61 10.895 6.533 1 1.161 2.5
4 0.685 10.163 2.3571 1.010 3.4
Table 4.10: Effect of GDNF on the PPT-A promoter. Adult DRG cultures were infected with AAV
vectors containing the PPT promoter (-865+92) driving the luciferase reporter gene and maintained in
the presence or absence of 25 ng/ml GDNF. Cells were harvested and assayed for luciferase activity 7
days post-infection. Units of expressed luciferase are given as mean and std. error of triplicate or
quadruplicate wells for each sample. Fold increase represents the increase in expression induced by
the addition of GDNF compared to cells that were maintained in the absence ofGNDF (untreated).
Experiment Luciferase values
- BDNF + BDNF Fold incr. BDNF
treated over untreated
1 0.39610.051 0.929 10.405 2.3
2 1.81810.042 3.103 + 0.520 1.7
3 0.781 10.133 1.26310.108 1.6
4 0.048 10.003 0.13510.023 2.8
Table 4.11: Effect ofBDNF on the PPT-A promoter. Adult DRG cultures were infected with AAV
vectors containing the PPT promoter (-865+92) driving the luciferase reporter gene and maintained in
the presence or absence of 25 ng/ml BDNF. Cells were harvested and assayed for luciferase activity 7
days post-infection. Units of expressed luciferase are given as mean and std. error of triplicate or
quadruplicate wells for each sample. Fold increase represents the increase in expression induced by
the addition ofBDNF compared to cells that were maintained in the absence ofBDNF (untreated).
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Experiment Luciferase values








l 34.11 ± 1.010 17.13 ±2.586 52.12 ±20.24 2.0 1.5 (I)
2 2.553 ±0.855 - 9.522 ±0.878 - 3.5 (I)
3 5.594 ±2.913 1.41 ±0.908 1.027 ±0.277 4.0 5.5 (D)
4 4.898 ±2.718 1.543 ±0.431 1.881 ±0.303 3.2 2.6 (D)
5 0.166 ±0.052 0.086 ±0.014 0.151 ±0.041 2.0 1.1 (D)
6 0.535 ±0.055 0.262 ± 0.064 1.600 ±0.576 2.0 3.0(1)
Table 4.12: Effect ofLIF and NGF together and LIF alone on the PPT-A promoter. Adult DRG
cultures were infected with AAV vectors containing the PPT promoter (-865+92) driving the
luciferase reporter gene and maintained in the presence or absence of 25 ng/ml LIF or 25 ng/ml LIF +
100 ng/ml NGF. Cells were harvested and assayed for luciferase activity 7 days post-infection. Units
of expressed luciferase are given as mean and std. error of triplicate or quadruplicate wells for each
sample. Fold increase or decrease represents the increase or decrease in expression induced by the
addition of LIF and NGF compared to cells that were maintained in the absence ofNGF and LIF
(untreated).
Experiment Luciferase values
-IL-6 + IL-6 Fold incr. IL-6 treated
over untreated
1 54.27 ± 18.81 88.39 ± 12.64 1.6
2 4.467 ± 1.456 5.051 ± 1.359 1.1
3 2.021 ±0.304 12.10 ±5.036 6.0
Table 4.13: Effect of IL-6 on the PPT-A promoter. Adult DRG cultures were infected with AAV
vectors containing the PPT promoter (-865+92) driving the luciferase reporter gene and maintained in
the presence or absence of 25 ng/ml IL-6. Cells were harvested and assayed for luciferase activity 7
days post-infection. Units of expressed luciferase are given as mean and std. error of triplicate or
quadruplicate wells for each sample. Fold increase represents the increase in expression induced by
the addition of IL-6 compared to cells that were maintained in the absence of IL-6 (untreated).
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Growth factor Experiment Luciferase values




NGF (100 ng/ml) 1 0.294 ± 0.024 0.276 10.043 0.9 (D)
2 0.394 + 0.038 0.56010.051 1.4 (I)
LIF (25 ng/ml) 1 0.121 ±0.006 0.16510.018 1.4 (I)
2 0.20410.041 0.22410.014 1.1(1)
GDNF (25 ng/ml) 1 0.96610.306 0.864 10.075 0.9 (D)
2 0.311 ±0.094 0.58910.080 1.9(1) j
IL-6 (25 ng/ml) 1 0.94210.157 0.788 10.269 0.8 (D) ;
2 1.51210.117 2.426 1 0.269 1.6 (I)
BDNF (25 ng/ml) 1 1.39410.220 0.846 1 0.098 1.6 (D)
2 1.52610.256 1.923 ±0.589 1.3 (I)
Figure 4.14: Effect of growth factors on the CMV promoter. Adult DRG cultures were infected with
AAV vectors containing the CMV promoter driving the luciferase reporter gene and maintained in the
presence or absence of growth factors (GF). Cells were harvested and assayed for luciferase activity 7
days post-infection. Luciferase values are given as mean and std. error of quadruplicate wells for each
sample. Fold increase or decrease represents the increase or decrease in expression induced by the








5 £ £ £




Figure 4.12: Effect of growth factors on the PPT-865+92 and CMV promoters. Adult DRG cultures
were infected with AAV vectors containing the PPT promoter spanning base pair -865+92 or the CMV
promoter driving the luciferase reporter gene and maintained in the presence or absence of growth
factor (GF). Cells were harvested and assayed for luciferase activity 7 days post-infection. Values are
given as fold increase or decrease in promoter activity induced by the addition of GF compared to
samples maintained in the absence of GF. Data is expressed as mean ± SEM from two to five
independent experiments, whereby each experiment incorporated triplicate or quadruplicate wells.
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4.4.3 Discussion
It has been previously shown that exogenous NGF induces the PPT-A
proximal promoter in cultured DRG neurons (Harrison et al., 1999). This study set
out to examine the effect of other growth factors on this promoter fragment spanning
base pairs -865+92. Since adult DRG neurons survive in culture independently of
added neurotrophic factors (Lindsay, 1988), the effect of trophic factors on promoter
activity was investigated without the complications arising from variations in
survival. To further ensure that the growth factors were acting specifically on the
promoter the effect of these factors on the CMV promoter was also compared. This
eliminated the possibility of growth factors exerting their effects by increasing
survival or by influencing the AAV vector delivery system. The results of these
studies are summarised in figure 4.12. It was found that NGF and GDNF induced
luciferase actvity, reflecting an increase in PPT-A promoter activity whereas LIF
acted to decrease PPT promoter levels in DRG neurons. The effects ofBDNF, IL-6
and LIF and NGF together was not so obvious as in some of the experiments
performed no effect was observed. To understand more about the signal transduction
pathways that regulate the PPT-A gene and the regulatory elements involved, it is
important to relate these promoter results to studies that have focused on examining
the effect of growth factor on endogenous PPT-A gene expression in vitro and in
vivo.
4.4.3.1 Action of NGF and LIF
Following nerve injury, neuropeptide expression in DRG neurons is seen to
be altered: neuropeptides galanin and NPY are upregulated, whereas SP and CGRP
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have been shown to be down-regulated (Zigmond et al., 1996). Both LIF and NGF
have been implicated as triggers for these changes in peptide phenotype since LIF
expression is induced (Banner and Patterson, 1994; Curtis et al., 1994) and target-
derived factors such as NGF are lost following axotomy (Hokfelt et al., 1994). In
addition to having a role following nerve injury in the adult peripheral nervous
system, NGF is thought to interact with nociceptive processing (Lewin and Mendell,
1993; Lewin and Barde, 1996). NGF can increase SP and PPT mRNA levels in DRG
cells in vitro (Mulderry, 1994; Lindsay and Harmar, 1989; Jiang and Smith, 1995)
and in vivo (Otten and Lorez, 1983; Vedder et al., 1993). This suggests that NGF
may be acting at the level of transcription to modulate these changes in expression.
Harrison et al. (1999) examined the effect ofNGF on the PPT-A proximal promoter
spanning base pairs -865+92 and found a 30-fold increase in PPT-A promoter
activity following treatment with NGF. In this thesis, the effect ofNGF on PPT-A
promoter activity was again examined and was found to induce promoter activity 2.5
to 7.8 fold. Although consistent with the work of Harrison et al. (1999) a large
variation in the activation of promoter activity by NGF is apparent. This variability
can be associated with a range of factors such as quality and quantity of DRG
neuronal cultures, quality and titre ofAAV prep used. This variability is apparent in
all growth factor experiments performed, however it is particularly large when the
effect ofNGF alone and NGF together with LIF on promoter activity are examined.
One explanation for the variability is that nonneuronal cells within cultured
primary neurons express LIF (Banner and Patterson, 1994; Sun and Zigmond, 1996a)
and LIF is known to antagonise the effect ofNGF (Verge et al., 1995; Corness et al.,
1998; Mulderry, 1994). The percentage of satellite cells present in the cultures and
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the amount of endogenous LIF expressed may therefore influence the levels of
induction by NGF. Another consideration is that these primary cultures are thought
to mimic axotomised populations ofDRG neurons and following axotomy it is
generally accepted that SP levels are decreased. However it has also been suggested
that SP levels are increased in a population of neurons (Verge et al., 1995). Therefore
depending on the population of neurons present in the cultures, the overall result of
induction observed may be affected by this.
As stated above, an essential consideration is the titre and also the method of
preparation ofAAV samples. Harrison et al. (1999) reported a 30-fold increase in
promoter activity following treatment with NGF in DRG cultures. The work
presented here also shows induced promoter activity, however this is on a much
smaller scale (table 4.9). Harrison et al. generated virus vectors using the two
plasmid-adenovirus helper method (section 1.4.7) and it is possible that this could
have considerable influence on these studies. AAV vectors generated in this way
often contain residual adenovirus and adenoviral proteins and generally result in
lower titres ofAAV (section 1.4.8). The presence of adenovirus is known to enhance
expression from rAAV vectors (Fisher et al., 1996). Furthermore, other contaminants
in these AAV stocks can mimic transduction ofAAV vectors and may be capable of
generating artifactual results (Alexander et al., 1997; Tenebaum et al., 1999;
personal observations, section 4.6.3).
LIF is also known to regulate peptide levels in sympathetic and sensory
neurons. It has been shown that galanin induction in sensory neurons is LIF
dependent, and LIF can regulate SP expression in vivo and in cultured sympathetic
neurons (Nawa et al, 1991; Zigmond et al., 1996; Zigmond and Sun, 1997).
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Conflicting results regarding the effect of LIF on SP expression in sensory neurons
have been reported. Zhang et al. (1995) report that high levels of exogenous LIF
applied to cut sciatic nerve can significantly act to increase the percentage of SP
mRNA positive cells, therefore preventing the reduction in SP associated with
axotomy. However, experiments using LIF knock out mice suggest that LIF does not
influence SP expression (Sun and Zigmond, 1996b) and in vitro, it has been shown
that LIF alone has no effect on SP expression (Mulderry, 1994). In this thesis the
effect of LIF alone on the PPT-A promoter was examined and found to decrease
activity by 2 to 4 fold. Consistent with these results, Nawa et al. (1990) report that
LIF acts to decrease SP expression in neuron enriched DRG cultures by 60%.
It has been reported that when exogenous LIF is applied together with NGF,
the effect ofNGF on SP expression is antagonised by the presence of LIF (Mulderry,
1994). When the effect of NGF and LIF together on the PPT-A promoter was
investigated in this study, in two experiments a small increase in PPT-A promoter
activity was observed compared to samples maintained in the absence of exogenous
NGF and LIF. However, in another two experiments a decrease was seen and in
another two experiments, no effect was observed in comparison to untreated. It is
therefore not possible from these results to define what effect NGF and LIF together
are having on the PPT-A promoter. However, this variation in promoter activity
could again be explained by endogenous LIF expression in the cultures and LIF may
still be performing this antagonistic role. The range of induction by NGF is variable,
ranging from 2.5 to 7.8 fold and therefore the antagonist effect exerted by LIF in the
presence ofNGF will be highly variable. For example, if LIF and NGF are applied
together and a 2 fold increase in promoter activity compared to untreated cells is
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observed, this result may also be equivalent to a decrease in promoter activity when
compared to an 8 fold induction of activity by NGF. In this set of experiments, the
treatment with NGF alone was not included due to limitations of sample size. Such
controls would therefore need to be performed before any conclusions could be
drawn regarding the effects ofLIF and NGF on the PPT-A promoter.
4.4.3.2 Action of GDNF
Much attention has been paid to the role of GDNF in sensory neurons as it
exerts trophic effects on sensory neurons (Buj-Bello et al., 1995; Matheson et al.,
1997; Moore et al., 1996). It has been shown to be present in DRG neurons
(Holstege et al., 1998) and following axotomy, downregulation ofGDNF in the
dorsal horn is observed (Jongen et al., 1999). This response is similar to that of SP
expression following axotomy and GDNF immunoreactivity in the dorsal horn is
similar to the expression pattern of SP (strong in laminae I and Il-outer). This
suggests that GDNF, like SP may have a role in nociception, and under normal
nociceptive responses, GDNF may be acting to modulate SP.
When the effect of exogenous GDNF on the PPT-A promoter was studied, it
was found that GDNF induced promoter actvity 2.4 to 4 fold. This is consistent with
previous studies that examined the effect of exogenous GDNF on endogenous SP
expression. Ogun-Muyiwa et al. (1999) showed a 3-fold increase in the percentage of
SP mRNA expressing neurons and a 3-fold increase in the amount SP (measured by
ELISA) in cultured DRG neurons following GDNF treatment. In addition, Adler
(1998) found that the addition of exogenous GDNF to cultured DRGs increased
endogenous SP concentrations by 3 fold. The effect of GDNF on the PPT-A
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proximal promoter is consistent with effect ofGDNF on the endogenous PPT-A
gene. This is an important result and implies that the elements present on the
proximal promoter spanning -865+92 are important for this induction of endogenous
gene expression.
4.4.3.3 Action of IL-6
IL-6 may have a role in inflammation and the phenotypic responses
associated with sensory neurons following axotomy. Peripheral nerve injury induces
the production of IL-6 from Schwann cells (Bolin et al., 1995) and DRG neurons
(Murphy et al., 1995). IL-6 mRNA and IL-6 receptor mRNA are highly expressed in
rat (neonatal and adult) sensory and sympathetic ganglia (Gadient and Otten, 1996).
Furthermore, 60% of IL-6 positive cells are colocalised with substance P and CGRP
in DRG cell populations (Nordlind et al., 2000) implying that DRGs may be
responsive to IL-6. No studies so far have looked at the effect of IL-6 on endogenous
PPT mRNA in DRG neurons, however like the other factors studied, IL-6 has trophic
effects on DRG neurons and IL-6 is essential to modulate sensory functions in vivo
(Gadient and Otten, 1997; Grud and Nelson, 1997; Campbell, 1998; Zhong et al.,
1999). In addition, IL-6 in high doses has been shown to induce SP mRNA in
cultured sympathetic neurons (Fann and Patterson, 1994) and intrathecally applied
IL-6 induces allodynia and hyperalgesia in rats (DeLeo et al., 1996). These facts
together suggest that IL-6 might act to regulate SP expression in DRG neurons.
When the effect of exogenous IL-6 on the PPT-A promoter in DRG cultures was
examined it was found that promoter activity was slightly induced. It would be useful
to determine if IL-6 can regulate endogenous PPT-A mRNA before speculation can
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be made regarding the role of IL-6 in regulating SP levels. However, IL-6 expression
is induced following inflammation (Vallieres and Rivest, 1997) and inflammation
also known to induce PPT-A mRNA in DRGs (Leslie et al., 1995) therefore it is
feasible to postulate that IL-6 may be involved in mediating this complex process.
Studies to investigate the effect of IL-6 on endogenous PPT-A gene expression are
ongoing.
4.4.3.4 Action of BDNF
Studies on the role ofBDNF in the peripheral nervous system have focused
on defining BDNF as a central modulator of pain (Thompson et al., 1999). BDNF is
constitutively expressed in DRG neurons (Ernfors et al., 1990; Apfel et al., 1996;
Cho et al., 1997) and it has been shown that this expression is associated with the
NGF responsive population of neurons (Kashiba et al., 1997b; Micheal et al., 1997).
Following inflammation BDNF expression is increased in DRG neurons in a NGF-
dependent manner (Cho et al., 1997) and this upregulated BDNF expression is
thought to contribute to persistent inflammatory pain states (Mannion et al., 1999;
Kerr et al., 1999). A change in BDNF expression is also seen following peripheral
axotomy, whereby BDNF expression is increased in the large diameter population of
DRG neurons and decreased in the small diameter nociceptive population (Tonra et
al., 1998). This is similar to the expression patterns of SP following both axotomy
and inflammation. It was therefore thought that BDNF could have a role in
influencing these changes in peptide expression in DRG neurons. The effect on
BDNF on endogenous SP expression in cultured DRG neurons has been investigated
and revealed that BDNF exerted no effect on expression or neuronal survival
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(Mulderry, 1994). Mulderry suggested that this lack of effect on peptide expression
could reflect the presence of significant quantities of endogenous BDNF in cultured
DRG neurons since these DRGs themselves express BDNF.
The work carried out here examined the effect of BDNF on the PPT-A
proximal promoter in cultured DRG neurons and a small increase in PPT-A promoter
activity follwing BDNF treatment was observed in half the experiments performed.
In the other experiments addition ofBDNF did not influence PPT promoter activity.
These contrasting results may be due to differences in cultures between experiments
and reflect the presence of varying amounts of endogenous BDNF as Mulderry
suggested. Under certain conditions, BDNF may influence regulation of the PPT-A
promoter and under other conditions this regulatory effect is not found.
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4.5 AAV vectors as a tool for studying transcriptional regulation of the
PPT-A promoter in DRG cultures
The promoter experiments described have revealed possible functional
elements involved in regulating the PPT-A promoter in both neonate and adult DRG
cultures. In addition, it has shown that under certain conditions the PPT-A promoter
is stimulus inducible and therefore contains important transcriptional elements that
can mediate this effect. AAV vectors have been crucial for these studies, however
various difficulties associated with this system of studying transient promoter
activity delivered by virus vectors in heterogeneous primary neuronal cultures have
also been highlighted. Two main difficulties have come to light. First the difficulties
with generating and studying DRG cultures from adult rats and secondly, the lack of
established controls when using the AAV vectors for transduction. Together these
factors ultimately mean that high levels of variability were observed. Generating
primary DRG cultures can be difficult and it is sometimes difficult to achieve high
numbers of neuronal cells, making this a quite inconsistent technique. For example,
over the course of this study a very large number of dissections were performed to
produce adult DRG cultures (a minimum of 500) however, only 70% of these, at best
would have provided successful cultures suitable for experimental use. In addition,
because cells were maintained in culture for around 10 days, this time span meant
that often cultures did not survive for numerous reasons such as contamination or
unexplained death. Subsequently, from the number of infection experiments
performed, only around 50% of these actually provided meaningful data. Therefore
although use ofDRG primary cultures is necessary for investigating promoter
regulation in sensory neurons and can provide extremely interesting data, it is not an
easy system to work with. Ideally, a cell line derived from DRG neurons may
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provide insight into PPT-A promoter regulation in sensory neurons and eliminate
these difficulties.
Another major factor associated with the use of DRG heterogeneous primary
cultures for these experiments has been the difference between each set of cultures,
including how the number of nonneuronal cells present in the cultures may be an
important influencing factor when investigating stimulus inducibility. Although,
nonneuronal cells are reduced by the method of culturing, they can never be
completely eliminated and the fact that cells must be maintained in culture for 7 days
adds to this difficulty. Schwann cells and fibroblasts are known to produce LIF and
possibly other factors to affect phenotype. Therefore the presence of endogenous
growth factors influencing outcome is always a possibility. In future experiments
concerns of endogenous growth factors affecting results could be eliminated by first
treating cultures with growth factor neutralising antibodies before addition of the
exogenous growth factor. This way only the effect of the exogenous factor would be
observed.
These cultures also introduce the complexity of studying unidentified
intermediate molecules that are produced only under particular circumstances. For
example, studies on SP expression in cultured sympathetic superior ganglia showed
that IL-1 can increase SP expression only in cultures which contained nonneuronal
cells implying the presence of an intermediate molecule (Freidin and Kessler, 1991).
The problem of variability was not only restricted to the growth factor studies, as it
was also apparent in the promoter analysis. The relative level of increase of promoter
activity over the minimum promoter was varied and again this was likely to be a
reflection of the cultures used for individual experiments.
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Another major problem in this work was the lack of controls in order to
normalise the luciferase values obtained to neuronal cell number and virus
transduction efficiency, or to measure total protein concentration in order to express
luciferase activity per mg of protein. This was due to the fact that the absolute
protein concentration was too low to be accurately measured. In the future it would
be useful to design vectors which express a marker molecule, perhaps via a
functional IRES or to co-infect cells with another AAV vector expressing for
example LacZ in order to normalise luciferase activity to (3-gal activity. Although,
this is not always possible due to the size constraints associated with AAV vectors.
Despite these highlighted problems, useful insight regarding regulation of the
PPT-A promoter has been established and has provided a framework for future
studies. This work has shown that this system of using AAV vectors to study
promoter activity in cultured DRG neurons is a worthwhile system and could be
greatly improved in the future. Attempts to establish an improved system have been
carried out in parallel with these promoter studies (section 3.2). These studies have
improved titres and purity ofAAV preparations, and have investigated the infection
ofDRG neurons by AAV vectors, which contain the PPT promoter. In future, it
would be beneficial to ensure all growth factor experiments are performed using the
same known titre ofAAV vectors, as this may also be a potential reason for variation
between experiments. In addition, it may be advantageous to further purify the crude
cell lysate to eliminate as many contaminating factors as possible.
By comparison between parameters such as promoter fragment or growth
factor responses, it has not been possible to study quantitative values of promoter
activity. However overall this system has been shown to be extremely useful for
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investigating trends in promoter induction in response to various stimuli and
determining potential transcriptional regulatory elements.
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4.6 Miscellaneous and preliminary experiments
A number of experiments were performed which provided interesting
preliminary data and if time permitted, these would have been repeated. These
experiments were all concerned with the regulation of the PPT-A promoter in DRG
neurons and in future may be interesting to follow up. The individual experiments
will be described and the potential implications briefly discussed
4.6.1 Length of exposure to NGF may be important for promoter induction
For all previous growth factor work, DRG cultures were maintained in the
appropriate growth factor for duration of the experiment. It is not known if this is
necessary to achieve a response or whether only one exposure to the growth factor
may be sufficient to cause an effect. This is relevant to the role of growth factors in
vivo as chronic and acute exposure to NGF may define the physiological condition.
Short term exposure to NGF may have a role in nociception whereby PPT-A gene
expression is temporarily increased, whereas chronic exposure may be related to
conditions such as arthritis in which PPT-A expression is upregulated over a long
period of time.
4.6.1.1 Results
Adult DRG neurons were infected with AAV-865+92-LUC. Media
containing NGF was added and removed at varying time points following infection.
In all experiments cultures were harvested and assayed for luciferase activity 7 days
post-infection as described in section 4.4. In experiment (1) NGF was added to the
infected cultures 5 days post-infection (table 4.15). This experiment was only
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performed once in duplicate. The results show that no NGF response was observed.
In the following experiment, NGF was added immediately after infection, NGF was
added 2 days post-infection or NGF was added 5 days post-infection. All were
maintained in the additional NGF until cells were harvested on day 7 (table 4.16).
Again this was performed once in duplicate. These preliminary results show that the
PPT-A promoter is induced approximately 19 fold when NGF is added immediately
after infection compared to untreated samples. This induction is reduced to around 3-
fold when NGF is added 2 days following infection. In experiment (3), NGF was
added immediately after infection. Cells were either maintained in NGF for the 7 day
period or NGF was removed 3 days post-infection. Table 4.17 shows that when cells
were treated with NGF for the 7 days there is a 14 fold increase in promoter activity
compared to untreated cells and this induction is not seen in those samples where





Table 4.15: Experiment 1. DRG cells were infected with AAV recombinant vectors containing the
PPT-A promoter -865+82 driving the luciferase reporter gene. 5 days post-infection NGF was added
to treated cells. Cultures were harvested and assayed for luciferase activity 7 days post-infection.
Luciferase activity
NGF treatment day post-infection Untreated
0 2 5
67.56 11.85 4.337 3.5
67.77 9.64 4.397 3.74
Table 4.16: Experiment 2. DRG cells were infected with AAV recombinant vectors containing the








Table 4.17: Experiment 3. DRG cells were infected with AAV recombinant vectors containing the
PPT-A promoter -865+92 driving the luciferase reporter gene. NGF was added immediately after
infection and then maintained in NGF for the duration of the experiment or removed at 3 days post¬
infection.
4.6.1.2 Discussion
It has been shown that NGF can induce the PPT-A proximal promoter in
cultured adult DRG neurons (section 4.4.2.1). The preliminary results presented here
suggest that to achieve this induction by NGF, cultures must be maintained in NGF
for the 7 day infection period. Obviously, absolute conclusions cannot be drawn from
the insufficient data presented here, particularly in light of the large variation
observed between experiments. However, this is potentially an interesting area for
future studies.
4.6.2 Effect of growth factors on the PPT-A promoter in neonate DRG
cultures
It was also hoped to investigate the effect of growth factors on the PPT-A
proximal promoter in neonate DRG cultures. However the difficulty associated with
using neonate DRG cultures for such studies is that growth factors greatly influence
the survival of the neurons therefore it is difficult to determine if the growth factor is
truly having an effect. Numerous preliminary experiments were performed. The
effects ofGDNF, BDNF and LIF were investigated in addition to ciliary
neurotrophic factor (CNTF) and neurotrophin-3 (NT-3). GDNF, BDNF and LIF have
been described previously (section 4.4). NT-3 is a member of the NGF related family
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of neurotrophins and like LIF, CNTF is a member of the cytokine family of growth
factors (section 1.3). These growth factors were added in addition to NGF as neonate
DRGs require NGF to survive in culture. Some experimental conditions were
performed more than others therefore this growth factor study is incomplete and
would have to be repeated before any conclusions could be drawn.
4.6.2.1 Results
Cultured DRG neurons were infected with AAV-865+92-LUC and
maintained in medium containing NGF only or medium containing NGF in addition
to other growth factors. The effect of LIF was examined three times in triplicate
(table 4.16, experiments 1, 2 and 3). The data shown does not provide solid results
regarding the role of LIF in neonate cultures. Experiment 1 and 2 suggest that LIF
may act to increase promoter activity, however experiment 3 showed a reduction in
luciferase activity in samples that were treated with NGF. Similarly, when the effect
ofGDNF was examined four times, each time in triplicate (experiments 2, 4, 5 and
7), conflicting results were obtained. Experiments 5 and 7 showed no difference
between NGF only treated samples and samples treated with NGF together with
GDNF. However experiments 2 and 4 showed an increase and decrease respectively
in luciferase values compared to NGF only treated cultures. The effect ofNT-3
together with NGF was examined twice in triplicate (experiments 6 and 8) and was
shown not to influence luciferase values implying addition ofNT-3 did not effect
PPT-A promoter activity. When the effect of BDNF was examined (experiments 4, 5
and 6) more consistent results were observed. In the presence ofBDNF in addition to
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NGF, the luciferase values were reduced slightly compared to NGF only treated
samples.










Expt LIF BDNF GDNF GDNF+
BDNF
NT-3
1 1.4 (I) 2.6 (D) 11.1(1) 1.4 (I) 0
2 4.8 (I) 1.8 (D) 3.6 (D) 2.3 (D) 0
3 1.6 (D) 1.7 (D) 1.2 (I) - -
Table 4.18: Effect of growth factors on the PPT-A promoter in neonate DRG cultures. Neonate DRG
cultures were infected with AAV vectors containing the PPT promoter (-865+92) driving the
luciferase reporter gene and maintained NGF + presence or absence of growth factor (GF). Cells were
harvested and assayed for luciferase activity 7 days post-infection. Data is represented as fold increase
or decrease in expression induced by the addition ofNGF+GF compared to 100 ng/ml NGF alone.
4.6.2.2 Discussion
This study set out to examine the effect of various growth factors on the PPT-
A promoter in cultured neonate DRG neurons. The preliminary results revealed that
this may be more difficult than initially planned compared to performing these
experiments in adult cultures (section 4.4). The situation regarding neonate DRGs is
much more complex since growth factors influence their survival. In addition, the
molecular contents of neonate neurons change over the first and second postnatal
weeks. This adds to the complexity when investigating the effects of growth factors
since growth factor dependency and the presence of growth factor receptors change.
For example, when the expression ofNGF receptor and GDNF receptor was
examined in newborn rat DRG neurons, it was found that in the first week of life,
expression of the NGF receptor is downregulated. In contrast, expression of the
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GDNF receptor is upregulated, changing the responsiveness of the neurons (Molliver
and Snider, 1997; Molliver et al., 1997; Bennett et al., 1998b). As a result of these
complexities, inconclusive and contrasting results were obtained. The only consistent
result seen was when examining the effect ofBDNF. The results showed that BDNF
is acting to reduce luciferase activity and therefore possibly transcription from the
PPT-A promoter. There are many ways BDNF could achieve this reduction in
promoter activity. It may be that BDNF is antagonising NGF since they can act upon
the same receptors or it may be due to activation of appropriate signal transduction
pathways that can act specifically on the PPT-A promoter.
4.6.3 Potential problems associated with AAV vectors to investigate promoter
regulation
In investigating regulation of the PPT-A promoter in adult and neonate DRG
neurons (section 4.2), potential difficulties associated with using AAV vectors
generated from the two plasmid-adenovirus method were encountered. Cultured
neonate DRG neurons were infected with AAV preparation containing different PPT
promoter fragments as described in section 4.2.2.2. On two occasions anomalous
results were obtained and were thought to be associated with one particular
preparation ofAAV vectors.
4.6.3.1 Results
When the promoter activities ofAAV-865+447-LUC, AAV-865+92, AAV-
431+92 and AAV-47+92 were compared in both neonate DRG neurons as described
in section 4.2.2, two surprising results were obtained. Cells were infected with the
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AAV vectors, maintained in culture for 7 days, harvested and assayed for luciferase
values as standard. However, when preparations ofAAV from 25/4/00 were
examined the promoter fragment -865+447, was found to be vastly increased.
Induction over the minimum promoter was seen to be 675 and 9360 fold (table 4.19)
in neonate DRG neurons. This same preparation ofAAV was employed in three
separate studies in adult DRG neurons. In contrast, a 31 to 116 fold induction of-
865+92 promoter compared to the minimum promoter was observed, which was
















1 7666+1323 22.28+2.415 0.819+0.042 9360 27.2
2 999+70.65 14.65+3.805 1.481+0.110 675 9.9
Adult 1 32.46+18.92 3.807+0.342 0.28+0.047 116 13.6
2 30.15+19.67 19.34+1.408 0.9+0.086 33.3 21.5
3 26.02+5.702 10.64+1.405 0.84+0.298 31 12.7
Table 4.19: Expression ofPPT-A promoter vectors in neonate and adult DRG neurons. DRG
cultures were infected with AAV vectors from 25/4/00 containing the PPT-A promoter fragments -
865+447, -865+92 and -47+92. Cells were maintained in medium for 7 days and then harvested and
assayed for luciferase activity. The luciferase values shown are represented as mean and std. error of
triplicate wells for each sample.
4.6.3.2 Discussion
It is unclear why these inconsistent results were observed compared to all
other promoter data (section 4.2.2.). The only distinction between the experiments
described above and all others in section 4.2.2, was the sample ofAAV-865+447-
LUC employed. This preparation was significantly different from all other samples
as it had been generated by the two plasmid-adenovirus helper system whereas all
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other AAV samples were generated from the three-plasmid system (section 1.4.8.1).
It is unclear what caused this induction however it does seem to be unique to AAV
vector expression in neonate DRG cultures as a similar increase in expression was
not observed in adult DRG cultures infected with this sample (table 4.19). It was
initially thought that it might be the result of contaminating adenovirus or viral
proteins in the AAV stocks. To test this AAV-865+447-LUC, AAV-862+92 and
AAV-47+92 were generated using both the three plasmid and the two plasmid-
adenovirus methods for AAV production. The resulting AAV preparations were used
to infect both adult and neonate DRG cultures and the activities compared. No
induction in promoter activity was observed in those samples generated by the two
plasmid-adenovirus system and the expression of promoter -865+447 was in
accordance with all other experiments (data not shown).
Although this data is clearly aberrant, it has emphasised the future importance
of employing highly purified AAV preparations to investigate transcriptional
regulation of promoters. Many studies that employ AAV described in the literature
actually generate rAAV preparations by this two plasmid-adenovirus method. The
fact that AAV samples might contain factors, which under certain conditions have
the potential to influence expression of the gene it is delivering, has important
potential implications for future studies that use AAV. Therefore the possibility of
artifactual results should be considered in the interpretation of studies involving
AAV vectors, and these effects could be eliminated in future by improved
purification procedures.
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CHAPTER 5: GENERATION OF AAV VECTORS EXPRESSING PPT cDNA
5.1 Introduction
The purpose of this study was to generate AAV vectors that could be used as
a tool to investigate the function of the PPT-A gene products in vivo and in vitro. The
generation ofmice in which the PPT-A gene was disrupted has allowed the function
of the PPT-A gene to be defined in vivo. These studies have shown that when the
PPT-A gene is disrupted in mice, although the fine detail is different between studies,
generally the animals show reduced responses to painful stimuli and that local
inflammatory responses were impaired (Zimmer et al., 1998; Cao et al., 1998;
DeFelipe et al., 1998). The use of virus vectors as an alternative or complementary
method to transgenic analysis, in the manipulation of the nervous system has become
increasingly popular. The availability of virus vectors that can express the PPT-A
gene products would be a useful complement to the knockout mice available for
investigating the function of this gene. The PPT-A knock out mice has defined the
role of all the PPT-A gene products in mediating pain responses however most other
studies investigating the function of the tackykinins have focused on the role of SP.
Virus vectors may be a useful vehicle for studying specifically the role of SP and the
other tachykinins individually. The creation of virus vectors, which express the
desired gene products, can be delivered in vivo and can sustain long-term expression,
would allow the individual gene products of the PPT-A gene to be investigated. In
addition to complementation studies on mice in which the PPT-A gene has been
disrupted, these vectors can be delivered to wild-type animals since overexpression
of gene products can be as indicative of function as the generation of knockout mice
(Magdaleno and Curran, 1999). The generation of virus vectors would also allow the
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expression gene products to be targeted to specific tissues and allow analysis in other
model systems in addition to mice.
These AAV vectors expressing the PPT-A gene products will also provide
information about delivery ofPPT-A gene products by AAV vectors and the protein
requirements necessary for the regain of loss of neuronal function associated with the
absence of SP. For example, SP expression has been studied in response to several
neurodegenerative disorders and Parkison's (Gresch and Walker, 1999), Alzheimer's
(Bouras et al., 1990) and Huntington's (Richfield et al., 1995) diseases are all
associated with a progressive loss ofPPT-A and SP expression in the brain.
Information regarding the expression of exogenous SP in neurons would have
important implications for future gene therapy protocols.
For these purposes AAV virus vectors were generated which contain both
intact wild-type PPT cDNA and modified PPT cDNA, which lacks the sequences
encoding SP, driven by either the PPT promoter (spanning base pairs -865 to +92) or
the CMV promoter.
5.2 Generation of AAV vectors expressing PPT cDNA
5.2.1 Generation of rAAV vectors expressing PPT cDNA
In order to generate rAAV vectors that express the PPT-A gene products,
NKA and SP, a cloning strategy was devised which would allow PPT cDNA
expression to be driven by either the CMV or the PPT-A promoter. It has been
shown that the CMV promoter can drive high levels of reporter gene expression in
the context ofAAV vectors (section 3.4.1) and therefore would allow high levels of
expression of PPT cDNA in neurons and other cell types. It has also been shown that
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the PPT-A promoter fragment spanning base pairs -865+92 contains many important
c/s-acting elements and can drive restricted reporter gene expression to populations
of neurons and some nonneuronal cell types in cultured DRG cells (section 3.4.1).
Production ofAAV constructs termed AAV-CMV-PPTcDNA and AAV-
865+92-PPTcDNA that drive the PPT cDNA under control of the CMV and PPT
promoters respectively required three cloning steps for each vector (figure 5.1 and
section 2.2.4.1) due to the size restrictions imposed on AAV vectors. In order for
constructs to be successfully packaged DNA fragments for insertion into pSub201
plasmids must be between 4.1 and 4.9 kb (section 1.4.8).
The first cloning step involved the replacement of the luciferase reporter
genes of previously generated plasmids pGL3-CMV-LUC and pGL3-865+92-LUC
with the PPT cDNA from plasmid pGl-pPPT cDNA (McGregor et al., 1989)
(cloning strategy described in detail section 2.2.4.1; figure 5.1). The DNA fragment
consisting of promoter (CMV or -865+92) driving the PPT cDNA was then
subcloned into plasmid pSnaBl-stuffer. This plasmid was constructed from the
pGL3-basic backbone together with a stuffer DNA fragment derived from the mouse
herpesvirus-68 (MHV-68) glycoprotein B gene which contains no known promoter
or enhancer elements (Harrison et al., 1999). This is a useful tool for the addition of
so called 'stuffer' DNA to achieve the necessary size and incorporates the
appropriate restriction sites for insertion into plasmid pSub201. The final cloning
step inserted the DNA fragment consisting of the promoter driven PPTcDNA
together with additional DNA into the pSub201 backbone to generate plasmids
pSub201 -CMV-PPTcDNA and pSub201-865+92-PPTcDNA.
191
Before converting these AAV packaging substrate plasmids into AAV
particles it was first investigated whether these plasmids were functioning and
expressing the appropriate products. Plasmid pSub201-CMV-PPTcDNA or no DNA
was transfected into BHK cells (section 2.2.6.3). 2 days post-transfection mRNA was
extracted (section 2.2.5.1) and RT-PCR analysis (section 2.2.5.2) was used to
determine (3PPT mRNA expression. In PCR reactions, plasmid pSub201-CMV-PPT
was used as a DNA template as a positive control.
Since promoter fragment -865+92 does not support reporter gene expression
in cell lines, plasmid pSub201-865+92-PPTcDNA could not be similarly analyzed.
However the cloning steps were equivalent in the production of these constructs, and
both restriction enzyme and sequencing analysis suggested no reason for this plasmid
not to be viable. Figure 5.2 shows the results of this assay for mRNA expression
from plasmid pSub201-CMV-PPTcDNA.
Plasmid pSub201-CMV-PPT was also analyzed for SP expression in cell
culture. BHK cells were transfected with pSub201-CMV-PPT (section 2.2.6.2) and
48 h post-transfection cells were harvested and assayed for SP expression by SP
immunoassay however no SP expression was found. SP immunoassay was also
performed on DRG neurons to ensure the assay was functional (data not shown). It is
conceivable that since endogenous SP is not expressed in this cell line and SP is
produced as a result of both post-transcriptional and post-translational modification,
expression of PPT cDNA may not processed correctly to generate the gene products.
The resulting plasmids pSub201-CMV-PPTcDNA and pSub201-865+92-
















Figure 5.1: Three step cloning strategy to produce pSub201-CMV/PPT-pPPT for rAAV
packaging. PPT cDNA was first inserted into either plasmid pGl3-CMV-LUC or pGl3-865+92-LUC.
The cassette containing promoter, PPT cDNA and luciferase reporter gene was then subcloned into the
stuffer plasmid. This DNA cassette containing additional DNA to make a 4.4 kb fragment was then
transferred into plasmid pSub201.The resulting plasmids were termed pSub201-CMV-pPPT and
pSub20l-865+92-PPPT.
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Figure 5.2 : Agarose gel electrophoresis of PCR products. BHK cells were transfected with
pSub201-CMV-PPT and pSub201-CMV-PPTAexon3 and RNA extracted 48h post-transfection.
cDNA was synthesised from poly(A) RNA and amplified by PCR. Lane 1 :-ve control
(untransfected cells); 2: +ve control (plasmid pSub201-CMV-PPT; 3: pSub201-CMV-PPTAexon3;
4: pSub201-CMV-PPT. Red arrow indicates the 470 bp PCR product from those cells transfected
with pSub201-CMV-PPT, blue arrow represents 372 bp product from pSub201-CMV-PPTAexon3
transfected cells.
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5.2.2 Generation of rAAV plasmids expressing PPTcDNAAexon3
To define more specifically the role of SP, a rAAV vector containing the PPT
cDNA but lacking the specific SP encoding sequences was generated. Exon 3
contains the sequence information for SP and was therefore removed completely
from the PPT cDNA. This was achieved by carrying out two separate PCR reactions
that allowed the incorporation of a Nsil restriction enzyme site in both PCR products
(sections 2.2.4.2 and 2.2.4.3; figure 5.3). The first PCR reaction amplified the region
of DNA upstream of exon 3 and the second reaction amplified the DNA downstream.
Subsequent digestion of the PCR products and simultaneous ligation of both PCR
products into plasmid pCRII effected the removal of exon 3. This was confirmed by
restriction enzyme digestion and sequence analysis of the mutated PPT cDNA
sequence, which also verified that no secondary mutations in the cDNA had been
introduced (figure 5.4).
The PPTAexon3 fragment then replaced the wild-type PPT cDNA of
plasmids pSub201-CMV-PPTcDNA and pSub201-865+92-PPTcDNA. The resulting
plasmids were termed pSub201-CMV- PPTAexon3 and pSub201-865+92-
PPTAexon3 (figure 5.3). Plasmid pSub201-CMV- PPTAexon3 was analyzed as
described above (section 5.2.1) for possible mRNA expression from PPTAexon3.
Figure 5.2 shows that when plasmid pSub201-CMV- PPTAexon3 is transfected into

















Figure 5.3: Strategy for the production of pSub201-CMV-PPT exon 3. (1) Two separate PCR
reactions allowed the amplification of PPT cDNA upstream and downstream of exon 3 with the
introduction ofNsil restriction enzyme sites. (2) Subsequent digestion of PCR fragments with
Nsil and ligation into TA cloning vector pCRII resulted in the generation of PPT cDNA which




CAAC ATG AAA ATC CTC GTG GCG GTG GCG GTC TTT TTT CTC GTT TCC ACT CAA
CTG TTT GCA GAG GAA ATC GGT GCC AAC GAT GAT CTA AAT TAT TGG TCC GAC
TGG TTC GAC AGT GAC CAA ATC AAG GAG GCA ATG CCG GAG CCC TTT GAG CAT CTT
CTT CAG AGA ATC GCG CGA AGA CCC AAG CCT CAG CAG TTC TTT GGA TTA ATG GGC
AAA CGG GAT GCT GAT TCC TCA ATT GAA AAA CAA GTG GCC CTG TTA AAG GCT CCT
TAT GGG CAT GTG CAG ATC TCT CAC AAA AGG CAT AAA ACA GAT TCC TTT GTT GGA
CTA ATG GGC AAA AGA GCT TTA AAT TCT GTG GCT TAT GAA AGA AGC GCA ATG CAG
AAC TAC GAA AGA AGG CGT AAA
TAAACCCTGTAACGCACTACTTATTCATCTCCATCTGGTCCGCGAG
id;
CAAC ATG AAA ATC CTC GTG GCG GTG GCG GTC TTT TTT CTC GTT TCC ACT CAA
CTG TTT GCA GAG GAA ATC GGT GCC AAC GAT GAT CTA AAT TAT TGG TCC GAC TGG
TTC GAC AGT GAC CAA ATC AAG GAG GCA ATG CAT AAA CGG GAT GCT GAT TCC TCA
ATT GAA AAA CAA GTG GCC CTG TTA AAG GCT CTT TAT GGG CAT GGT CAG ATC TCT
CAC AAA AGG CAT AAA ACA GAT TCC TTT GTT GGA CTA ATG GGC AAA AGA GCT TTA
AAT TCT GTG GCT TAT GAA AGA aGC GCA ATG CAG TAC TAC GAA AGA AGG CGT AAA
TaaaCCCTGTAACGCACTATCTATTCATCTCCATCTGTGTCCGGAT
Figure 5.4: Nucleotide sequence of cDNA coding for (A) wild-type PPT and (B) mutant PPTAexon3.
Underlined nucleotides represent exon 3. In wild-type sequence red nucleotides indicate bases that were
mutagenised to produce Nsil restriction enzyme site (ATGCAT). Bold bases in mutant sequence show
resulting Nsil site following removal of exon 3.
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5.2.3 Expression of SP from AAV-CMV-PPTcDNA
To investigate whether cells infected with AAV-CMV-PPTcDNA actually
express SP, adult DRG neurons were cultured (section 2.2.7.1) and infected with
increasing amounts of virus (section 2.2.10.1). No virus, lxlO6, 5xl06 and lxlO7
infectious particles of AAV-CMV-PPTcDNA were each used to infect
approximately 500 neurons. Infected cells were maintained in culture for 7 days and
then immunostained for SP expression (section 2.2.5.3). DRG cultures were also
infected with the same amounts ofAAV-CMV-PPTAexon3 as a control experiment.
Figure 5.5(a) shows that when no virus was used, antibodies against SP showed
staining in only a small population of neurons, which is compatible with the expected
expression pattern for SP whereby approximately 20 to 30% ofDRG neurons are SP
positive. When increasing concentrations of AAV-CMV-PPTcDNA were used for
infection, SP expression increased, particularly in the nonneuronal population (figure
5.5 (b)-(d)). Cells infected with AAV-CMV-PPTAexon3 showed similar expression
levels to those cells in which no virus was added (figure 5.5 (a) and (e)). This
experiment was not performed using AAV-865+92-PPTcDNA and AAV-865+92-
PPTAexon3. Since expression from the PPT promoter is greatly restricted in DRG
neurons (section 3.4.2), it is highly probable that expression of endogenous SP from
the DRG cultures could not be distinguished from SP expression as a result of virus
infection. Ideally this experiment should have been performed in DRG cultures from
mice that lack the PPT-A gene to ensure SP staining is a result of virally infected
cells.
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Figure 5.5: Adult DRGs infected with (a) no virus, (b) lxlO6, (c) 5xl06 and (d) lxlO7 infectious
particles of AAV-CMV-PPTcDNA and immunostained for SP. Those cells positive for SP expression
are pink in colour. DRGs were also infected with increasing concentrations ofAAV-CMV-PPTAexon3.
(e) shows cells infected with lxlO7 infectious particles of AAV-CMV-PPTAexon3 and (f) lxlO7
infectious particles of AAV-CMV-PPTcDNA when primary antibody was omitted as a negative
control. All pictures shown are 25 x magnification and scale = 25 pm
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5.2.4 Discussion
pSub201 plasmids were generated that contain the PPT promoter or
the CMV promoter driving intact wild-type PPTcDNA or mutant PPTcDNA. These
were used to produce AAV vectors and termed AAV-CMV-PPTcDNA, AAV-CMV-
PPTAexon3, AAV-865+92-PPTcDNA and AAV-865+92-PPTcDNA Aexon3. One
AAV vector, AAV-CMV-PPTcDNA was shown to express SP upon infection of
cultured DRG neurons and this suggested that all other AAV vectors would be
capable of expressing SP. As DRG neurons express endogenous SP, it is difficult to
prove that the SP expression detected is a result of expression from the AAV vectors.
However increasing concentrations ofAAV-CMV-PPT did correlate with increased
SP immunostaining in nonneuronal cells. This shows that SP is capable of being
expressed in noneuronal cells of DRG, although it was also found that SP was not
expressed in BHK cells. Therefore, unlike BHK cells, noneuronal cells populations
are capable of processing the PPT-A pro-peptide and expressing SP. This has
important implications for understanding the expression and role of SP in
nonneuronal cells in vivo.
Unequivocal evidence of SP expression from the rAAV vectors would have
been provided by infection of cultured DRG neurons from the PPT-A knockout mice.
Many attempts were made to culture DRG neurons from these mice, however
difficulty was encountered in achieving healthy cells for used in these experiments.
As a result of this, expression from AAV-865+92-PPTcDNA could not be examined.
If future attempts to generate the DRG cultures from the knockout mice prove
problematic, other options could be considered to examine expression from AAV-
865+92-PPTcDNA. For example, intact ganglia or other neuronal populations of
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embryonic origin from PPT-A knockout mice could be cultured, if these prove more
successful. Future experiments should also include determination ifAAV-CMV-
PPTAexon3 expresses NKA, however at the time this work was performed, no good
commercial antibodies for this peptide were available.
The generation and partial validation of these AAV vectors means that
valuable tools will be available for investigating the role of the PPT-A gene products.
It is hoped these vectors will be used in a variety of experiments not only to define
the tachykinins function in nociceptive pathways but in other physiological functions
such as depression and anxiety. The availability ofPPT-A gene knockout mice,
whose phenotype has been described (Ciao et al., 1998; Zimmer et al., 1998) will
allow the AAV-CMV-PPT vectors be used to attempt to rescue phenotypic
characteristics associated with these mice. As an alternative approach,
overexpression of the PPT-A gene in vivo in wild-type animals might provide a
clearer understanding of the function of the various PPT-A gene products
(Magdaleno and Curran, 1999).
The generation of PPT cDNA expressing vectors, which are driven by the
PPT promoter, will allow expression to be restricted to various populations in DRG
cultures and possibly in vivo. This might be useful for determining the role of SP in
neurons compared to nonneuronal cells in mixed primary cultures or heterogenous
tissue in vivo. Under basal conditions SP expression is limited to neurons however it
has been shown in this thesis that nonneuronal cells can express SP and it known that
SP is expressed in glial cells under certain conditions such as nerve injury (Too et al.,
1994; Lin et al., 1995). This might indicate a differential function for SP in neurons
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and noneuronal cells and the production of these AAV vectors could contribute to
understanding the role of SP in noneuronal cells.
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS
6.1 Summary
The work presented in this thesis describes the use ofAAV vectors as a tool
for the transduction of recombinant DNA constructs into cultured DRG neurons.
This subsequently allowed transcriptional regulation of the PPT-A promoter to be
investigated. The initial aims of this study were to optimise the conditions ofAAV
production and investigate the transduction of DRG neurons by these vectors. AAV
vectors containing either the CMV promoter or PPT promoter (-865 to +92) were
able to drive long-term expression of the GFP reporter gene in DRG cultures. All cell
types in a heterogenous primary culture of DRG neurons infected with AAV-CMV-
GFP showed high expression levels, which increased linearly with virus dose. Those
cells infected with AAV-PPT-GFP showed a more restricted expression pattern
whereby expression was mainly associated with neuronal populations. In addition, as
higher doses ofAAV-PPT-GFP virus particles were used for infection ofDRG
cultures, the number of GFP expressing cells was not similarly increased. This
highlighted the more restricted expression pattern of the PPT-A promoter that has
been previously reported (section 1.2.3) and provided important information about
the expression pattern ofCMV and PPT promoter fragments in cultured DRG when
delivered as a rAAV particle. These studies may also have important implications for
the generation of future vectors for gene therapy. AAV is a highly 'promiscuous'
virus and can infect a wide variety of cell types. Although this is considered an
advantage ofAAV vectors for use in gene therapy, it may also be negative if a
restricted expression pattern is desired. Studies have focused on targeting expression
from AAV vectors to particular cell types (section 1.4.8.4) and one way of achieving
203
this is by the use of promoter fragments that have a limited expression pattern. The
CMV promoter, although directing high expression levels, will drive expression in
all cell types therefore would not be a suitable candidate for cell specific expression
in the context of AAV vectors. As described above, the PPT-A promoter was
observed to have a restricted expression pattern in cultured DRG neurons. The
studies described have provided the basis for future analysis of cell types that can
support activity of the PPT-A promoter and determine if it has the necessary
requirements for driving neuronal specific expression.
Further knowledge of the expression pattern of the PPT-A promoter would be
increased by a greater understanding of the influences, which contribute to the
regulation of the PPT-A promoter. This was addressed by the second aim of this
thesis, which was to investigate the transcriptional regulation of the PPT-A promoter
in DRG neurons. AAV vectors containing deletion fragments of the PPT-A promoter
were used for infection of both adult and neonate DRG neurons. It was established
that in the presence ofNGF, different promoter fragments were differentially
regulated between adult and neonate DRG neurons, perhaps reflecting the normal
plasticity ofPPT-A expression observed in vivo. Potential enhancer and silencer
sequences were identified and provided important information about the promoter
elements that contribute to PPT-A promoter activity and gene expression in a tissue
specific and stimulus inducible manner. The region between +92 and +447 was
shown to possess enhancer activity in adult DRG neurons but was not observed to be
similarly active in neonate DRGs. In addition, in adult DRG neurons, the region
between base pairs -484 to -47 possessed further enhancer elements. In contrast, in
neonate DRG neurons potential repressor activity in this domain was observed.
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To investigate the stimulus inducible regulation of the PPT-A promoter, the
effect of various growth factors on the PPT-A promoter fragment -865 to +92 was
studied in adult DRG neurons. The effects ofNGF, BDNF, GDNF, IL-6 and LIF on
PPT-A promoter activity were analysed. These growth factors were selected on the
basis that they are thought to modulate SP or PPT-A expression under basal
conditions or in response to nerve injury (section 1.3.1). It was found that both NGF
and GDNF acted to induce PPT-A promoter activity, indicating the presence of
regulatory elements on this promoter fragment -865+92 that can mediate this effect.
This is similar to the effects ofNGF and GDNF on endogenous PPT-A gene
expression. NGF is known to regulate PPT-A mRNA and SP expression (Lindsay
and Harmar, 1989; Mulderry, 1994; Leslie et al., 1995) and GDNF can induce SP
levels in DRG cultures (Ogun-Muyiwa et al., 1999; Adler, 1998). In addition, LIF
was observed to decrease PPT-A promoter activity in cultured DRG neurons. Again
this suggested that elements of the PPT-A promoter are responsive to the presence of
this growth factor. It is unclear what effect LIF has on endogenous PPT-A expression
in DRG neurons, however one study has demonstrated that LIF can decrease SP
expression (Nawa et al., 1990).
These studies provided important information about the regulation of the
PPT-A promoter and the use ofAAV vectors was central to performing this work.
The only other method for successfully transfecting DRG neurons is microinjection
of plasmid DNA into cells however this system does not allow the investigation of
promoter inducibility by growth factors (Fiskerstrand and Quinn, 1995; Quinn et al.,
2000). In contrast, when PPT-A promoter fragments are delivered as a recombinant
AAV vector the PPT-A promoter can be activated or repressed by stimulus. However
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the problems associated with this experimental system were highlighted. It was
initially believed that crude cell lysate would be suitable for the transduction ofAAV
vectors into cultured DRG neurons. It became apparent over the course of this study
that it may be beneficial to the quality of future data to ensure that AAV preparations
are further purified. With the improvements and simplifications in protocols for the
purification ofAAV vectors this can be easily achieved for future work.
A final aim of this thesis was to create AAV vectors, which could be used to
investigate the function of the PPT-A gene products in vitro and in vivo. AAV
vectors containing the PPT-A promoter (-865+92) or the CMV promoter driving
intact PPT cDNA or mutated cDNA, which lacked the sequence information for
producing SP, were generated. These AAV vectors were shown to be functional in
that peptide was produced but further analysis would be required. Mice which, lack
the PPT-A gene, have been previously generated (Ciao et al., 1998; Zimmer et al.,
1998) and it is hoped that these virus vectors could be an important complement to
these animals to define a role for either SP or NKA. These vectors would also be
useful for overexpression of tachykinins in wild-type animals.
6.2 Future directions
The results obtained from this study, using AAV vectors to investigate
regulation of the PPT-A promoter, will lead to a number of further studies aimed at
both improving the experimental system and our understanding of regulation of the
PPT-A gene at the transcriptional level.
The investigation of the promoter deletion constructs provided valuable
information into potential regulatory regions of the promoter, that are involved in the
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regulation of the PPT-A promoter in cultured DRG neurons. The generation of site-
specific mutants in future studies would allow the specific elements of the PPT-A
promoter that are involved in tissue specific expression to be defined. In addition, the
deletion constructs described in this study could be used to define the regions that are
responsible for mediating the effects ofGDNF, NGF and LIF. This could be
achieved by investigating the promoter activities of each of these PPT-A promoter
fragments in the presence or absence of growth factors. It may also be interesting to
investigate the effects of different concentrations of exogenous growth factor and the
timing of addition to the AAV infected DRG cultures. One set of preliminary
experiments suggested that the long-term exposure (for the 7 day infection period)
might be necessary to achieve maximum PPT-A promoter induction in cultured DRG
neurons by NGF. Such studies could have important implications with respect to
induction ofPPT-A gene expression in vivo. Long-term exposure to NGF and
therefore long-term upregulation ofPPT-A gene expression may occur through
elements that are distinct from those involved in short-term exposure.
The generation of PPT cDNA expressing AAV vectors gives rise to many
potential studies. These AAV vectors could be used to investigate the function of all
PPT gene products and specifically SP in sensory neurons and other cell types that
express endogenous PPT-A. For example, characteristic phenotypes have been
described for mice that lack the PPT-A gene. The PPT-A gene products could be
delivered in vivo by these AAV to determine if the phenotypes are complemented by
expression of the tachykinins from the AAV vectors. Additionally, delivery of the
AAV vectors, which express the mutated PPT cDNA, to these transgenic mice will
determine the specific role of SP in generating these phenotypes. Another approach
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would be the overexpression of the tachykinins by these AAV vectors in wild-type
animals and examination of the resulting phenotype to give more insight into their
functions. At a cellular level, overexpression in cultured DRG neurons and other cell
types is likely to generate changes in electrophysiology or other marker molecules,
again contributing to defining the role of the PPT-A gene products. PPT cDNA
expressing AAV vectors driven by the PPT promoter -865+92, could be used to
restrict expression to neuronal populations. Together it is hoped that these vectors
will provide important information about using AAV to deliver a protein that has
been lost in disease, for example loss of SP expression has been associated with
degenerative diseases. Therefore this has particular importance to the field of gene
therapy and therapeutic protein delivery.
In this thesis it was also established that the PPT promoter spanning
nucleotides -865 to +92 demonstrated a more restricted expression pattern than that
of the CMV promoter. To further investigate the populations ofDRG neurons that
specifically support PPT promoter activity it would be useful to exploit the AAV
vectors which contain the PPT promoter driving the GFP reporter gene. GFP
expression could be analysed in conjunction with immunostaining ofmarker
molecules to define cell types and neuronal populations that can support promoter
activity.
It became apparent over the course of this study, that the use of highly
purified AAV preparations will be essential for future studies both in vitro and in
vivo. The presence of contaminants in AAV stocks might influence the PPT-A
promoter data generated and contaminants are known to give artefactual results
(Alexander et al., 1997). Essential future work should involve the establishment of a
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protocol for a purification procedure that can be performed routinely, and many such
methods have been described over the course of this thesis (section 1.4.8.5). It is
believed that this would make a marked improvement to the quality and quantity of
data generated, using AAV to investigate regulation of the PPT-A promoter in DRG
neurons.
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Appendix 1: Comparison of promoter deletion constructs - Raw
luciferase values
The promoter activity ofAAV vectors containing each promoter was examined three
times in each experiment in both adult and neonate DRG cultures. Each experiment
differs in the promoter fragments that are compared. Tables show the raw luciferase
and mean values form each experiment, together with the AAV preparation and the
amount of virus that was used in each experiment.





1 2 3 4 Mean
1 24/11/00 20pl -865+92 2.272 1.990 2.899 - 2.387
-671+92 7.708 3.556 3.515 - 4.926
-431+92 2.846 5.526 5.179 - 4.516
2 24/11/00 20pl -431+92 1.045 0.225 0.349 - 0.54
-345+92 0.799 0.487 0.684 - 0.657
-47+92 N/d N/d 0.038 - 0.013
3 24/11/00 5x10s -865+447 2.123 0.999 0.084 - 1.069
particles -865+92 1.259 0.208 0.128 - 0.532
-671+92 0.065 N/d N/d - 0.022









5 4/8/00 8pl -865+92 13.34 14.52 28.12 - 18.66
431+92** 23.07 40.76 51.79 - 38.54
-47+92 0.477 0.376 0.38 - 0.411
6 25/4/00* 12pl -865+447 26.25 3.18 3.032 - 10.82
-865+92 5.036 5.016 3.538 - 4.53
-47+92 0.296 0.178 0.373 - 0.28
7 25/4/00* 12pl -865+447 25.91 4.211 0.037 - 10.05
-865+92 60.62 7.155 1.258 - 23.01
-47+92 1.032 0.996 0.677 - 0.9
8 25/4/00* 12(0.1 -865+447 6.17 6.532 13.32 - 8.674
-865+92 11.3 9.999 16.68 - 12.66
-47+92 1.437 0.902 0.182 - 0.84
9 25/4/00* 15 pi -865+92 3.891 6.376 0.537 - 3.60
-671+92 3.279 0.809 3.604 - 2.56
-47+92 0.651 0.124 0.308 - 0.361
10 4/8/00 15pl -865+447 22.95 14.22 21.67 - 19.61
-865+92 30.55 50.84 26.16 - 35.83
-47+92 1.203 1.656 1.293 - 1.384
11 4/8/00 15pl -865+447 70.62 25.95 45.99 - 47.54
-865+92 62.94 101.7 84.97 - 83.2
-47+92 1.774 0.945 1.351 - 1.36
12 25/4/00 15pl -865+92 0.34 0.267 0.036 - 0.214
-671+92 0.41 0.24 0.094 - 0.248
































































































Table A1.1: Actual raw luciferase mean and values obtained for each experiment performed in adult
DRG cultures.
Expt AAV Amt Promoter Luciferase values (relative light units)
prep (pi) l 2 3 4 Mean
1 4/8/00 12 -865+447 106.4 126.6 132 - 121.7
-865+92 208.9 393.9 226 - 276.1
-431+92 64.66 83.83 58.31 48.01 63.70
-47+91 16.9 16.32 . . 16.16
2 4/8/00 12 -865+447 79.41 73 61.07 - 71.16
-865+92 136.3 117.9 75.63 - 109.9
-431+92 40.82 39.85 - - 40.34
-47+92 11.99 15.44 11.29 - 11.57
3 24/11/00 20 -865+447 11.31 22.66 11.76 - 19.70
-865+92 59.3 68.5 - - 63.9
-671+92 75.22 26.2 - - 50.71
-431+92 55.63 93.3 6.5 - 51.81
-345+92 51.15 72.44 28.10 - 50.56
4 24/11/00 20 -865+447 89.29 23.22 50.26 - 54.26
-865+92 149.7 142 159 - 150.23
-671+92 112.1 97.26 65.88 - 91.75
-431+92 10.79 18.81 214.9 - 81.5
-345+92 274.9 198.6 20.41 - 164.64
-47+92 3.606 51.1 28.84 - 27.85
5 25/4/00* 20 -865+447 1678 2440 2260 4010 4014
-865+92 27.92 20.23 25.44 15.54 22.28
-431+92 3.33 3.774 2.788 2.448 3.085
-47+92 0.884 0.691 0.906 0.796 0.819
6 25/4/00* 20 -865+447 405 330 273 324 333
-865+92 12.5 27.52 10.71 7.86 14.65
-431+92 3.125 2.078 4.690 3.339 3.308
-47+92 1.156 1.101 1.549 2.205 1.481
Table A1.2: Actual raw luciferase and mean values obtained for each experiment performed in
neonate DRG cultures.
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Table A1.3: Actual raw luciferase values - comparison of promoter fragments
-47+92 in the presence NGF Adult DRG cultures.
-865+92, -60mut,





1 2 3 Mean























































Table A 1.4: Actual raw luciferase values - comparison of promoter fragments -865+92, -60mut,
-47+92 in the absence NGF Adult DRG cultures.
When many of the experiments were performed, the titre of the AAV samples used
had not yet been established. Subsequently AAV preparations were titred and it was
therefore necessary to normalise this data to the amount of virus used for each
sample. Figures were normalised as follows:
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Date of AAV prep Promoter Titre To normalise results
4/8/00 -865+447 1.3 x 107/ml x 3
-865+92 4.0 x 107/ml x 1
-431+92a 2.8 x 10 /ml + 7
-431+92b 3.2 x 107ml - 8
-47+92 4.0 x 107/ml x 1
24/5/00 -865+447 1.0x107/ml x 3
-865+92 2.5 xl07/ml -r 1.2
-431+92 1.8 xl08/ml + 6
-47+92 3.0 xl07/ml x 1
24/11/00 -865+447 1.3 x 107/ml X 3
-865+92 4.0 x 107/ml x 1
-671+92 4.0 x 108/ml -r- 10
-431+92 4.5 x 108/ml + 11.25
-345+92 2.5 x 108/ml -s- 12.5
-47+92 4.0 x 107/ml
x 1
22/9/00 -865+447 2.0 x 107/ml x 2
24/11/00 -865+92 4.0 x 107/ml x 1
-60mut 6.0 x 106/ml x 6.7
-47+92 4.0 x 107/ml x 1
Table Al.5: Titres of each AAV sample and the resulting calculations used to normalise the raw
luciferase values obtained.
Expt AAV Amt Promoter Luciferase values (relative light units)




1 24/11/00 20pl -865+92 2.272 1.990 2.899 2.387
-671+92 0.771 0.356 0.352 0.493
-431+92 0.253 0.491 0.460 0.401
2 24/11/00 20pl -431+92 0.093 0.020 0.031 0.048
-345+92 0.064 0.039 0.055 0.053
-47+92 N/d N/d 0.038 0.013
3 24/11/00 5xl05 -865+447 2.123 0.999 0.084 1.069
particles -865+92 1.259 0.208 0.128 0.532
-671+92 0.065 N/d N/d 0.022
4 4/8/00 8pl -865+92 45.39 29.63 50.01 41.68
-431+92a 11.66 9.963 16.06 12.56
-47+92 1.471 1.706 - 1.59
5 4/8/00 8pl -865+92 13.34 14.52 28.12 18.66
431+92b 2.884 5.095 6.474 4.818
-47+92 0.477 0.376 0.38 0.411
6 25/4/00 12pl -865+447 78.75 9.540 9.096 32.46
-865+92 4.232 4.215 2.973 3.807
-47+92 0.296 0.178 0.373 0.28
7 25/4/00 12pl -865+447 77.73 12.63 0.111 30.15
-865+92 50.94 6.013 1.057 19.34
-47+92 1.032 0.996 0.677 0.9
8 25/4/00 12|al -865+447 18.51 19.60 39.96 26.02
-865+92 9.496 8.403 14.02 10.64
-47+92 1.437 0.902 0.182 0.84
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Table A 1.6: Normalised raw data from adult DRG cultures: Actual luciferase values were normalised
to the appropriate titre ofAAV preparation where neccessary.
Expt AAV Amt Promoter Luciferas values (relative light units)
prep (pl) 1 2 3 4 Mean
1 4/8/00 12 -865+447 319.2 379.8 396.0 - 365.0
-865+92 208.9 393.9 226 - 276.0
-431+92a 9.237 11.98 8.330 6.859 9.100
-47+91 16.9 16.32 - - 16.16
2 4/8/00 12 -865+447 238.2 219.0 183.2 - 213.5
-865+92 136.3 117.9 75.63 - 109.94
-431+92a 5.831 5.693 - - 5.763
-47+92 11.99 15.44 11.29 - 11.57
3 24/11/00 20 -865+447 33.97 67.98 35.29 - 59.09
-865+92 59.3 68.5 - - 63.9
-671+92 7.522 2.620 - - 5.007
-431+92 4.945 8.293 0.578 - 4.605
-345+92 4.092 5.795 2.248 - 4.045
4 24/11/00 20 -865+447 267.9 69.66 150.8 . 162.8
-865+92 149.7 142 159 - 150.23
-671+92 11.21 9.726 6.588 - 9.175
-431+92 0.959 1.672 19.1 - 7.244
-345+92 21.99 15.89 1.633 - 13.17
-47+92 3.606 51.1 28.84 . 27.85
214
5 25/4/00 20 -865+447 5034 7320 6280 12030 7666
-865+92 27.92 20.23 25.44 15.54 22.28
-431+92 0.55 0.629 0.465 0.409 0.513
-47+92 0.884 0.691 0.906 0.796 0.819
6 25/4/00 20 -865+447 1215 990 819 972 999
-865+92 12.5 27.52 10.71 7.86 14.65
-431+92 0.521 0.346 0.782 0.557 0.551
-47+92 1.156 1.1014 1.549 2.205 1.481
Table A 1.7: Normalised raw data from neonate DRG cultures: Actual luciferase values were
normalised to the appropriate titre ofAAV preparation where neccessary.
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Table A 1.8: Normalised luciferase values - comparison ofpromoter fragments
47+92 in the presence NGF Adult DRG cultures.
-865+92, -60mut, -
Expt AAV Amt Promoter Luciferase values
prep 1 2 3 Mean























































Table A1.9: Normalised luciferase values - comparison ofpromoter fragments -865+92, -60mut, -
47+92 in the absence NGF Adult DRG cultures.
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Expt AAV Amt Promoter NGF Luciferase values







































































Table ALIO: Effect ofNGF on AAV-60mut-LUC.
* AAV preparations generated using the two-plasmid/adenovirus method. All other preparations
generated using the three plasmid protocol.
216
Appendix 2: Effect of growth factors on the PPT-A promoter- raw
luciferase values
The effect of growth factors on the PPT-A promoter (-865+92) was examined at least
three times in triplicate or quadruplicate. In addition the effect of growth factors on
the CMV promoter were studied. Tables show the raw luciferase values obtained for
each experiment together with mean values. The rAAV preparation and the amount
of virus used for each experiment are also shown.




1 2 3 Mean
1 25/2/01 2.5x10" - 0.003 0.002 0.040 0.015
+ 0.086 0.02 0.092 0.066
2 25/2/01 2.5x10" - 4.603 7.887 - 6.245
+ 43.81 49.54 - 46.68
3 June lOpl - 3.5 3.74 25.56 10.93
1999* + 17.9 67.56 67.77 51.077
4 June lOpl - 0.121 0.105 0.17 0.199
1999* + 16.83 14.76 3.08 11.56
5 25/2/01 2.5x10" - 2.388 2.914 3.622 2.97
+ 5.104 5.446 11.84 7.483
Table A2.1 : Effect ofNGF on the PPT-A promoter
Expt AAV Amount GDNF Luciferase values (relative light units)
prep (pl) 1 2 3 4 Mean
1 June 5 - 66 17.14 10 - 33
1999* + 269.2 85.7 77.96 - 144.29
2 11/3/00 10 - 31.56 17.14 1.771 - 16.82
+ 75.38 53.56 - - 64.47
3 10/4/00 10 - 5.527 2.407 0.782 0.718 2.61
+ 10.32 4.854 4.431 6.527 6.533
4 25/4/00 10 - 1.047 0.649 0.36 - 0.685
+ 2.861 1.172 1.038 - 2.357
Table A2.2: Effect ofGDNF on the PPT-A promoter
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1 2 3 Mean
1 11/3/00 5 -GF 36.51 33.4 32.41 34.107
+LIF 23.43 14.49 13.47 17.13
+LIF 106.3 41.05 9 52.117
+NGF
2 11/3/00 5 -GF 4.642 2.032 1.164 2.553
+LIF - - - -
+LIF 11.67 8.509 8.387 9.522
+NGF
3 25/4/00 5 -GF 12.42 2.726 0.972 5.594
+LIF 3.627 0.427 0.175 1.41
+LIF 1.796 1.309 0.896 1.027
+NGF
4 10/4/00 10 -GF 11.54 2.1 1.053 4.898
+ LIF 2.584 1.174 0.872 1.543
+LIF 2.338 2.158 1.147 1.881
+NGF
5 10/4/00 15 -GF 0.231 0.229 0.038 0.166
+LIF 0.113 0.089 0.056 0.086
+LIF 0.223 0.175 0.056 0.151
+NGF
6 10/4/00 15 -GF 0.613 0.59 0.401 0.535
+LIF 0.409 0.233 0.144 0.262
+LIF 2.44 2.038 0.159 1.66
+NGF
Table A2.3: Effect ofLIF and NGF on the PPT-A promoter
Expt AAV Amout BDNF Luciferase values (relative light activity)















































Table A2.4: Effect of BDNF on the PPT-A promoter
218
Expt AAV Amt. IL-6 Luciferase values (relative light activity)




1 11/3/00 5 pi - 101.2 81.04 20.87 13.96 54.268
+ 111.2 99.3 97.51 45.56 88.393
2 11/3/00 5 pi - 6.932 2.568 2.162 0.124 4.467
+ 9.269 5.611 2.797 2.528 5.051
3 25/2/01 2.5xl06 - 3 2.029 1.666 1.389 2.021
+ 28.56 12.05 4.3 3.495 12.10
Table A2.5: Effect of IL-6 on the PPT-A promoter
Expt AAV Amt. (pi) NGF Luciferase values (relative light activity)
prep 1 2 3 4 Mean
1 24/11/00 15 - 0.217 0.343 0.318 0.299 0.294
+ 0.272 0.410 0.169 0.253 0.276
2 24/11/00 15 - 0.342 0.524 0.374 0.335 0.394
+ 0.422 0.649 0.667 0.501 0.560
Table A2.6: Effect ofNGF on the CMV promoter
Expt AAV Amt. (pi) GDNF Luciferase values (relative light activity)
prep 1 2 3 4 Mean
1 24/11/00 15 - 0.645 0.434 0.770 2.005 0.966
+ 0.917 1.083 0.748 0.706 0.864
2 24/11/00 15 - 0.288 0.211 0.621 0.123 0.311
+ 0.399 0.463 0.744 0.749 0.589
Table A2.7 Effect ofGDNF on the CMV promoter
Expt AAV Amt. (pi) LIF Luciferase values (relative light activity)
prep 1 2 3 4 Mean
1 24/11/00 15 - 0.108 0.124 0.114 0.138 0.121
+ 0.213 0.238 0.121 0.087 0.165
2 24/11/00 15 - 0.154 0.334 0.208 0.121 0.204
+ 0.208 0.267 0.190 0.229 0.224
Table A2i> Effect ofLIF on the CMV promoter
Expt AAV Amt. (pi) BDNF Luciferase values (relative light activity)
prep 1 2 3 4 Mean
1 4/8/00 15 - 1.023 1.460 2.089 1.004 1.394
+ 0.977 0.663 1.097 0.646 0.846
2 4/8/00 15 - 1.548 2.056 1.802 0.698 1.526
+ 1.374 3.352 1.042 - 1.923
Table A2.9 Effect ofBDNF on the CMV promoter
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Expt AAV Amt. (pi) IL-6 Luciferase values (relative light activity)





















Table A2.10 Effect of IL-6 on the CMV promoter
Expt AAV Amt NGF+ Luciferase values (relative light activity)

























































































































































Table A2.11: Neonate GF results
* AAV preparations generated using the two-plasmid/adenovirus method. All other preparations
generated using the three plasmid protocol.
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